Molecular mechanisms of Endothelial-Mesenchymal Transition in coronary artery stenosis and cardiac fibrosis by Vanchin, Byambasuren
  
 University of Groningen
Molecular mechanisms of Endothelial-Mesenchymal Transition in coronary artery stenosis
and cardiac fibrosis
Vanchin, Byambasuren
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Vanchin, B. (2018). Molecular mechanisms of Endothelial-Mesenchymal Transition in coronary artery
stenosis and cardiac fibrosis. [Groningen]: University of Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Molecular mechanisms of 
Endothelial-Mesenchymal Transition in 




The research described in this thesis was performed at the Cardiovascular Regenerative 
Medicine laboratory at the Department of Pathology and Medical Biology in University 
Medical Center Groningen. The work was funded by Mongolian State Training Fund and 
Groningen University Institute for Drug Exploration (GUIDE), Graduate School of Medical 
Sciences. 
The author gratefully acknowledges the inancial support for printing of this thesis by: 
The Graduate School of Medical Sciences and Centre for East Asian Studies Groningen 
(CEASG).
ISBN: 978-94-034-0756-2 (printer version)
ISBN: 978-94-034-0755-5 (digital version)
Front cover design: Viktoriia Starokozhko &  Byambasuren Vanchin
Layout design: Byambasuren Vanchin
Printed by: Gildeprint, Enschede, The Netherlands
© Copyright 2018 Byambasuren Vanchin
All right reserved. No parts of this publication may be reproduced, stored on retrieval 
system, or transmitted in any form or by any means, without the permission of the author. 
Molecular mechanisms of 
Endothelial-Mesenchymal Transition 
in coronary artery stenosis and 
cardiac ibrosis
PhD thesis 
      to obtain the degree of PhD at the 
    University of Groningen 
    on the authority of the 
    Rector Magniicus Prof. E. Sterken 
    and in accordance with 
     the decision by the College of Deans. 
 
     This thesis will be defended in public on  
    Tuesday 26 June 2018 at 09.00 hours
by 
Byambasuren Vanchin 
born on 13 December 1986 
in Ulaanbaatar, Mongolia
Supervisor 








Prof. J.L. Hillebrands  
Prof. M.J.T.H. Goumans  
Prof. E.M. Zeisberg
   Paranymphs
   Maroesjka Spiekman 
   Marloes Sol
6CONTENTS
CONTENTS
CHAPTER 1. INTRODUCTION AND AIM OF THIS THESIS                                          7 
CHAPTER 2. PLEIOTROPIC TREATMENT OF PRO-ATHEROGENIC ENDOTHELIUM: ARE SIRT1 
AND EZH2 PROMISING  CANDIDATES?                                               21
CHAPTER 3. MICRORNA-374B INDUCES ENDOTHELIAL-TO-MESENCHYMAL TRANSITION AND 
NEOINTIMA FORMATION THROUGH THE INHIBITION OF MAPK7 SIGNALING                                    43
CHAPTER 4. THE DECREASE IN HISTONE METHYLTRANSFERASE EZH2 IN RESPONSE TO 
FLUID SHEAR STRESS ALTERS ENDOTHELIAL GENE EXPRESSION AND PROMOTES QUIESCEN
CE                                                                                                                                                                                  75
CHAPTER 5. RECIPROCAL REGULATION OF ENDOTHELIAL-MESENCHYMAL TRANSITION BY 
MAPK7 AND EZH2 ACTIVITY IN INTIMAL HYPERPLASIA AND CORONARY ARTERY DISEASE   107
CHAPTER 6. INTRACELLULAR GALECTIN-3 FACILITATES TGFΒ-INDUCED ENDOTHELIAL-MES-
ENCHYMAL TRANSITION                    129
CHAPTER 7. RESEARCH SUMMARY                                    143
CHAPTER 8. EPILOGUE                                     153
CHAPTER 9. NEDERLANDSE SAMENVATTING                  161





GLOBAL BURDEN OF CARDIOVASCULAR DISEASE
Cardiovascular diseases (CVD) are the leading cause of mortality worldwide. In 2015, 
an estimated 17.7 million people died from CVD, representing 31% of all mortalities 
worldwide. The majority of cardiovascular deaths can be attributed to coronary heart 
disease and cerebrovascular diseases, representing 42 and 38% of CVD-related deaths, 
respectively (1) wherein arteriosclerosis is the main underlying pathology. 
From epidemiological studies, systemic risk factors for the development of 
atherosclerosis are identiied, including behavioral risk factors such as an unhealthy 
Western diet, physical inactivity, smoking and the excessive use of alcohol. These 
behavioral risk factors can culminate in intermediate risk factors such as hyperglycemia, 
hyperlipidemia, obesity and hypertension (2). The non-modiiable risk factors for 
arteriosclerosis development are aging, gender and genetic susceptibility (1, 3). Although 
the whole vasculature is exposed to the above mentioned systemic risk factors, 
atherosclerosis is a focal disease that primarily develops at the site of vascular branches 
and the inner curvatures of large vessels (4), implying that focal risk factors are involved in 
the pathogenesis of atherosclerosis (5). 
Atherosclerotic plaques are lesions in the arteries characterized by excessive 
accumulation of oxidized low-density lipoprotein cholesterol in the vessel wall (6, 7), 
inlammatory cell iniltration (8), smooth muscle cell proliferation, extracellular matrix 
accumulation and intimal thickening (9). It is commonly accepted that endothelial 
dysfunction is the initiating event in atherosclerosis development (10, 11), however, the 
underlying molecular mechanisms that cause endothelial dysfunction in the so-called 
atheroprone areas remain elusive. The current dogma revolves around biomechanical 
forces (igure 1) – luid shear stress (12) and cyclic strain (13) – that have distinct patterns 
in areas that are atherosclerosis-prone and areas that are resistant to atherosclerosis 
development (the so-called atheroprotected areas). 
Fluid shear stress, the frictional force per unit area generated by the blood low, plays a 
crucial role in endothelial homeostasis and disease (14, 15). Areas exposed to laminar low 
are protected from the atherosclerosis. In contrast, disturbed low can induce endothelial 
cell activation, oxidative stress and the expression of leukocyte adhesion molecules 
that might induce an inlammatory reaction in the vessel wall (extensively reviewed (16, 
17)) Indeed, in animal models wherein disturbed low is induced by the constriction of 
an otherwise healthy vessel, atherosclerotic lesions develop in the absence of systemic 
atherosclerosis risk factors (18, 19).
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Figure 1. Blood vessels are constantly exposed to biomechanical forces, namely shear stress and cyclic 
strain. Cyclic strain is the circumferential stretch of the vessel. Shear stress is the frictional force per unit area and its 
magnitude is measured by dyne/cm2. Depending on the direction of the low, shear stress can be further classiied 
into laminar shear stress (unidirectional) and oscillatory shear stress (disturbed). High laminar shear stress is 
atheroprotective low, whereas low oscillatory shear stress is considered as atheroprone low, present at sites where 
atherosclerotic lesions preferentially develop.
ENDOTHELIAL CELLS IN VASCULAR HOMEOSTASIS AND THE DEVELOPMENT OF CVD
The blood vessels serve as the conduits of circulation, transporting nutrients and 
oxygen and removing catabolites and carbon dioxide from the tissues. Besides the lymph 
system, there are 3 major type of blood vessels that difer in morphology and function, 
namely arteries, veins and capillaries. The arteries carry blood from the heart, then 
capillaries enable the exchange of gas, nutrients, and catabolites in the tissues, whereas 
veins transport the blood back to the heart. From the aorta to the smallest capillaries and 
back through the venous system, the endothelium covers the entire vasculature and is 
over 100.000 km in length, weighs about 1 kg and represents approximately 1% of the 
body mass (20). 
The endothelium is the most inner luminal cell layer of all blood vessels. In a landmark 
experiment, Furchgott demonstrated that the endothelial layer is not just a simple barrier 
between the blood and the surrounding tissues, but the endothelium has number of 
crucial functions in vascular homeostasis. The removal of the endothelium from isolated 
aortas precluded acetylcholine-induced vasorelaxation (21). These data exemplify that 
the endothelium is not solely a static barrier, but also a key player in vasomotor function. 
Since, many studies have reported on other pivotal functions of the endothelium in 
safeguarding vascular homeostasis, such as the semi-permeable regulation of oxygen 
and nutrient exchange from the blood to the underlying tissues, leukocyte recruitment, 
platelet adhesion/activation, blood clotting and angiogenesis (22, 23). 
Various stimuli, such as oxidative stress and oscillatory shear stress can disrupt 
endothelial homeostasis, which results in endothelial dysfunction. Endothelial 
dysfunction is a comprehensive concept referring to the reduction of the endothelium-
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derived relaxing factors (EDRFs) - in particular nitric oxide(NO) - while, the endothelial- 
derived contracting factors (EDCFs) are increased. 
Endothelial dysfunction not only impairs vasodilation, but  also comprises pro-
thrombotic, proliferative and pro-inlammatory phenotypes (Figure 2). As a result, the 
dysfunctional endothelium facilitates other pathophysiological pathways that might 
induce atherosclerosis (24, 25). 
Figure 2. Endothelial cells in health and disease. The healthy quiescent endothelium has anti-atherogenic 
capacities. Dysfunctional endothelial cells lose their protective capacities and acquire pro-atherogenic functions 
such as proliferation, vasoconstriction, inlammatory activation, and pro-thrombotic activity which contribute to 
atherogenesis. 
EPIGENETIC REGULATION OF ENDOTHELIAL GENE EXPRESSION
As phenotypic heterogeneity is the consequence of diferential gene and protein 
expression patterns, the molecular mechanisms that afect endothelial gene and 
protein expression are extensively investigated in the context of atherosclerosis(26, 
27). Although we have an increasing understanding about the endothelial behavior 
during atherosclerosis development, the contribution of endothelial biomechanical and 
epigenetic signaling during atherosclerosis development is still elusive. 
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Berger et al deined epigenetics as “the stable and heritable changes in genome 
function resulting from changes in the chromatin without alterations in the underlying 
DNA sequence”(28). As a blueprint of the human body, the DNA needs to be accessible 
to transcription factors in a spatiotemporal accurate manner in order to regulate gene 
expression. Each cell contains approximately 2 meters of DNA, which is folded into a 
nucleus of less than 10mm in diameter. To ensure this compaction, the DNA is wrapped 
around an octamer of core histone proteins (H2A, H2B, H3, H4 - two times each) which 
forms the nucleosomes (Figure 3). The nucleosomes are further compacted by the exterior 
histone H1 into 10nm ibers and complexed into 30nm ibers by scafolding proteins 
forming the chromatin (29). 
Figure 3. The nucleosome is a subunit of chromatin. Each nucleosome consists of an octamer of histone proteins 
(Two copies of H2A, H2B, H3 and H4) and approximately 147bp of DNA that wraps around the histone octamer in 1,7 
helical turns. Histone tails protrude from each core histone protein. Histone 1 binds to the histone/DNA complex and 
bridges neighboring nucleosomes. 
This high-order folding or 3D arrangement of the nucleosomes has distinct chromatin 
states in the genome; euchromatin is the state wherein a portion of the DNA is 
loosely wrapped and more accessible to the transcriptional machinery. In contrast, 
heterochromatin is densely packed and less accessible state (Figure 4). This higher-order 
folding is not merely in place to compact the DNA, but is also pivotal in the regulation of 
gene expression (30). Despite having the identical genomic information, a single fertilized 
egg can give rise over 200 types of morphologically and functionally distinct cell types. 
These structural and functional diversities are the consequence of diferential gene 
expression proiles. Epigenetic regulation poses a layer of transcriptional regulation that 
culminates in phenotypic diversities between cells (31). 
CHAPTER 1
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DNA methylation is a process where the addition of methyl group on a cytosine 
nucleotide forms 5-methylcytosine. DNA methylation mostly occurs on CpG islands, which 
are DNA sequences enriched in cytosine nucleotide followed by a guanine nucleotide 
coupled via phosphate bonds. CpG islands are mostly found in gene promoter areas (32). 
In mammals, de novo DNA methylation is performed by the methyltransferases DNMT3a 
and DNMT3b (33), whereas DNMT1 recognizes hemi-methylated DNA and copies the 
methylation to the secondary locus thereby allowing the daughter cells keep the same 
DNA methylation pattern.  
Figure 4. Heterochromatin versus Euchromatin. Heterochromatin is densely packed chromatin wherein the 
DNA is inaccessible for the transcriptional machinery. Repressive histone modiications (e.g. H3K27Me3) and DNA 
methylation induce heterochromatin formation. Euchromatin is loosely packed chromatin wherein the DNA is 
accessible to the transcriptional machinery. Acetylation of histone tail residues changes the charge of the histone 
core proteins which results in electrostatic repulsion and the opening of the chromatin.
Histone modiications: Each core histone molecules has N-terminal tail (29) which 
protrudes out of the histone protein and can undergo a number of modiications 
(Figure 3). Histone modiications include methylation, acetylation, ubiquitination, 
phosphorylation, sumoylation, ribosolyation and others. The orchestrated arrangement 
of the histone modiications is regulated by epigenetic enzymes. Depending on the 
histone modiication produced, epigenetic enzymes are divided into epigenetic writers, 
readers and erasers. Lysine acetylation on histone tails in general results in chromatin 
opening and thus enhanced gene expression, whereas the tri-methylation of lysine 9 and 
27 on histone 3 (H3K9me3 and H3K27me3, respectively) culminate in chromatin closure 
and gene silencing. 
Polycomb Repressive Complex mediated gene silencing: The Polycomb repressive 
complex is an evolutionary preserved transcriptional silencing system that plays a crucial 
role in stem cell identity and diferentiation (34). Two multiprotein Polycomb complexes 
are identiied; Polycomb Repressive Complex 2 (PRC 2) consists of Enhancer of Zeste 
Homologue 2 (EZH2) or its homologue (EZH1), Embryonic Ectoderm Development (EED), 
Suppressor of Zeste 12 (SUZ12) and Retinoblastoma binding protein 48 (RbAP48). 
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Among these proteins, EZH2 and its homologue EZH1 has SET domain holding 
methyltransferase activity, which enables the writing of the tri-methylation on the 27th 
lysine residue on the tail of Histone 3 (H3k27me3). H3K27me3 acts as docking site for 
the Polycomb Repressive Complex 1 (PRC1), which writes a mono-ubiquitination on the 
119th lysine residue on the tail of Histone 2A (H2AK119ub1) (35, 36). PRC1 precludes the 
activation of the RNA polymerase II complex thereby silencing gene expression(37). 
Post-transcriptional silencing - microRNAs: MicroRNAs are around 23 nucleotides in 
length, non-protein coding RNAs. They induce posttranscriptional repression by pairing 
to the transcripts of the protein coding genes (mRNAs). The microRNA precursors are 
transcribed from the DNA by the RNA polymerase II as longer transcript, the pri-microRNA. 
The precursor miRNAs undergoes a series of alterations to inally form the mature 
microRNA that is loaded into the RNA induced silencing complex (RISC). The RISC complex 
can bind to the 3’ UTR of a target mRNA, causing cleavage, destabilization or inhibition of 
mRNA translation. A single microRNA can target multiple mRNAs simultaneously, if their 
3’ UTR sequence match with the seed sequence of the microRNA (38, 39). 
PHENOTYPE SWITCHING OF ENDOTHELIAL CELLS: A DRIVING FORCE FOR DEVELOPING CARDIOVASCULAR DISEASE?
As mentioned above, the healthy endothelium is quiescent and performs valuable 
functions for vascular homeostasis, such as the regulation of vascular permeability and 
the prevention of vasospasms, inlammation, thrombosis and platelet activation. In this 
thesis, we investigated the inluence of a speciic epigenetic modiication (i.e. H3K27Me3) 
on the development of endothelial dysfunction and Endothelial-Mesenchymal Transition 
(EndMT).
Endothelial-mesenchymal transition (EndMT) is a speciic subtype of endothelial 
dysfunction wherein endothelial cells lose their endothelial speciic markers and 
morphology while acquiring a mesenchymal phenotype. The loss of endothelial speciic 
markers, such as VE-cadherin, CD31, Tie1/2 and VEGFRII and the concurrent gain in 
expression of mesenchymal marker proteins αSMA, SM22α, calponin, PAI and vimentin 
is prominent during EndMT. Functionally, endothelial cells acquire contractile behavior 
while their angiogenic and anti-thrombogenic capacities are constrained. Moreover, 
extracellular matrix (ECM) production by endothelial cells is increased during EndMT, 
culminating in the adaptation of a pro-atherogenic endothelial phenotype (16).
EndMT was irst described during the formation of the cardiac cushions and valves 
during cardiac development (40). In the adult, EndMT contributes to the development of 
various chronic diseases such as cancer (41), ibrosis (42) (43) (44) (45), cerebral cavernous 
malformations (46), and endocardial ibroelastosis (47). Recent studies show that EndMT 
also contributes to atherosclerosis (48, 49) and neointima formation (50, 51).
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Figure 5. Endothelial-Mesenchymal transition (EndMT). The healthy quiescent endothelium is a main 
mediator of vascular homeostasis. During EndMT, the expression of endothelial cell-speciic markers such as VE-
cadherin and CD31 is reduced whereas mesenchymal cell-speciic markers such as αSMA and Calponin is induced. 
TGFb, inlammation and oxidative stress induce EndMT, conversely BMP7, laminar low-mediated pMAPK7 activity 
and FGF2 inhibit EndMT. The TGFb, WNT, NOTCH signaling, histone modiications, transcription factors and post-
transcriptional modiications modulate EndMT. 
Postnatal EndMT is predominantly induced in a TGFb- or inlammation and oxidative 
stress-driven manner (Figure 5). TGFb-driven EndMT is extensively investigated in 
the context of ibrotic diseases. Canonical TGF-b signaling activates its downstream 
intermediates SMAD2/3, thereby inducing mesenchymal transcription factors and gene 
expression. Non-canonical TGF-b signaling can activate downstream molecules such 
as ERK1/2 and p38 MAPK, which activate the transcription factor SNAIL, the classical 
transcription factor for the induction of EndMT(16). 
INTRODUCTION AND AIMS OF THIS THESIS
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On the other hand, inlammation-driven EndMT is initiated by the signaling actions 
of inlammatory cytokines such as TNFα and IL1β or reactive oxygen species (ROS). 
This inlammation driven pathway might blend into the TGF-b-driven pathway, since 
inlammatory-activated endothelial cells induce the endogenous expression of TGF-b 
(16). Interestingly, the inlammatory cytokine IL1β and TGFβ can synergistically induce 
EndMT in viitro (52). These data indicate that these two distinct pathways are somehow 
interwined and synergize each other at the certain points (5).
Potent TGF-b antagonists such as BMP7 (53) and FGF2 (54) inhibit EndMT. Also high 
laminar shear stress inhibits EndMT via the activation of MAPK7 signaling (50). Systemic 
administration bone morphogenic protein 7 (BMP7) signiicantly inhibites EndMT and 
the progression of ibrosis in the heart and kidney(42), and the endothelial cell-speciic 
ablation of FGFRI culminates in the activation of TGFβ signaling and the development of 
EndMT in vitro and in vivo(55). 
AIM OF THIS THESIS
Signiicant advancements have been made in the development of new treatments 
of cardiovascular diseases, yet CVD are still the leading cause of mortality worldwide. 
Although the endothelium and atherosclerosis are extensively studied and Endothelial-
mesenchymal transition is established as a key component of atherosclerosis, the relative 
contribution, speciic form of-, and functional contribution of endothelial-mesenchymal 
transition is elusive. The aim of this thesis is to elucidate the molecular and epigenetic 
mechanisms of how uniform laminar shear stress might modulate endothelial 
homeostasis and how these mechanisms are disrupted during intimal hyperplasia 
and cardiac ibrosis.  
OUTLINE OF THIS THESIS
A general introduction to the topics under investigation is presented here (Chapter 
1). The altered function of the endothelium is an important component of atherosclerosis 
yet no current anti-atherosclerosis therapies are speciically focused on the amelioration 
of endothelial dysfunction. Hence, in Chapter 2, we review the current atherosclerosis 
treatments and investigate how some epigenetic enzymes might be beneicial to 
normalize endothelial function in disturbed low areas to preclude atherosclerosis 
development and its progression
In healthy blood vessels, the vascular lumen is lined with a quiescent endothelium. 
In contrast, during vascular pathologies such as atherosclerosis, the endothelium has a 
ibro-proliferative phenotype, characterized by intimal hyperplasia and mesenchymal 
phenotype. Uniform laminar low activates MAPK7 signaling thereby inhibiting Endothelial-
Mesenchymal transition. However, how this protective mechanism is overruled in the 
atheroprone regions is unknown. In Chapter 3, we investigate the mechanism by which 
TGFb reduces the expression and activity of MAPK7 signaling during intimal hyperplasia 
with a focus on TGFb-sensitive microRNAs that might target the MAPK7 signaling cascade. 
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Next, we investigate how endothelial quiescence is governed by luid shear stress 
and how the histone methyltransferase EZH2, as a pivotal epigenetic mediator, regulates 
endothelial quiescence. In Chapter 4, we investigate how high laminar shear stress 
and EZH2 modulate the gene expression proile in endothelial cells by using an RNA 
sequencing approach. We focus on genes that regulate the cell cycle in endothelial cells 
and investigate how these are regulated by luid shear stress and EZH2. Surprisingly, 
we uncovered that the epigenetic enzyme EZH2 crosstalk’s with MAPK7 signaling in a 
reciprocal fashion. This inding intrigued us to investigate the crosstalk between these 
two molecules in Chapter 5. Also, we questioned whether this reciprocity is in imbalance 
during coronary artery stenosis. 
EndMT plays a pivotal role in the development of cardiac ibrosis. Zeisberg et al found 
that around 30% of myoibroblasts in cardiac ibrosis are derived from the endothelium 
(42). Meanwhile, Galectin 3 was identiied as a key initiator of cardiac ibrosis, and plasma 
Galectin 3 levels associate with the increased risk of heart failure and mortality (56). 
However, the molecular mechanism of Galectin 3-induced cardiac ibrosis is elusive. In 
Chapter 6 we assessed if Galectin 3-induced cardiac ibrosis might originate from EndMT. 
In Chapter 7, we summarize our main indings of this thesis, describing the complex 
and multilayered regulation of endothelial-mesenchymal transition by epigenetic and 
post-transcriptional silencing mechanisms (i.e. EZH2 and microRNAs) and how these are 
inluenced by luid shear stress. Moreover, we describe how these mechanisms are in 
imbalance during the development of intimal hyperplasia and cardiac ibrosis. In Chapter 
8, we propose future perspectives resulting from our indings.
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Cardiovascular diseases are the leading cause of mortality worldwide and account 
for almost 17.7 million deaths worldwide annually. Atherosclerosis is one of the main 
underlying pathologies of coronary artery and cerebrovascular diseases. Current 
atherosclerosis care is well developed at the emergency room or in the operation theatre 
by performing percutaneous intervention and vascular grafting per occasion when local 
atherosclerosis plaque cause infarction or severe ischemia. Moreover, preventative and 
follow-up therapies of atherosclerosis are predominantly limited by the reduction of 
cholesterol levels and inhibiting platelet aggregation. 
It is well established that endothelial dysfunction is the major initiating event in 
atherogenesis and continues throughout atherosclerosis progression, yet no endothelial 
cell-speciic therapies are available for the treatment of atherosclerosis. In this perspective, 
we review the contribution of the endothelium to atherogenesis and postulate that the 
dysregulation of epigenetic enzymes aggravate endothelial dysfunction in a pleiotropic 
fashion.  We propose that targeted delivery of a SIRT1 activator or an EZH2 inhibitor to 
the pro-atherogenic endothelium might reduce the atherosclerosis development and 
prevent from the life-threatening complications.
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I. THE ATHEROSCLEROTIC ENDOTHELIUM 
The endothelium forms the innermost layer of all blood vessels and is a major 
regulator of vascular homeostasis. The endothelium plays a critical role in the 
regulation of vascular permeability, leukocyte traicking, vascular tone, inlammation, 
thrombogenesis, ibrinolysis and angiogenesis. The healthy quiescent endothelium 
mediates vascular homeostasis by the inhibition of unwarranted inlammation, blood 
clotting and vasoconstriction and the maintenance of the vascular barrier, whereas 
endothelial dysfunction refers to a proinlammatory, prothrombotic and vasoconstrictive 
state of the endothelium wherein vascular permeability if often increased. Endothelial 
dysfunction is the initial stage of atherosclerosis (1). Dysfunctional endothelial cells 
facilitate lipid accumulation in the vessel wall, leukocyte extravasation, the secretion of 
pro-inlammatory cytokines, vasoconstriction, thrombogenesis and the accumulation of 
ibrous elements in the vessel wall, which form the basic elements of atherogenesis (2, 3).
Even before the irst anatomical evidence of atherosclerotic plaque formation, 
endothelial dysfunction is appeared in hypercholesteremic children (Familial 
hypercholesterolemia) and young adult smokers (4). Moreover, the contribution of the 
endothelium to the pathogenesis of atherosclerosis has been established in a clinical 
long-term follow-up study, which compared non-obstructive coronary artery disease 
patients in which endothelial function was severely impaired to patients with only mild 
or moderate endothelial dysfunction. This study revealed that the group of patients with 
severe endothelial dysfunction has a higher incidence of  cardiac events compared to the 
patients with mild and moderate  endothelial dysfunction, implying the importance of 
endothelial dysfunction in the progression of atherosclerosis to cardiovascular events (5).
Responses to ow Leucocyte recruitment Platelet activation
Smooth muscle cells contractionLipid accumulation
Figure 1. Endothelial cells are a pivotal mediator of atherogenic pathways. Located on luminal side of the 
blood vessels, endothelial cells regulate smooth muscle cell contraction and platelet activation. Forming a barrier 
between the blood and the underlying tissue, the endothelium plays a crucial role in the selective recruitment of 
leukocytes and the lipid accumulation in the vessel wall. 
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The classical risk factors for the development of atherosclerosis, such as physical 
inactivity, obesity, diabetes, hypertension, smoking, dyslipidemia and aging (6) act at 
the systemic level, yet atherosclerotic lesions preferentially develop in areas where 
endothelial cells are exposed by low oscillatory low, suggesting that focal risk factors 
for the development of atherosclerosis exist (7-9). The vascular areas at risk, the so-called 
atheroprone regions, are commonly found at the outer wall of vascular bifurcations and the 
inner wall of vascular curvatures. Interestingly, the induction of blood low disturbances 
in animals by for instance arteriovenous istula (10),  aortic ligation/constriction model 
(11) and partial carotid ligation (12) induces intimal hyperplasia and the development 
of a neointima even in absence of systemic atherosclerosis risk factors. A distinct gene 
expression proile is observed in endothelial cells exposed to high laminar shear stress vs 
low oscillatory shear stress in the human and porcine aorta (13, 14). 
Endothelial cells in atheroprone areas produce less nitric oxide (NO) compared to 
endothelial cells at atheroprotected sites (15, 16). Furthermore, atheroprone, or low 
oscillatory shear stress induces a proinlammatory phenotype in endothelial cells (17). 
Inlammation is crucial in atherosclerosis development, progression and plaque stability 
(extensively reviewed (18, 19)). The inlammatory reaction at the atheroprone site increases 
the endothelial permeability to circulating lipids and initiates leukocyte recruitment, 
wherein the expression of leukocyte adhesion molecules by endothelial cells crucially 
regulates inlammatory cell inlux into the forming atherosclerotic plaque (20). Attracted 
by monocyte chemotactic protein-1, monocytes transmigrate through the vessel wall, 
diferentiate into macrophages and start to take up oxidized LDL (ox-LDL) and other 
cholesterol esters using their scavenger receptors, thereby diferentiating in foam cells 
(21, 22). The foam cells which release more chemokines, cytokines and reactive oxygen 
species aggravating disease progression (23). Besides this fatty streak formation and 
inlammation, a hallmark of the initial stages of atherosclerosis is intimal hyperplasia or 
neointimal formation. Medial smooth muscle cells, adventitial ibroblasts and circulating 
ibrocytes are all implicated as origin of neointimal cells, however, an increasing body 
of evidence suggest that upon TGFb and inlammatory activation, endothelial cells 
might acquire a mesenchymal-like or ibroproliferative phenotype and migrate into the 
neointima (24, 25). Endothelial lineage-tracing studies indicate that luminal endothelial 
cells undergo a process called Endothelial-Mesenchymal Transition (EndMT) and form 
myoibroblast-like cells that accumulate in the neointima and ibrous cap of atherosclerotic 
lesions (26, 27). EndMT is a cellular transdiferentiation process wherein endothelial 
cells lose the expression of endothelial cell-speciic markers while the expression of 
mesenchymal cell markers is induced. Moreover, at the functional level, endothelial cells 
lose the ability to produce NO, loosen their endothelial cell-cell junctions, transit from a 
quiescent to a (hyper)proliferative state, acquire migratory and contractile properties and 
start to produce extracellular matrix components, culminating in enhanced leukocyte 
diapedesis, intimal lipid accumulation, intimal accumulation of ibroproliferative cells and 
the accumulation of ibrotic elements(28, 29). Also ageing is the major non-modiiable risk 
factor for the development of atherosclerosis. Cellular senescence is the phenomenon 
by which cells cease to divide in response to telomere shortening ageing or biochemical 
damages (e.g. ROS accumulation and DNA damage)(30). 
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Senescent endothelial cells adopt pro-inlammatory, pro-thrombotic phenotype and 
lose their cell-cell junction and regenerative capacity(31). Senescent endothelial cells are 
found in the atherosclerotic lesion (32), which indicates that endothelial senescence might 
contribute to the development and aggravation of atherosclerotic lesions. 
From the above, we can conclude that endothelial dysfunction (i.e. endothelial oxidative 
stress, mesenchymal transition and senescence) plays a pivotal role in atherogenesis 
and therefore postulate that the endothelium might serve as an eicacious therapeutic 
target cell for anti-atherogenic therapies. In this perspective, we discuss the potential to 
ameliorate atherogenesis via the restoration of endothelial homeostasis using epigenetic 
drugs.  
II. CURRENT ATHEROSCLEROSIS TREATMENTS
Current medical treatments to prevent atherosclerosis development, progression and 
plaque rupture encompass lipid lowering and the prevention of blood clotting (Figure 
2) and emerging anti-inlammatory therapies are currently under clinical investigations 
to increase the eicacy of anti-atherosclerosis treatment. Below, we discuss the currently 




Figure 2. Current anti-atherosclerosis therapies. Established atherogenic pathways are depicted in blue bars and 
if treatments are currently available to counteract these pathways, it is depicted in the according brown bars. Current 
anti-atherogenic therapies successfully preclude dyslipidemia, platelet aggregation and systemic inlammation, 
however the fundamental problem “endothelial dysfunction” is not suiciently addressed therapeutically.  
ATHEROSCLEROSIS PATHOGENESIS THERAPIES
II.1 HYPERCHOLESTEROLEMIA: 
The principal current pharmaceutical intervention for the treatment of atherosclerosis 
aims to reduce the lipid risk. As evidenced by epidemiological cohort studies as well as 
the clinical trials and meta-analysis, increasing levels of low density lipoproteins-C (LDL-C) 
associate strongly to the development of atherosclerosis and other cardiovascular diseases 
(extensively condensed in (33)). Extensive basic and clinical research has supported the 
dyslipidemia hypothesis and several groups of lipid lowering medications are currently 
available in the clinical practice. 
Statins: Although a reduction in dietary cholesterol intake is able to reduce the serum 
cholesterol level, over two-thirds of serum cholesterol is synthesized in the liver. Statins, 
also known as HMG-CoA reductase inhibitors, act by reducing the liver’s production 
of cholesterol via the inhibition of the conversion of HMG CoA to mevalonic acid (34). 
Besides reducing serum LDL-C levels, statins ofer anti-inlammatory (35) efects and 
increase endothelial NO production primarily through the activation of the endothelial 
nitric oxide synthase (eNOS) (36), which might alleviate endothelial oxidative stress. These 
pleiotropic efects might explain why statins outperform other lipid lowering drugs and 
statins are considered as the irst-choice medicament to reduce lipid risk in the secondary 
prevention of multiple CVD. The reduction of LDL cholesterol by 1.0 mmol/L with statins 
reduces the risk of a major vascular events (myocardial infarction or coronary death, 
stroke, coronary revascularization) by 25%, regardless of the baseline LDL cholesterol 
level (37). According to the European Society for Cardiology (ESC) clinical guideline for 
dyslipidemias (ESC), statin treatment is recommended when patients have a LDL-C level 
greater than 3.0 mmol/L or have a (very) high 10-year risk to develop a fatal cardiovascular 
event (38). 
PCSK9 inhibitors (Evolocumab, Bococizumab and Alirocumab): Although 
statins are the most-efective therapy available now for lowering LDL-C level, in part of 
the treatment population, the desired LDL-C level can’t be reached with the maximal 
tolerated dose of statin therapy. Proprotein convertase subtilisin/kexin type 9 (PCSK9) 
is an enzyme which regulates the degradation of LDL-receptors (LDLR) in the liver. 
Monoclonal antibodies against PCSK9 reduce the degradation of LDL receptors and 
increase the clearance of the LDL-C (39). On the other hand, atorvastation treatment 
reciprocally increased PCSK9 protein levels in serum by 34% compared to the placebo 
controlled group (40). This data suggested that PCSK9 inhibition in combination with 
statin treatment can further decrease LDL-C levels. Phase III clinical trial results proved 
that combination of statin and PCSK9 inhibitors can further decrease the LDL-C level and 
combination therapies are recommended if necessary (38, 41). 
PLEIOTROPIC TREATMENT OF PRO-ATHEROGENIC ENDOTHELIUM
27
2
Cholesterol absorption inhibitors (Ezetimibe): Ezetimibe reduces the absorption 
of cholesterol from the intestine via a mechanism involving the Niemann-Pick C1-like 1 
(NPC1L1) protein on the gastrointestinal epithelial cells (42). Ezetimibe itself can decrease 
LDL-C around 15-22% and in combination with statin treatment and additional 15-20% 
LDL-C lowering observed (38). 
LDL-C reduction through the above-mentioned medications is one of the most eicient 
secondary prevention to decrease both relative and absolute risk. In certain extend, 
several clinical trial results indicated these beneicial efect is achieved not only through 
the lipid lowering, but also reducing the inlammation, implying that anti-inlammatory 
medications are important part of atherosclerosis treatment (43).
II.2 ANTI-INFLAMMATORY AGENTS 
Inlammation plays critical role in the development and progression of atherosclerosis 
(18, 19) and the discovery of drugable targets that reduce inlammation in atherosclerosis 
has been a topic of intense research in cardiovascular medicine for several decades. 
Inlammation regulatory pathways such as interleukin-1(IL-1), tumor necrosis factor α (TNF 
α), interleukin-6 (IL-6) are extensively targeted by selective inhibitors and monoclonal 
antibodies and some medicaments are in Phase III clinical trials. Also vascular targeted 
antioxidants, selective phospholipase A2 (PLA2) inhibitors, adhesion molecule inhibitors, 
serpines/sirtuins, FLAP inhibitors, 5-LO inhibitors, CCL2-CCR2 inhibitors and other 
molecules underwent extensive experimental and clinical research (extensively reviewed 
(44, 45)) Recently, promising results were reported by the CANTOS trial using monoclonal 
antibody named canakinumab.
Canakinumab:  Canakinumab is a monoclonal antibody against Interleukin 1b (IL1b) 
and an approved drug for treating cryopyrin-associated periodic syndrome (CAPS) (46). 
IL1b is released from macrophages and one of the main mediators of innate immunity. 
In Canakinumab-treated patients, markers of inlammation such as  Interleukin 6 (IL-6) 
and high sensitivity CRP (hs-CRP) were decreased without changes in their lipid proile 
(47) resulting in an reduced cardiovascular event risk score. A randomized double blinded 
clinical trial result indicated that canakinumab signiicantly lowers the occurrence of 
cardiovascular events and cardiovascular deaths compared to the placebo control group. 
However, an increasing incidence of fatal infections, sepsis and mild thrombocytopenia 
was  associated with Canakinumab treatment (48).
II.3 ANTI-THROMBOTIC AGENTS 
Arterial thrombosis is commonly initiated by the rupture of an atherosclerotic plaque 
which triggers platelet aggregation and thrombus formation (49). This process is called 
atherothrombosis and is the main cause of mortality in atherosclerosis. Hence, inhibiting 
platelet aggregation (anti-aggregants) and inhibiting blood coagulation (anti-coagulants) 
are pivotal parts of anti-atherosclerosis treatment, especially in the late stages. The 
damaged endothelium recruit platelets and enables primary and secondary hemostasis. 
In contrast, the quiescent healthy endothelium prevents these thrombogenic processes 
via prostaglandin I2 activation (50) and NO induction (51).
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Thromboxane A2 inhibitor (Aspirin):  Low dose aspirin (acetylsalycilic acid) 
inhibits platelet cyclooxygenase which is vital enzyme for thromboxane A2 generation. 
Thromboxane A2 triggers platelet aggregation and adhesion. The long-term usage of 
antiplatelet therapies shown to reduce vascular events around 25% among patients who 
have already experienced occlusive vascular diseases (52). In primary prevention trials, 
aspirin usage reduced the frequency of cardiovascular events over 12% in patients that 
have a myocardial infarction in their history (53). 
P2Y12 inhibitors (Clopidegril, Ticagrelor, Prasugrel, Cangrelor): Inhibiting the P2Y12 
receptor blocks the binding of extracellular adenosine diphosphate (ADP) to its receptor, 
which prevents thrombocyte aggregation. The P2Y12 inhibitor (clopidegril) combined with 
aspirin reduced serious vascular events by 20% in myocardial infarction patients with ST-
segment elevation.  (54). Clopidegril is prodrug which is  metabolized and converted into 
its active form by Cytochrome P 450 enzyme (CYP). Patients who have diferent isoforms 
of the CYP enzyme respond diferent to clopidegril treatment  (49). Prasugrel, another 
P2Y12 inhibitor, acts faster and was shown to reduce recurrent vascular events and stent 
complications compared to clopidegril after angioplasty and PCI (55). 
GPIIb/IIIa inhibitors (Tiroiban, Eptiibatide, Abciximb): GPIIb/IIIa inhibitors(GPIs) 
are potent and rapid acting antiplatelet drugs. The GPIs target the aIIbb3 integrin on the 
platelet membrane, thereby inhibiting platelet aggregation (56). Meta-analysis indicted 
that 30-day death or myocardial infarction was moderately decreased after using these 
medications compared to the placebo group, the efect was highly pronounced in 
patients  undergoing PCI (57). 
PAR-1 inhibitors (Voraxapar): The novel class of antiplatelets drugs are developed 
to inhibit protease activated receptors (PAR-1) which mediates thrombin-induced platelet 
activation. Interestingly, the PAR-1 receptors are not only present at the platelets but also at 
endothelial cells, smooth muscle cells and ibroblasts (58). A phase III clinical trial indicates 
that Voraxapar addition to the standard treatment can decrease the risk of cardiovascular 
death and ischemic events, but moderate and severe bleedings occur more often (59). 
From the above, it becomes evident that among the core atherogenic pathways, 
only lipid accumulation, inlammation and platelet aggregation are addressed by 
currently available therapeutic agents and therapeutic agent in development. As 
emphasized above, the endothelium plays a pivotal role in all atherogenic pathways, yet 
no endothelial-targeted therapy is available. In the next section, we elaborate on how 
endothelial-speciic epigenetic molecules might ofer a potential therapeutic beneit for 
patients sufering from atherosclerosis. 
III. ENDOTHELIAL SPECIFIC PRO-ATHEROGENIC TREATMENT
Endothelial cells play a crucial role in the development and progression of 
atherosclerosis. Stimulated by uniform laminar low, the endothelial cells acquire healthy 
quiescent phenotype that precludes atherosclerosis pathways (24). In contrast, disturbed 
low alters the endothelial phenotype, which enables atherosclerosis pathways. This 
phenotypic shift might be the consequence of diferential gene expression regulated by 
epigenetic modiications. An important feature of the epigenetics is the reversibility. 
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Following the fact that epigenetic molecules are well established as mediators of 
health and disease, epigenetic enzymes or their activator/inhibitors can be exploited as 
therapeutic target (60, 61).  
III.1. EPIGENETIC MOLECULES ARE PROMISING CANDIDATES TO TREAT THE PRO-ATHEROGENIC ENDOTHELIUM
Epigenetics refers to heritable yet stable changes in genome function resulting 
from changes in the chromatin without alterations in the underlying DNA sequence. 
In other words “changing the cells’ phenotype without changing genotype”(62). 
Epigenetic modiications can explain how one fertilized egg gives rise to more than 200 
diferent cell types that compose the human body (63). Moreover, epigenetics explain 
novel mechanisms for complex and chronic diseases such as diabetes (64), cancer (65, 
66) and cardiovascular diseases (67). Epigenetic traits consist of several interconnected 
parameters, i.e. histone modiications and DNA methylation (68). 
On average, a human cell has a 2-metre long DNA molecule. Cell size and timely 
transcriptional activity requires organized folding of the DNA. In the nucleus, the DNA 
strand is 1.7 times coiled around an octamer of core histone proteins, forming the 
nucleosomes.  (H2A, H2B, H3 and H4, 2 copies of each) (69). Core histone proteins contain 
a globular domain and an amino terminal tail which can undergo post-transcriptional 
modiications such as acetylation, methylation (lysines/arginines), phosphorylation, 
sumoylation, ubiquitylation, ADP ribosylation, deamination, proline isomerization and 
other modiications (70). Many of these modiications are known to play functional roles 
in gene expression. The functional role of lysine acetylation and methylation of histone 
core proteins on transcriptional level are well studied. For instance, histone acetylation 
is associated with transcriptional activation by amongst others neutralizing the basic 
charges of lysine residues (71), whereas the consequence of histone methylation depend 
on the speciic lysine or arginine residue that is methylated. Methylation of H3K27 
and H3K9 correlate with the transcriptional repression, but methylation of H3K4 and 
H3K36 correlates transcriptional activation (72). Thus, histone modiications afect gene 
expression via altering chromatin structure and accessibility. 
DNA methylation refers to the addition of a methyl group (-CH3) on 5th carbon atom 
of cytosine of the DNA. When DNA methylation occurs at gene promoter areas rich in 
cytosine and guanidine residues (so-called CpG islands) linked to the transcriptional 
repression (73). However, 5 methylcytosine (5mC) also found in gene body (transcribable 
region) and related to the supportive function in transcription (74, 75). The contribution 
of epigenetic mechanisms to atherosclerosis development is under extensive research. 
Here, we focus on the contribution of epigenetic modiications in the early stages of 
atherosclerosis and question if reversing those changes may have anti-atherosclerosis 
capacity. 
One of the main epigenetic features found in early atherogenesis is DNA 
hypomethylation. CpG islands in newly forming atherosclerosis lesions are mostly 
hypomethylated compared to non-atherogenic vessel areas. However, several 
hypermethylated genes also be identiied (76). By using high performance liquid 
chromatography analysis, the 5mC content was 3.2%±0.2 in healthy arteries and declined 
to 2.9%±0.1 in advanced atherosclerosis lesions (77). 
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The inding was supported by the study results implicating that 84% of diferentially 
methylated promoter sites were hypomethylated (de-methylated) in femoral artery 
atherectomy samples compared to the non-sclerosed mammary artery samples (78). 
These studies indicate that DNA hypomethylation is dominantly occurring during 
atherosclerosis.
Human carotid artery atherosclerosis samples showed increased acetylation (active 
mark) of H3K9 and H3K27 in endothelial cells in early stage of atherosclerosis and this 
increment was consistently kept high in advanced atherosclerotic plaques. Quantitative 
PCR result revealed that the expression of histone acetyltransferase GCN5L is elevated in 
advanced atherosclerotic plaques compared to control. Also, H3K4 methylation (active 
mark) was increased in endothelial cells in early stage maintained high during the 
advanced atherosclerosis (79).This inding matches with the previous inding from Wierda 
et al (80), who showed increased H3K4 methylation and expression of the H3K4 writer 
MLL2/4 in endothelial cells in atherosclerotic lesions compared to non-atherogenic sites. 
The methylation level of H3K27 (repressive mark) is higher in early stages of atherosclerosis 
and normalizes during the advanced atherosclerotic plaques in endothelial cells (79). 
It is interesting phenomenon that  concurrent increment of H3k27 methylation, H3k27 
acetylation and H3k4 methylation was observed in early stage of atherosclerosis, which 
may imply the presence of “bivalent domains” (81) that might contribute to endothelial 
dysfunction and atherosclerosis.  However, it is still elusive whether these opposing 
modiications are occurring at the same gene locus or relect epigenetic regulation across 
diferent loci. 
The above-mentioned data indicate that during atherosclerosis, the epigenome of the 
endothelial cells changes, and it raises the question if we can we ameliorate atherosclerosis 
progression via reversal of these modiications? Here we demonstrate the beneicial efects 
of epigenetic therapies by exemplifying two histone modifying enzymes as molecules for 
targeting the pro-atherogenic endothelium and promote endothelial homeostasis.
EZH2- ENHANCER OF ZESTE HOMOLOGUE 2
Rationale: Methylation of H3K27 is increased during the early stage of atherosclerosis in 
endothelial cells. Thereby, decreasing Ezh2 might be beneicial to ameliorate pro-atherogenic 
endothelium via reducing the methylation of H3K27. 
Enhancer of zeste homologue 2 (Ezh2) is the catalytic subunit of Polycomb Repressive 
Complex 2 (PRC 2). In mammals, Polycomb Repressive Complex 2 core subunits are EED, 
SUZ12 and EZH2/EZH1. EZH2 and its close homologue EZH1 have SET domain which 
encompasses its histone methyltransferase activity. EZH2 trimethylates lysine 27 on N 
terminal tail of histone 3 protein. H3K27me3 act as docking site for chromobox-domain 
(CBX) of Polycomb Repressive Complex 1. H3K27me3 is a repressive chromatin mark that 
leads to the formation of condensed chromatin and transcriptional silencing of the target 
gene.(82) The rationale of targeting EZH2 in the endothelium to ameliorate atherogenesis 
is summarized in Table 1. Shear stress regulates the protein expression of histone 
methyltransferase EZH2. Under atheroprotective -laminar low, EZH2 protein expression 
is low, thereby inducing a quiescent phenotype in endothelial cells (83). Elevated serum 
homocysteine is one of the independent risk factors of the atherosclerosis and has adverse 
efects on endothelial cells. 
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Interestingly, homocysteine enhanced fat accumulation and increased EZH2 and 
H3K27me3 levels are found in atherosclerosis-prone APOE-/- mice (84). The metabolic 
conversion of homocysteine Hcy-thiolactone induces the expression of EZH2 in a dose-
dependent manner in endothelial cells (85).  Moreover, LDL-C can reduce the expression 
of KLF2 – a well-established antiatherogenic transcription factor - which can be precluded 
by inhibiting EZH2 (86). These indings indicate that the elevated expression levels of EZH2 
during atherogenesis is detrimental for endothelial homeostasis and might aggravate 
atherogenesis. One of the main representatives of the statin therapies, i.e. simvastatin 
decreased the transcriptional and translational levels of EZH2 in colorectal cancer cells. 
This inding suggest that some beneicial efects of statin outside the lipid-lowering 
efects might be achieved through the reduction of EZH2 in endothelial cells (87). 
Besides the endothelium, elevated expression of EZH2 in marcophages enhances 
foam cell formation via ABCA1 gene promoter DNA methylation(88) and EZH2 afects 
DNA methylation in polycomb target gene areas via modulating DNMTs (89). Based on 
the above, EZH2 inhibition might be beneicial to endothelial homeostasis and may 
ameliorate atherosclerosis progression. 
SIRT1- NAD+ DEPENDENT DEACETYLASE GROUP III 
Rationale: Acetylation of H3K9 and H3K27 is increased during the early and advanced 
stages of atherosclerosis in endothelial cells. Thereby increasing histone deacetylase SIRT1 
might be beneicial via reversing the acetylation of H3K9 and H3K27.
Sirtuin 1, the mammalian ortholog of yeast Sir2, is a nicotinamide adenine dinucleotide 
(NAD) dependent deacetylase. SIRT1 removes acetyl group from histone tails and non-
histone proteins. Higher expression levels of SIRT1 positively correlate with lifespan in 
yeast, lies and mice.(90) SIRT1 activation protects cardiomyocytes from endoplasmic 
reticulum(ER) stress-induced apoptosis by attenuating PERK/eIF2α pathway activation. 
The rationale of using SIRT1 to ameliorate atherogenesis is exempliied in Table 1.
SIRT1 is also a shear stress responsive protein. Atheroprotective - uniform laminar 
low induces SIRT1 protein expression, while static or oscillatory shear stress inhibits 
SIRT1 expression(91). As mentioned above, inlammation plays a key role in endothelial 
dysfunction and atherogenesis. NF-kB is the core transcription factor of inlammation and 
inlammation mediated responses. SIRT1 can de-acetylate and deactivate NF-kB, thereby 
inhibiting inlammation(92). Also endothelial senescence contributes to the atherosclerosis 
development and SIRT1 induction was shown to prevent from H202-induced endothelial 
senescence(93). Moreover, SIRT1 elevates NO production in endothelial cells. Albeit that 
the SIRT1-dependent favorable efects on the endothelium are pleiotropic, in synergy 
these efects enable endothelial homeostasis and might ofer therapeutic beneit in 
atherosclerosis.
Several clinical trials have demonstrated and  the SIRT1 activator SRT2014 can 
decrease serum LDL levels (94) via decreasing the PCSK9 secretion of from hepatic cells 
(95). Interestingly, SIRT1 modulates DNA methylation and the target genes overlap with 
the Polycomb group proteins (96), implying an interconnection between these two 
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Laminar low decreases Ezh2 
and upregulation of Ezh2 post-
transcriptionally inhibit MAPK7 
activity
Static condition upregulates Ezh2 (83)
Laminar low increases SIRT1 and its 
activity
Static/oscillatory shear stress inhibits 
SIRT1 level (91)
Lipid accumulation
Homocystein induced atherosclerosis 
via upregulating EZH2 and H3K27me3 
in APOE-/- mice(84)
Homocystein metabolite HCy- 
thiolactone(1000uM)  stimulation 
induce EZH2 gene expression 5.36 
fold in endothelial cells (85)
SIRT1 activator SRT3025 reduces 
serum LDL-C via reducing hepatic 
PCSK9 secretion (95)
Inlammation / leukocyte 
recruitment
Overexpression of EZH2 induces lipid 
accumulation in macrophages by 
methylating ABCA1 gene promoter 
thereby accelerate atherosclerosis 
progression in apoE-/- mice (88)
Hyperglycemia induced endothelial 
dysfunction is prevented via SIRT1 
dependent P66shC downregulation 
(97)
SIRT1 deacetylase NFkB thereby 
prevent chronic inlammation (92)
Blood clotting
EZH2 knockdown prevents LDL 
induced downregulation of 
thrombomodulin (TM) thereby 
prevents from the unnecessary 
platelet aggregation  (86)
Endothelial senescence
H202 induced endothelial senescence 
rescued by the SIRT1 (93)
SIRT1 downregulates PAI thereby 
prevents replicative senescence (98)
Accumulation of ibrous 
element (EndMT)
Ezh2 regulates sm22a/TAGLN 
expression (99)
SIRT1 modulates EMT in cancer (100)
NO production
EZH2 knockdown prevents LDL 
induced downregulation of the NO 
decline through the KLF2 promoter 
methylation (86)
SIRT1 induce NO production via 
increasing eNOS production (101)
Vitamin D rescues endothelial cells 
from oxidative stress mek/erk- SIRT1 
cascade(102)
SIRT1 promotes mitochondrial 
biogenesis via activation of PGC1α 
DNA methylation
Ezh2 directly controls DNA 
methylation (89)
SIRT1 afects DNA methylation of 
polycomb group target genes (96)
Table 1. EZH2 and SIRT1 role in endothelial homeostasis and contribution to the development of atherosclerosis
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III.2. AVAILABILITY OF THE EPIGENETIC ENZYME MEDICAMENTS
The current therapeutic strategies and possibilities of using epigenetic molecules for 
the treatment of cancer and other diseases have been reviewed previously (103, 104) and 
several studies are already using EZH2 and SIRT1 as epigenetic targets in clinical trials.(see 
table 2) 
The possibility of using histone methyltransferases and demethylases(105) especially 
EZH2 inhibitors (106) in cancer therapy have been reviewed previously. EZH2 inhibitors are 
being tested in Phase I/II clinical trials in cancer ield, but they are not yet used in trials for 
atherosclerosis. (Table 2).  Compared to the EZH2, SIRT1 activators are well known in ield 
of the cardiovascular medicine. Several SIRT1 activators are recognized and being tested 
and cardiovascular outcomes were measured (Table 2). Resveratol, a well-known activator 
of SIRT1 was used in cancer, neurological disorder, cardiovascular diseases, diabetes and 
other diseases clinical trials (extensively reviewed in (107)). 
Drug name Mechanism of action Phase Indication Clinical trial #
Tazemetostat EZH2 inhibitor II INI1-negative tumors NCT02601950
GSK2816126 EZH2 inhibitor
I Difuse B cell Lymphoma, other 
Non- Hodgkin Lymphoma, solid 
tumors and multiple myeloma
NCT02082977
SRT2104 SIRT1 activator I 60-80 years old males NCT00964340
SRT2104 SIRT1 activator II Otherwise healthy smokers NCT01031108
Table 2. EZH2 inhibitors and SIRT1 activators in clinical trials. Showing early phase clinical trials using above 
mentioned epigenetic enzymes – implying these therapeutic molecules are already available and tolerated to use 
in human.
From above mentioned results we can see that EZH2 inhibition (open chromatin) and 
SIRT1 induction (closed chromatin) can be beneicial in providing endothelial homeostasis 
thereby slowing down atherosclerosis progression. Moreover, small molecules that 
inhibit EZH2 or activate SIRT1 are available in clinical trials which warrants the adaptation 
of cardiovascular endpoints in these trials. Moreover, given the current safety record of 
these experimental medicines, the clinical testing in the context of atherosclerosis could 
















































Figure 3. SIRT1 activator and EZH2 inhibitor  based treatment of atherosclerotic endothelium. We explained 
how epigenetic molecules can be promising candidates to treatment pro-atherogenic endothelium using two pre-
examplary molecules namely SIRT1 and EZH2.  Together with the current medications, our proposed pro-athero-
genic endothelium treatment may slow down the atherosclerosis progression and prevent from the life-threatening 
complications. 
Although the chromatin modeling consequence of these two enzymes is controversial, 
the efect is target gene dependent. Epigenetic modiications can be reversed and 
“Epigenetic editing” is an emerging research ield in medicine (extensively reviewed (108, 
109)). Epigenetic repression and epigenetic activation are successfully accomplished by 
using Zinc Finger Proteins (ZFP), Transcription- Activator-Like Efectors (TALEs) arrays or 
Clustered Regulatory Interspaced Short Palindromic Repeats (CRISPR). Moreover, the 
newly edited modiications are shown sustainability through the cell division (110).
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III.3. TARGETED APPROACH TO ENDOTHELIAL CELLS IN ATHEROPRONE AREAS
Since atherosclerosis lesions develop exclusively at vascular branches and curvatures, 
the ideal treatment would be to target the afected endothelial cells at these atheroprone 
areas only. Moreover, lineage committed cell have a distinct epigenome landscape 
including DNA methylation and histone modiications, (111, 112) which might make the 
systemic application of epigenetic drugs harmful to non-target cells in the human body. 
Promising liposome-based drug delivery approaches are available that might be suitable 
to deliver therapeutic agents to the pre-atherogenic activated endothelium exclusively 
(113). For instance, SAINT-O-Somes directed to microvascular endothelial cells expressing 
VCAM-1 (114) successfully inhibited inlammatory genes in microvascular endothelial cells 
without toxic efects liver and kidney (115). Also, E-selectin targeted immunoliposomes 
successfully abrogated ANCA-induced glomerulonephritis via targeted delivery of siRNA 
against NF-kB in glomerular endothelial cells (116).   Some studies used speciic peptides 
for the targeted treatment approach. For example, the ICAM-targeted CLIRRTSIC peptide 
was successful in  targeting endothelial cells in disturbed low exposed areas in vivo (117). 
Outcome of endothelial cells-speciic SIRT1 overexpression was tested in ApoE-/- mice; 
this study revealed an enhancement of the endothelium-dependent vasodilation and less 
atherosclerosis lesion development (118). 
CONCLUSION
Endothelial dysfunction is a critical component of the development of the 
atherosclerosis. Current atherosclerosis treatment encompasses lipid lowering, inhibiting 
platelet aggregation and anti-inlammatory drugs, however there is no treatment 
available that targets pathway “endothelial dysfunction”. In this review, we proposed the 
targeting of two epigenetic pathways (i.e. SIRT1 and EZH2) to ameliorate atherogenesis 
and exemplify a number of established medicaments that would allow for rapid clinical 
valorization. Moreover, we set forth a future strategy that utilizes a cell-targeted strategy 
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Endothelial-mesenchymal transition occurs during intimal hyperplasia and neointima 
formation via mechanisms that are incompletely understood. Endothelial MAPK7 
signaling is a key mechanosensitive factor that protects against endothelial-mesenchymal 
transition, but its signaling activity lost in vessel areas that undergoing pathological 
remodeling.
At sites of vascular remodeling in mice and pigs, endothelial MAPK7 signaling was 
lost. The TGFβ-induced microRNA-374b targets MAPK7 and its downstream efectors in 
endothelial cells and its expression induces endothelial-mesenchymal transition. Gain-
of-function experiments, where endothelial MAPK7 signaling was restored, precluded 
endothelial-mesenchymal transition. In human coronary artery disease, disease severity 
associates with decreased MAPK7 expression levels and increased miR-374b expression 
levels.
Endothelial-mesenchymal transition occurs in intimal hyperplasia and neointima 
formation and is governed in part by microRNA-374b-induced silencing of MAPK7 
signaling. Restoration of MAPK7 signaling abrogated these pathological efects in 
endothelial cells expressing miR-374b. Thus, our data suggest that the TGFβ-miR-374b-
MAPK7 axis plays a key role in the induction of endothelial-mesenchymal transition 
during  intimal hyperplasia and neointima formation and might pose an interesting target 
for anti-atherosclerosis therapy.




The development of atherosclerosis is preceded by intimal hyperplasia and neointima 
formation [1]. Although the commonly recognized risk factors for the development of 
neointimal lesions and atherosclerosis are present at the systemic level [2], neointima 
formation and atherosclerosis manifest focally in so-called atheroprone regions [3]. These 
atheroprone regions are characterized by low levels of non-uniform shear stress, typically 
encountered at the outer walls of vascular bifurcations and at the inner wall of vascular 
curvatures, whereas atheroprotected regions are characterized by high levels of uniform 
laminar shear stress [4].
We and others have recently described a major contribution of endothelial cells to intimal 
hyperplasia and atherosclerosis development [5-7]. Upon exposure to inlammatory and 
pro-ibrotic growth factors (i.e. TGFβ) and cytokines, endothelial cells lose their endothelial 
cell markers and functionality, start to express markers of the mesenchymal lineage and 
gain contractile behavior [8-10]. During neointimal lesion formation, endothelial cells that 
undergo this Endothelial-Mesenchymal Transition (EndMT) acquire a ibroproliferative 
mesenchymal phenotype and migrate from the endothelial monolayer to the underlying 
neointima [5,6]. 
TGFβ is a major inducer of EndMT and highly expressed in neointimal lesions [11], 
which may cause EndMT. We uncovered that high levels of uniform laminar shear stress 
- observed at atheroprotected regions of the arteries - activates a speciic mitogen-
activated kinase (MAPK), namely MAPK7 (also known as Erk5 or Big MAPK (BMK1)), which 
inhibits the induction of EndMT by TGFβ1 [5]. Corroboratively, knockdown of MAPK7 in 
endothelial cells causes EndMT, even in the absence of exogenous TGFβ1 [5], suggesting 
a pivotal balance between TGFβ and MAPK7 signaling in the induction of EndMT and the 
formation of neointimal lesions. Indeed, TGFβ1 represses endothelial MAPK7 expression 
through unidentiied mechanisms (unpublished data) and the loss of endothelial MAPK7 
signaling aggravates atherosclerosis development [12].
MicroRNAs (miRNAs) are small non-coding RNAs that cause post-translational 
repression of their target genes. MicroRNAs elicit translational repression by imperfect 
base-pairing to the 3’UTR of their gene targets [13], which allows any speciic microRNA 
to target multiple genes simultaneously. Moreover, multiplicity of microRNA targets 
might also allow one microRNA to speciically target multiple genes within one signal 
transduction cascade [14], eiciently abolishing its activity. 
TGFβ induces a shift in endothelial miRNA expression levels [15-18] that may reduce 
MAPK7 signaling and thus facilitate EndMT induction. Here, we hypothesized that 
TGFβ1 induces the expression of a speciic miRNA that targets MAPK7 and its signaling 





Human coronary arteries were obtained from autopsy specimens from 10 patients 
that died from an acute coronary episode at the Heart Institute (InCor), Sao Paulo, Brazil. 
During necropsy each dissected coronary artery was ixed in neutral-bufered formalin 
with constant perfusion at a quasi-normal perfusion pressure. The mean age of subjects 
contributing pathology specimens was 65 years. Hypertension was resent in 9 subjects, 
and diabetes in 6. Five individuals were active smokers. Next-of-kin gave informed 
consent and the investigation was performed according to institutional guidelines (InCor, 
Sao Paulo #SDC 3723/11/141 and #CAPPesq 482/11) and the Declaration of Helsinki.
ANIMALS AND SURGICAL PROCEDURES 
Porcine abdominal trifurcations were obtained from healthy male slaughterhouse 
Yorkshire pigs (12-13 weeks of age; body weight 30-35 kg, n =3, V.O.F. van Beek, Lelystad, 
The Netherlands). Animals were fed a normal diet and were euthanized under anesthesia 
(ketamine (Nimatek) and midazolam with a bolus of pentobarbital and heparin (Actrapid)). 
Male C57Bl/6j wild-type mice (8–12 weeks of age, n = 8, Harlan, Horst, The Netherlands) 
were subjected to transverse aortic constriction under anesthesia (2% Isoluorane (Forene/
Abbott, The Netherlands) and oxygen) and analgesia (Carprofen, 5 mg/kg). Briely, an 
incision was made in the second intercostal space and a small incision was made in the 
parietal pleura to expose the ascending loop of the aorta. The aorta was supported with a 
27G needle and a suture was placed around the aorta, drawn tight after which the needle 
was removed. Next, the pleura, muscle layers, and skin were closed by sutures. Animals 
received post-operative analgesia (Carprofen, 5 mg/kg/day for 48 h). Animals were kept 
on a 12 h light:dark cycle with ad libitum access to standard laboratory chow and water. 
Eight weeks after aortic constriction, animals were sacriiced under deep anesthesia [3% 
Isoluorane (Forene/Abbott, The Netherlands] by exsanguination, after which the thoracic 
aorta was explanted. Experiments on mice were approved by the local Institutional Animal 
Care and Use Committee (University of Groningen, #DEC-5910).
HUMAN UMBILICAL VEIN ENDOTHELIAL CELL CULTURE 
Human umbilical vein endothelial cells (HUVEC, Lonza, Walkersville, MD) were 
cultured in endothelial cell medium up to passage 5 as described previously [8]. EndMT 
was initiated by re-plating the HUVEC in RPMI1640, supplemented with 20% FCS, 1% 
Penicillin–Streptomycin, 2 mM L-glutamine, 5 U·mL−1 heparin, and 10 ng·mL−1 TGFβ1 
(Peprotech, NJ, USA). For shear stress experiments, HUVEC were plated on 1% gelatin-
coated µ-Slides (Ibidi, Martinsried, Germany) and grown to conluence prior to exposure 
to 20 dynes·cm-2 of unidirectional uniform laminar shear stress (LSS). LSS was generated 
using the Ibidi Pump System (Ibidi, Martinsried, Germany). 
3’UTR REPORTER ANALYSIS 
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Gene speciic 3’ UTR fragments were isolated from a cDNA pool derived from 
various human tissues using oligonucleotides extended with SgfI (GCGATCGC) and 
NotI (GCGGCCGC) restriction sequences at the sense and antisense primer (Table S1), 
respectively. Ampliication was performed using the DyNAzyme EXT PCR kit (Finnzymes, 
Vantaa, Finland) according to the manufacturer’s instructions. Amplicon size was validated 
by gel electrophoresis on 1% agarose gels. 3’UTR fragments were cloned into the SgfI/
NotI-sites of the psiCHECK-2 dual luciferase reporter vector (Promega, Madison, WI). COS-
7 cells were transfected with 100 ng/ml 3’UTR reporter plasmid and 50 nM miR-374b 
mimic or scrambled control (Life Technologies, Carlsbad, CA) using Lipofectamine2000 
(ThermoFisher, Waltham, MA). 48 h post-transfection, luciferase activity was assayed 
using the DualGlo Luciferase assay system (Promega, Madison, WI) and recorded for 1 s 
on a Luminoskan ASCENT (Thermo Scientiic, Waltham, MA).
PLASMIDS AND LENTIVIRAL EXPRESSION OF MIR-374B, SHRNA AND MAPK7 SIGNALING MEMBERS 
For lentiviral expression of miR-374b and small hairpin RNA (shRNA) against MAPK7 
signaling members, DNA oligonucleotides containing the endogenous miR-374b hairpin 
or speciic 21-mer targeting sequences for human MAP3K3, MAPK7, MEF2D or KLF4 (all 
Biolegio, Leiden, The Netherlands, Table S2) were cloned into the BamHI/EcoRI sites of 
the pGreenPuro shRNA expression vector (Systems Bioscience, CA, USA). Scrambled 
sequences were used as control. 
Gene-CDS fragments were isolated from a cDNA pool derived from various human 
tissues using oligonucleotides extended with EcoRI (GAATTC) and BamHI (GGATCC) 
restriction sequences at the sense and antisense primer (Table S3), respectively. 
Ampliication was performed using the DyNAzyme EXT PCR kit (Finnzymes, Vantaa, 
Finland) according to the manufacturer’s instructions. Amplicon size was validated 
by gel electrophoresis on 1% agarose gels. Gene-CDS fragments were cloned into the 
EcoRI/BamHI sites of the pCDH-CMV-MCS-EF1-Puro lentiviral expression vector (Systems 
Biosciences, Palo Alto, CA). Empty vectors served as control.
For lentiviral transduction, HEK293 cells were transfected with pGreenPuro or pCDH- 
CMV-MCS-EF1-Puro shuttle vectors and second-generation lentiviral helper plasmids 
using Endofectin (GeneCopoeia, MD, USA). Viral supernatants were collected every 24 
hours, supplemented with 6 µg·mL-1 polybrene and directly transferred to HUVEC cultures 
for two consecutive rounds. Transduced cells were selected for puromycin resistance 72 h 
post-transduction (4 µg·mL−1 puromycin) for 24 hours and reseeded into puromycin-free 
medium for the experiments.  
MICRORNA AND GENE TRANSCRIPT ANALYSIS  
Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA) according to 
manufacturer’s instructions. For microRNA transcript analyses, 20 ng of total RNA was 
reversely transcribed using the Taqman MicroRNA Reverse Transcription kit (Applied 
Biosystems) using microRNA-speciic stemloop primers (Table S4). For gene transcript 
analysis, 1 1 µg of total RNA was reversely transcribed using the RevertAid irst Strand 
cDNA synthesis kit (Applied Biosystems, Carlsbad, CA) according to manufacturer’s 
protocol.  Quantitive PCR expression analysis performed on a reaction mixture containing 
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10ng cDNA equivalent, 0.5 µM sense primers and 0.5 µM antisense primers (for 
microRNA primers see Table S4 and gene transcript primers see Table S5, all Biolegio, 
Leiden, The Netherlands). Analyses were run on Viia7 real-time PCR system (Applied 
Biosystems, Carlsbad, CA)
IMMNUNOFLUORESCENCE 
Heat-induced antigen retrieval was performed with 0.1 M Tris-HCl (pH 9.0, 80°C, 20 
mins) on the formalin ixated, parain-embedded sections prior to immunohistochemistry. 
Sections were incubated with primary antibodies at room temperature for 2 hours, 
followed by incubation with secondary antibodies at room temperature for 1 hour (Table 
S6). Detailed description of the imaging procedures is provided in the Supplementary 
Methods.
IMMUNOBLOTTING 
Whole cell lysates were prepared in RIPA bufer (Thermo Scientiic, IL, USA) 
supplemented with 1% protease inhibitor cocktail (Sigma-Aldrich, Germaby) and 1% 
HALT-phosphatase inhibitor cocktail (ThermoFisher Scientiic). Protein concentrations 
were determined using the detergent compatible protein assay (Bio-Rad, VA), according 
to manufacturer’s protocol. Equal amounts of protein were loaded on a 10% denaturing 
SDS–polyacrylamide gel and separated by gel electrophoresis (110V). Next proteins were 
blotted onto nitrocellulose membranes using the Trans-Blot Turbo System (Bio-Rad, 
AV) according to manufacturer’s instructions. Blots were blocked in Odyssey Blocking 
Bufer (Li-COR Biosciences, NE, USA) at room temperature for 30 mins and incubated at 
4°C with primary antibodies (Table S7) in Odyssey Blocking Bufer overnight, after which 
membranes were incubated with secondary antibodies (Table S7) in Odyssey Blocking 
Bufer at room temperature for 1 hour. Protein was detected using the Odyssey Infrared 
Imaging System (Li-COR Biosciences). Densitometric analysis was performed using 
Totallab 120 (Nonlinear Dynamics, Newcastle upon Tyne, England).
ANGIOGENIC SPROUTING CAPACITY 
10 µl of MatriGel (BD Biosciences, San Jose, CA) was solidiied in µ-Slide Angiogenesis 
(Ibidi, Martinsried, Germany). 10.000 cells per well were cultured on the solidiied MatriGel 
in endothelial growth medium and the formation of sprouts was analyzed by conventional 
light microscopic analysis after overnight incubation.
COLLAGEN CONTRACTION ASSAY 
Cells were suspended in a solution of rat tail Collagen type I (Corning, Corning, NY) 
containing 3 mg·mL-1 NaHCO3 and 0.1M Na2HPO4. Aliquots of 50 µL (containing 100.000 
cells and 0.5 mg Collagen type I) were solidiied at 37°C in a humidiied incubator with 5% 
CO2 for 30 mins. The collagen gels were released from the culture dishes by the addition 
of 2 ml endothelial growth medium and were imaged using a common Flatbed-scanner 
and allowed to contract for an additional 24 h. 
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The degree of gel contraction was determined by measuring the total gel area and 
dividing the areas of the contracted gels by the areas of the gels before contraction.
STATISTICAL ANALYSIS 
Data are presented as means ± s.e.m. N-values relate to independent experiments/
samples. P-values were calculated using one-way analysis of variance followed by 
Bonferroni’s post-hoc comparisons tests using Prism Graphpad (Graphpad Software, La 
Jolla, CA, USA). P < 0.05 was considered statistically signiicant.
RESULTS
MICRORNA-374B TARGETS MAPK7 SIGNALING 
 Database analysis (miRanda [19,20]) identiied 12 microRNAs that putatively target 
MAPK7 (Suppl.ig.1). Next, we cross-checked these microRNAs against other genes in 
the MAPK7 signaling cascade (Suppl.ig.1) and found that the miR-374 family (miR-374a 
and miR-374b) target not only MAPK7, but also its upstream activators Rac1, MAP3K3 
and MAP3K7. Moreover, miR-374 also putatively targets the downstream transcription 
factors of the myocyte enhancer factor (MEF)-2 family as well as Krüppel-like factor (KLF)-
4 (Suppl.ig.2). TGFβ1 induced the expression of miR-374a, miR-374b, miR-143, miR-24 and 
miR-410 in endothelial cells (p<0.05 vs unstimulated control cells), whereas it decreased 
the expression of miR-488 (p<0.05 vs unstimulated control cells). The expression of miR-
429, miR-200b, miR-200c, miR-183, miR-124 and miR-506 were unchanged (Suppl.ig.3) 
upon TGFβ1 treatment. 
MicroRNA-374a and miR-374b collectively have 1305 putative gene targets, of which 
527 and 434 are unique to miR-374a and miR-374b, respectively (Suppl.ig.2). 344 putative 
gene targets are shared between miR-374a and miR-374b. Analysis of genes within the 
MAPK7 signaling cascade indicates that MAP3K7 (TAK1), MAPK7 (ERK5), MEF2A and MEF2C 
are putative targets of miR-374a and miR-374b, whereas Rac1, MAP3K3 (MEKK3), MEF2D 
and KLF4 are targets of miR-374b only. None of the genes with in the MAPK7 signaling 
cascade where unique targets to miR-374a (Suppl.ig.2).
MICRORNA-374B AND MAPK7 ARE DIFFERENTIALLY EXPRESSED AT ATHEROPRONE REGIONS 
EndMT contributes to the formation of intimal hyperplasia [5], which is aggravated 
by the loss of protective MAPK7 signaling [12]. Cells co-expressing endothelial speciic 
molecule (ESM)-1 and the mesenchymal protein SM22α were abundantly present in the 
hyperplastic intima of the porcine trifurcation compared to the non-hyperplastic intima 
(11.5 vs 1.0%; p<0.001, ig.1a). In the atheroprone hyperplastic regions, endothelial MAPK7 
activity was decreased 2-fold (p=0.01) compared endothelial cells in the atheroprotected 
regions within the same trifurcation (ig.1b). 
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Figure 1. MicroRNA-374b and MAPK7 are diferentially expressed in neointimal lesions. Porcine intimal 
hyperplastic lesions contain myo-endothelial cells (myoEC) that co-express the endothelial cell marker ESM-1 (red) 
and mesenchymal cell marker SM22α (green). Nuclei are stained with DAPI (blue) (A). The activity of MAPK7 (pMAPK7, 
green) was is reduced in endothelial cells (ESM-1, red) in the atheroprone regions of the porcine trifurcation (B, n=5), 
whereas the expression of miR-374b was increased in the atheroprone areas compared to atheroprotected areas of 
the same porcine trifurcation (C, n=5). Mice were subjected to transverse aortic constriction (TAC). Eight weeks after 
TAC, myoEC that co-express the endothelial cell marker CD31 (red) and the mesenchymal cell marker SM22α (green) 
were detected at the areas exposed to disturbed low (D, n=5, *=ligation). The activity of MAPK7 (pMAPK7, green) 
was is reduced in endothelial cells (CD31, red) in the areas exposed to disturbed low compared to areas exposed to 
laminar low (E, n=5), which coincides with an increase in the expression of miR-374b (F, n=5). In vitro, endothelial 
cells treated with TGFβ1 were hyperplastic, which was inhibited by the ALK5-inhibitor SB431542 (G) and increased 
their expression of miR-374b (H, n=6). The expression of MAPK7 was reduced in TGFβ1-stimulated endothelial cells, 
compared to untreated control cells or endothelial cells treated with TGFβ1 and the ALK5-inhibitro SB431542 (I, n=6). 
The expression levels of miR-374b inversely associated with MAPK7 expression levels (J, n=6). Laminar luid shear 
stress (20 dyne·cm2) antagonized the cellular hypertrophy induced by TGFβ1 (K) in endothelial cells and inhibited the 
increase in miR-374b expression (L, n=5). Concurrently, when exposed to luid shear stress, MAPK7 expression was 
unaltered in TGFβ1-treated endothelial cells compared to unstimulated control cells (M, n=5). T-test for comparison 
between two groups; One-way ANOVA for analyses between multiple groups. *p<0.05, **p<0.01, ***p<0.001.
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We dissected the atheroprone and atheroprotected areas of the porcine trifurcation 
and found increased expression levels of miR-374b in the atheroprone regions (~3-fold, 
p=0.04, ig.1c).  Concurrently, in mice with transverse aortic banding, atheroprone regions 
characterized by disturbed luid shear stress were characterized by the accumulation of 
cells expressing both the endothelial marker CD31 and the mesenchymal protein SM22α 
(12.3%, ig.1d), indicative of EndMT. At these atheroprone sites, endothelial MAPK7 activity 
was decreased (1.6-fold, p=0.04, ig.1e), whereas the expression of miR-374b was elevated 
(4-fold, p=0.01, ig.1f).
In vitro, endothelial cells treated with TGFβ1 displayed apoptosis and hypertrophy 
(ig.1g) and increased their expression of miR-374b (~9-fold compared to non-stimulated 
cells, p<0.001), which was completely abolished by the addition of a small molecule 
inhibitor of ALK5 (SB431542)(ig.1h). The increase in miR-374b expression associated with 
decreased expression of MAPK7 (r2=0.797, p<0.001, ig.1i,j) and intermediates of MAPK7 
signaling, i.e. Rac1 (r2=0.595, p<0.01), MAP3K7 (r2=0.688, p<0.01), MAPK7 (r2=0.797, p<0.01), 
MEF2D (r2=0.682, p<0.001) and KLF4 (r2=0.555, p<0.01, Suppl. ig.4a), as well as a decreased 
expression of endothelial markers VE-Cadherin (r2=0.678, p<0.001) and eNOS (r2=0.546, 
p<0.01, Suppl.ig.4b) and increased expression of mesenchymal markers SM22α (r2=0.872, 
p<0.001) and CNN1 (r2=0.814, p<0.001, Suppl.ig.4c). 
Under LSS, endothelial cells aligned in the direction of low, indicating mechanosensory 
behavior (ig.1k). In contrast to the static cell cultures, endothelial cells exposed to LSS 
did not became hypertrophic and did not increase their expression of miR-374b, even 
when exogenous TGFβ1 was applied (ig.1l). Corroboratively, MAPK7 expression, which is 
diminished by TGFβ1 in static cultures, remained high under LSS even in the presence of 
TGFβ1 (ig.1m).
MIR-374B TARGETS MULTIPLE MEMBERS OF THE MAPK7 SIGNALING CASCADE 
 Computational analysis of putative miR-374b targets identiied multiple members of 
the MAPK7 signaling cascade (ig.2a). Reporter assays, wherein the 3’UTR regions of miR-
374b gene targets are coupled to the Luciferase gene, revealed that the MAPK7 Signaling 
members Rac1, MAP3K3, MAP3K7, MAPK7, MEF2d and KLF4 are genuine miR-374b target 
genes (ig.2b) as co-transfection of these reporter plasmids with miR-374b mimics reduced 
luciferase activity (all p<0.01). In contrast, co-transfection of reporter plasmids with a 
scrambled miR-374b sequence did not alter luciferase activity (ig.2b). MEF2a and MEF2c 
were identiied as putative gene targets of miR-374b by in silico analyses, however, co-
transfection of their respective reporter constructs with miR-374b mimics, did not result 
in decreased luciferase activity (ig.2b) implicating that MEF2a and MEF2c are not genuine 
targets of miR-374b. To establish if MAPK7 signaling members are factual endogenous 
miR-374b targets in mature endothelial cells, we lentivirally overexpressed miR-374b 
or its scrambled sequence. Unstimulated control cells readily expressed MAPK7 and its 
signaling members (ig.2c). Stimulation of mature endothelial cells with TGFβ1 drastically 
reduced expression of these molecules (ig.2c) to approx. 50% of control endothelial cells 
(all p<0.01). Endothelial cells that expressed miR-374b had reduced expression of MAP3K3 
(~33%, p<0.01), MAPK7 (~47%, p<0.01), MEF2d (~37%, p<0.01) and KLF4 (~42%, p<0.001) 
compared to endothelial cells treated with scrambled controls (ig.2c) indicating that miR-
374b decreases endogenous MAPK7 signaling.
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Figure 2. MicroRNA-374b interferes with MAPK7 signaling at multiple levels. In silico analysis (Tarbase [39]) 
reveals that miR-374b putatively targets multiple genes within the MAPK7 signaling cascade with diferent eicacies 
(miRSVR-scores indicate the predicted target site eicacy [20])(A). Co-transfection of 3’UTR reporter constructs with 
miR-374b mimics or scrambled control sequences in COS7 cells suggests that Rac1, MAP3K3, MAP3K7, MAPK7, MEF2D 
and KLF4 are genuine miR-374b target genes (B, n=5). Transfection of miR-374b mimics in endothelial cells mimics 
the TGFβ1-induced decrease in expression of MAPK7 signaling members (C,D; n=3). One-way ANOVA, *p<0.05, 
**p<0.01, ***p<0.001.
TGFβ-1 SUPPRESSES MAPK7 EXPRESSION THROUGH INDUCTION OF MIR-374B AND CAUSES 
ENDOTHELIAL-MESENCHYMAL TRANSITION 
We next questioned if ectopic expression of miR-374b in endothelial cells would 
facilitate EndMT. Lentiviral expression caused a ~4-fold increase of miR-374b in endothelial 
cells (ig.3a). Consequently, endothelial cells lost their typical cobblestone morphology 
and started to show signs of hypertrophy (ig.3b). Consistent with EndMT, the expression 
of typical endothelial cell markers, i.e. VE-Cadherin and eNOS, was lost (ig. 3b,c) whereas 
expression of mesenchymal cell markers, i.e. SM22α and Calponin 1 (CNN1), was induced 
(ig. 3b,c). Additionally, miR-374b gain-of-function in endothelial cells, reduced the ability 
to form capillary-like sprouts on Matrigel (ig.3d) and fostered the gain of contractile 
behavior (ig.3e), all consistent with mesenchymal transition.
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Figure 3. MicroRNA-374b gain-of-function induces EndMT. Transformation of endothelial cells with a lentivirus 
encoding the stemloop sequence of miR-374b increased its expression ~4-fold (A). MiR-374b expressing endothelial 
cells where hypertrophic and decreased their expression of the endothelial cell marker VE-cadherin and increased 
expression of the mesenchymal cell marker SM22α, compared to endothelial cells that expressed a scrambled 
control sequence (B). VE-Cadherin and eNOS expression were decreased in endothelial cells expressing miR-374b, 
whereas the expression of SM22α and CNN1 was increased (C). Endothelial cells expressing miR-374b had a reduced 
angiogenic sprouting capacity (D) and increased contractile capacity (E) compared to endothelial cells that expressed 
a scrambled control sequence. All n=5, T-test for comparison between two groups, *p<0.05, **p<0.01, ***p<0.001. 
LOSS OF SPECIFIC MIR-374B TARGETS INDUCES ENDOTHELIAL-MESENCHYMAL TRANSITION 
We questioned if the loss-of-function of speciic miR-374b targets would suice for 
EndMT induction and used a shRNA approach to speciically decrease MAP3K3, MAPK7, 
MEF2d or KLF4 expression in endothelial cells (Supl.ig.5). Decreased expression of MAPK7 
signaling members caused the dissociation of endothelial cell-cell contacts and decreased 
the expression of VE-cadherin. Concurrently, the expression of SM22α was increased upon 
loss of MAPK7 signaling (ig.4a). The expression of endothelial markers VE-Cadherin and 
eNOS was abrogated and the expression of mesenchymal markers SM22α and Calponin 
was induced (ig.4b,c). Moreover, angiogenic sprouting ability decreased (ig.4d) and In 
contrast to the EndMT induction by the loss of downstream MAPK7 signaling members, 
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MAP3K3 deiciency did not alter the expression of endothelial, nor mesenchymal 
marker proteins (ig.4b,c). Yet, angiogenic sprouting ability was lost (ig.4d) and contractile 
behavior acquired (ig.4e) by endothelial cells deicient in MAP3K3.
Figure 4. Knockdown of speciic microRNA-374b gene targets induces EndMT. Transformation of 
endothelial cells with lentiviruses encoding shRNA sequences to MAP3K3, MAPK7, MEF2D and KLF4 induced cellular 
hypertrophy, decreased the expression of the endothelial cell marker VE-cadherin, and increased expression of the 
mesenchymal cell marker SM22α, compared to endothelial cells that expressed scrambled control sequences (A). 
VE-Cadherin and eNOS expression were decreased in endothelial cells expressing shMAPK7, shMEF2D and shKLF4, 
whereas their expression was unaltered in endothelial cells expressing shMAP3K3. The expression of SM22α and 
CNN1 was increased in endothelial cells expressing shMAPK7, shMEF2D and shKLF4 (B,C). Endothelial cells expressing 
shRNA sequences to MAP3K3, MAPK7, MEF2D and KLF4 had a reduced angiogenic sprouting capacity (D) and 
increased contractile capacity (E) compared to endothelial cells that expressed a scrambled control sequence. All 
n=6, One-way ANOVA, *p<0.05, **p<0.01, ***p<0.001. 
MAINTENANCE OF ENDOTHELIAL MAPK7 SIGNALING ABROGATES MIR-374B-INDUCED 
ENDOTHELIAL-MESENCHYMAL TRANSITION 
     To investigate if restoration of MAPK7 signaling members could block miR-374b-induced 
EndMT, we lentivirally expressed miR-374b together with the protein-coding sequences 
of MAP3K3, MAPK7, MEF2D and KLF4 (ig.5a). VE-cadherin expression was reduced in 
endothelial cells that express miR-374b, whereas the expression of SM22α was induced. 
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In contrast, cells that co-expressed MAP3K3 or MAPK7 together with miR-374b 
maintained their expression of VE-cadherin and eNOS and were refractory to the 
induction of SM22a and Calponin by miR-374b (ig.5b-d), whereas cells co-expressing KLF4 
and miR-374b maintained only the expression of eNOS (ig.5c,d). Restoration of MEF2D 
in endothelial cells expressing miR-374b, inhibited the expression of the mesenchymal 
proteins SM22α and Calponin, but failed to maintain the expression of endothelial 
marker proteins VE-Cadherin and eNOS (ig.5b-d). Restoration of all MAPK7 signaling 
members in endothelial cells expressing miR-374b maintained the angiogenic ability 
(ig.5e) and precluded the contractile behavior induced by miR-374b expression (ig.5f). 
Figure 5. Re-expression of microRNA-374b target genes inhibits EndMT. The expression of miR-374b target 
genes was restored by lentiviral transformation using plasmids encoding the coding sequences (CDS) of MAP3K3, 
MAPK7, MEF2D and KLF4 in endothelial cells that overexpress miR-374b. The (re-)expression of these genes was 
conirmed by qPCR (A). Endothelial cells that express miR-374b decreased their expression of VE-Cadherin and 
increased their expression of SM22α. These efects were counteracted by the expression of MAPK7 signaling members 
(B-D). Endothelial cells that expressed MAP3K3, MAPK7, MEF2D or KLF4 have an enhanced angiogenic sprouting 
capacity (E) and decreased contractile capacity (F) compared to endothelial cell that express miR-374b. The levels of 
angiogenic sprouting and contractile behavior were similar to that of endothelial cells transformed using scrambled 
control sequences. All n=5, One-way ANOVA, *p<0.05, **p<0.01, ***p<0.001. 
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MICRORNA-374B IS INCREASED IN HUMAN CORONARY ARTERY STENOSIS 
Lastly, we assessed the expression levels of miR-374b and MAPK7 in samples from 
progressive human coronary artery stenosis. Increasing intima-media thickness (IMT) 
associates with the severity of coronary stenosis (ig.6a,b) and increased miR-374b 
expression (ig.6c). Moreover, miR-374b levels associated with IMT (r2=0.5874, p<0.01, 
ig.6d). Conversely, MAPK7 expression levels progressively decrease with increasing 
stenosis (ig.6e). In human coronary artery stenosis, the levels of miR-374b are associated 
with the expression levels of MAPK7 (r2=0.3341,p<0.01, ig.6f), suggesting that the miR-
374b-induced loss of MAPK7 signaling might contribute to stenosis development and 
progression.
Figure 6. MicroRNA-374b is increased in human coronary artery stenosis. Verhoef stain of progressive 
coronary artery stenosis characterized by an increasing intima/media ratio (A). MiR-374b expression is elevated in 
human coronary artery stenosis and correlated to the degree of stenosis (B). Conversely, the expression levels of 
MAPK7 decrease with progressive stenosis and are inversely associated to the expression level of miR-374b (C). One-
way ANOVA for comparison between groups, Pearson correlations, two-tailed. **p<0.01, ***p<0.001.




Here, we show that EndMT occurs in intimal hyperplasia and neointima formation 
and is governed in part by microRNA-374b. We have previously identiied the inhibitory 
efects of MAPK7 signaling on EndMT [5] and questioned if MAPK7 signaling is silenced 
at atheroprone areas in the vasculature. We uncovered that the TGFβ-induced microRNA-
374b silences MAPK7 signaling and induces EndMT in the absence of exogenous TGFβ. 
Moreover, restoration of MAPK7 signaling abrogated these pathological efects in 
endothelial cells expressing miR-374b. Interestingly, we uncovered that miR-374b levels are 
elevated in human coronary artery disease and inversely related with MAPK7 expression. 
These data suggest that the TGFβ-miR-374b-MAPK7 axis plays a detrimental role in the 
induction of EndMT during  intimal hyperplasia and neointima formation and might pose 
an interesting target for antiatherosclerosis therapy.
Atherosclerosis is characterized by systemic risk factors, and anti-atherosclerosis 
therapies are focused on maintaining these systemic contributors within clinically 
acceptable ranges (e.g. anti-hypertensives, anti-inlammatory agents and lipid-lowering 
drugs) [21-23]. Yet, it is becoming increasingly clear that focal risk factors, such as luid 
shear stress levels, play a major role in the pathogenesis of atherosclerosis. Indeed, 
endothelial MAPK7 signaling has been identiied as a major contributor to the initiation 
and severity of atherosclerosis [5,12]. The atheroprotective efects of MAPK7 include anti-
inlammatory efects, the reduction of oxidative stress and the increased biosynthesis of 
Nitric Oxide [24-26], which decrease smooth muscle cell proliferation and inlammatory 
cell iniltration into the atherosclerotic neointima. We recently uncovered that endothelial 
MAPK7 signaling additionally confers atheroprotective efects through the inhibition of 
EndMT [5], a process increasingly recognized in the initial phases of intimal hyperplasia and 
neointima formation [5,7,27,28]. Indeed, the inhibition of MAPK7 activity by SUMOylation 
increases atherosclerosis [29,30] and endothelial speciic deletion of MAPK7 aggravates 
atherosclerosis development and progression [12].
MicroRNAs are involved in atherosclerosis development and progression [31], and 
microRNA-based therapies that target endothelial dysfunction reduce atherosclerosis 
development in mice [32-34]. MicroRNAs regulate gene expression by imperfect base-
pairing with the 3’ UTR region of their gene target, causing translational repression [35]. 
This imperfect base-pairing allows for gene target multiplicity, wherein one microRNA 
targets multiple genes with a speciic signaling cascade [36]. Hence, we questioned if 
MAPK7 signaling would be regulated by a speciic microRNAs and if such microRNA would 
be diferentially expressed at atheroprone and atheroprotected sites. We found that miR-
374b expression is elevated at atheroprone areas in the vessel wall and is associated with 
decreased MAPK7 activity.
A role for miR-374b in atherosclerosis has not been described before, yet elevated 
levels of miR-374b have been reported in the plasma of acute coronary syndrome patients 
[37] and in stenosis of the arteriovenous istulae of dialysis patients [38], however its 
relevance in these pathologies remains elusive. Here, we show that miR-374b is a shear 
stress-sensitive microRNA that targets MAPK7 signaling at multiple levels ranging from 
its upstream activating kinase (i.e. MAP3K3) to its downstream transcription factor (i.e. 
KLF4). The loss of MAPK7 signaling culminates in the induction of EndMT in the absence 
of exogenous triggers, which contributes to intimal hyperplasia and neointima formation. 
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Moreover, we show that restoration of MAPK7 signaling in endothelial cell 
that express miR-374b abolishes EndMT. From a clinical perspective, our data 
imply that targeting miR-374b in atherosclerosis might restore endothelial 
MAPK7 activity and limit neointima formation through the inhibition of EndMT.
Figure 7. Schematic representation of miR-374/MAPK7 signaling in atheroprone and atheroprotected 
areas. High laminar luid shear stress induces the expression and activation of atheroprotective MAPK7 signaling, 
which maintains endothelial homeostasis and inhibits the proatherogenic TGFβ signaling (A). At areas of low, or 
non-uniform disturbed shear stress, MAPK7 activity is low and its expression is decreased by the TGFβ1-induced miR-
374b, resulting in enhanced TGFβ signaling in endothelial cells, culminating in EndMT (B).
In conclusion, here we show that miR-374b expression is elevated in coronary artery 
stenosis and neointima formation and abolishes endothelial MAPK7 activity, culminating 
in EndMT. The restoration of endothelial MAPK7 activity surmounts the induction of 
EndMT by miR-374b. 
 





 Human coronary arteries were obtained from autopsy specimens from 10 patients 
that died from an acute coronary episode at the Heart Institute (InCor), Sao Paulo, Brazil. 
Coronary arteries were ixed in neutral bufered formalin prior to parain embedding. 
During necropsy each dissected coronary artery was ixed in neutral-bufered formalin 
with constant perfusion at a quasi-normal perfusion pressure. The mean age of subjects 
contributing pathology specimens was 65 years. Hypertension was recent in 9 subjects, 
and diabetes in 6. Five individuals were active smokers. Next-of-kin gave informed 
consent and the investigation was performed according to institutional guidelines (InCor, 
Sao Paulo #SDC 3723/11/141 and #CAPPesq 482/11) and the Declaration of Helsinki.
Human coronary artery samples were deparainized using 100% Xylol for 10 mins and 
rehydrated using a series of EtOH solution of decreasing concentration (100%; 75%; 50%; 
0%, all 10 mins). Samples were stained in Verhoef’s solution (92 mM hematoxylin, 137 
mM FeCl3, 27 mM KI, 4 mM I2 in 55% EtOH) at room temperature for 1 hour. Samples were 
rinsed in tap water and diferentiated in FeCl3 (123 mM in dH2O) for 1 minute and treated 
with Sodium Thiosulphate (316 mM in dH2O) at room temperature for 1 min. Samples 
were dehydrated using increasing concentrations of EtOH (50%; 75%; 100%, all 1 min) and 
cleared in 100% xylene. Samples were mounted in Permount resinous mounting medium.
ANIMALS AND SURGICAL PROCEDURES  
Porcine abdominal trifurcations were obtained from healthy male slaughterhouse 
Yorkshire pigs (12-13 weeks of age; body weight 30-35 kg, n =3, V.O.F. van Beek, Lelystad, 
The Netherlands). Animals were fed a normal diet and were euthanized under anesthesia 
(ketamine (Nimatek) and midazolam with a bolus of pentobarbital and heparin (Actrapid)). 
Male C57Bl/6j wild-type mice (8-12 weeks of age, n=8, Harlan, Horst, The Netherlands) 
were subjected to transverse aortic constriction under anesthesia (2% Isoluorane (Forene/
Abbott, The Netherlands) and oxygen) and analgesia (Carprofen, 5 mg·kg-1). Briely, an 
incision was made in the second intercostal space and a small incision was made in the 
parietal pleura to expose the ascending loop of the aorta. The aorta was supported with a 
27G needle and a suture was placed around the aorta, drawn tight after which the needle 
was removed. Next, the pleura, muscle layers, and skin were closed by sutures. Animals 
received post-operative analgesia (Carprofen, 5 mg·kg-1·day-1 for 48 h). Animals were kept 
on a 12 h light:dark cycle with ad libitum access to standard laboratory chow and water. 
Eight weeks after aortic constriction, animals were sacriiced under deep anesthesia [3% 
Isoluorane (Forene/Abbott, The Netherlands] by exsanguination, after which the thoracic 
aorta was explanted. Experiments on mice were approved by the local Institutional Animal 
Care and Use Committee (University of Groningen, #DEC-5910).
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HUMAN UMBILICAL VEIN ENDOTHELIAL CELL CULTURE 
Human umbilical vein endothelial cells (HUVEC, Lonza, Walkersville, MD) were 
cultured on 1% gelatin (#G9391 Sigma-Aldrich, St. Louis, MO) coated tissue culture plastics 
in endothelial cell medium up to passage 5 in RPMI1640 (#BE12-702F, Lonza, Verviers, 
Belgium) supplemented with 20% fetal bovine serum (#SH30071, HyClone Laboratories, 
Logan, UT), 50 µg·ml1 ECGF (own isolation according to Burgess et al 1985)[39], 2 mM 
L-glutamine (#G7513, Sigma-Aldrich, St. Louis, MO), 1% Penicillin/Streptomycin (#P4333, 
Sigma-Aldrich, St. Louis, MO) and 5 U·ml-1 heparin (Leo Pharma, Ballerup, Denmark). 
EndMT was initiated by re-plating the HUVEC in RPMI1640, supplemented with 20% FCS, 
1% Penicillin–Streptomycin, 2 mM L-glutamine, 5 U·mL−1 heparin, and 10 ng·mL−1 TGFβ1 
(Peprotech, NJ, USA) for 96 hours. For shear stress experiments, HUVEC were plated on 
1% gelatin-coated µ-Slides (Ibidi, Martinsried, Germany) and grown to conluence prior 
to exposure to 20 dynes·cm-2 of unidirectional uniform laminar shear stress (LSS). LSS 
was generated using the Ibidi Pump System (Ibidi, Martinsried, Germany) according to 
manufacturer’s instructions. 
3’UTR REPORTER ANALYSIS 
Gene speciic 3’UTR fragments were isolated from a cDNA pool derived from 
various human tissues using oligonucleotides extended with SgfI (GCGATCGC) and 
NotI (GCGGCCGC) restriction sequences at the sense and antisense primer (Table S1), 
respectively. Ampliication was performed using the DyNAzyme EXT PCR kit (Finnzymes, 
Vantaa, Finland) according to the manufacturer’s instructions. 10 ng of cDNA was ampliied 
in a 50 µl reaction volume containing 50 mM Tris-HCl (pH 9.0), 1.5 mM MgCl2, 15 mM 
(NH4)2SO3, 0.1% Triton X-100, 200 µM dNTPs, 0.6 µM 3’UTR primers and 2U DyNAzyme EXT 
DNA Polymerase (all Finnzymes, Vantaa, Finland) in a Biometra TProfessional thermocycler 
(Biometra, Göttingen, Germany) using an initial denaturation step of 94°C for 5 mins and 
30 cycles of 94°C for 30 sec, 58-72°C for 2 mins, and 72°C for 2 mins, followed by a inal 
extension step of 72°C for 10 mins. The reaction was halted at 82°C for 5 mins. 
Amplicon sizes were validated by gel electrophoresis on 1% agarose gels and 
amplicons were dissected from the gels. 3’UTR fragments were puriied using the 
QIAquick PCR Puriication Kit (#28104, Qiagen, Venlo, The Netherlands) according to 
manufacturer’s protocol. Purity and concentration of 3’UTR fragments was determines 
spectrophotometrically on a Nanodrop 1000 (ThermoFisher, Waltham, MA). 3’UTR 
fragments were inserted into the SgfI/NotI (both Fermentas, Vilnius, Lithuania)-linearized 
psiCHECK-2 dual luciferase reporter vector (Promega, Madison, WI) using T4 DNA Ligase 
(Sigma-Aldrich, St. Louis, MO). 3’UTR-containing plasmids were ampliied in competent 
TOP10 E.coli (Invitrogen, Carlsbad, CA) and plasmids were isolated using the QIAprep Spin 
Miniprep Kit (Qiagen, Venlo, The Netherlands) according to manufacturer’s instructions. 
COS-7 cells were transfected with 100 ng/ml 3’UTR reporter plasmid and 50 nM miR-374b 
mimic or scrambled control (Life Technologies, Carlsbad, CA) using Lipofectamine2000 
(ThermoFisher, Waltham, MA). 48 h post-transfection, luciferase activity was assayed 
using the DualGlo Luciferase assay system (Promega, Madison, WI) and recorded for 1 s 
on a Luminoskan ASCENT (Thermo Scientiic, Waltham, MA).
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PLASMIDS AND LENTIVIRAL EXPRESSION OF MIR-374B, SHRNA AND MAPK7 SIGNALING MEMBERS 
For lentiviral expression of miR-374b and small hairpin RNA (shRNA) against MAPK7 
signaling members, equimolar amounts of DNA oligonucleotides  containing the 
endogenous miR-374b hairpin or speciic 21-mer targeting sequences for human MAP3K3, 
MAPK7, MEF2D or KLF4 (all Biolegio, Leiden, The Netherlands, Table S2) were annealed in 
a 100 µl reaction volume, containing 100 µM sense and antisense oligonucleotides, 10 
mM Tris-HCl (pH 8.0), 50 mM NaCl and 1 mM EDTA. Annealing was performed by heating 
the reaction mixture to 98°C  for 5 mins and cooling the reaction mixture at 1.5°C·min-1 to 
20°C in a Biometra TProfessional thermocycler. Duplexed oligonucleotides were cloned 
into the BamHI/EcoRI (both Fermentas, Vilnius, Lithuania)-linearized pGreenPuro shRNA 
expression vector (Systems Bioscience, CA, USA) using T4 DNA Ligase (Sigma-Aldrich, St. 
Louis, MO). Scrambled sequences were used as control. 
Gene-CDS fragments were isolated from a cDNA pool derived from various human 
tissues using oligonucleotides extended with EcoRI (GAATTC) and BamHI (GGATCC) 
restriction sequences at the sense and antisense primer (Table S3), respectively. 
Ampliication was performed using the DyNAzyme EXT PCR kit (Finnzymes, Vantaa, 
Finland) according to the manufacturer’s instructions. 10 ng of cDNA was ampliied in a 
50 µl reaction volume containing 50 mM Tris-HCl (pH 9.0), 1.5 mM MgCl2, 15 mM (NH4)2SO3, 
0.1% Triton X-100, 200 µM dNTPs, 0.6 µM 3’UTR primers and 2U DyNAzyme EXT DNA 
Polymerase (all Finnzymes, Vantaa, Finland) in a Biometra TProfessional thermocycler 
using an initial denaturation step of 94°C for 5 mins and 30 cycles of 94°C for 30 sec, 
58-72°C for 2 mins, and 72°C for 2 mins, followed by a inal extension step of 72°C for 
10 mins. The reaction was halted at 82°C for 5 mins. Amplicon size was validated by gel 
electrophoresis on 1% agarose gels and amplicons were dissected from the gels. 3’UTR 
fragments were puriied using the QIAquick PCR Puriication Kit (#28104, Qiagen, Venlo, 
The Netherlands) according to manufacturer’s protocol. Purity and concentration of 3’UTR 
fragments was determines spectrophotometrically on a Nanodrop 1000 (ThermoFisher, 
Waltham, MA). Gene-CDS fragments were cloned into the EcoRI/BamHI sites of the pCDH-
CMV-MCS-EF1-Puro lentiviral expression vector (Systems Biosciences, Palo Alto, CA) using 
T4 DNA Ligase (Sigma-Aldrich, St. Louis, MO). Empty vectors served as control.
ShRNA and Gene-CDS-containing plasmids were ampliied in competent TOP10 E.coli 
(Invitrogen, Carlsbad, CA) and plasmids were isolated using the QIAprep Spin Miniprep Kit 
(Qiagen, Venlo, The Netherlands) according to manufacturer’s instructions. For lentiviral 
transduction, 1.0·106 HEK293 cells were transfected with 1 µg pGreenPuro or pCDH-CMV-
MCS-EF1-Puro shuttle vectors and 1 µg second-generation lentiviral helper plasmids 
using Endofectin (GeneCopoeia, MD, USA). Viral supernatants were collected every 24 
hours, supplemented with 6 µg·mL-1 polybrene and directly transferred to HUVEC cultures 
for two consecutive rounds. Transduced cells were selected for puromycin resistance 72 h 
post-transduction (4 µg·mL−1 puromycin) for 24 hours and reseeded into puromycin-free 
medium for the experiments.  
MICRORNA AND GENE TRANSCRIPT ANALYSIS 
Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA) according to 
manufacturer’s instructions. In brief, 1·106 cells or 10 mg of tissue was homogenized in 1 
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ml TRIzol reagent and supplemented 0.2 ml Chloroform. After centrifugation 
(12.000xg for 15 min) the aqueous phase was supplemented with 0.5 ml 2-propanol and 
the RNA pelleted by centrifugation (12.000xg for 10 min). RNA was further puriied using 
two consecutive washes with 75% EtOH. RNA integrity was validated on 2% agarose 
gels and RNA purity and concentration were determined spectrophotometrically on a 
Nanodrop 1000 (ThermoFisher, Waltham, MA). For microRNA transcript analyses, 20 ng of 
total RNA was reversely transcribed using the Taqman MicroRNA Reverse Transcription kit 
(Applied Biosystems) in a 10 µl reaction volume containing 1 µl 10x RT reaction bufer, 1.6 
µM microRNA-speciic stemloop primers (Table S4), 1 mM dNTPs, and 3U RT enzyme (all 
Taqman, ThermoFisher, Waltham, MA) in a Biometra TProfessional thermocycler at 16°C 
for 30 mins, 42°C for 60 mins, and the reaction was stopped at 85°C for 5 mins. For gene 
transcript analysis, 1 µg of total RNA was reversely transcribed using the RevertAid First 
Strand cDNA Synthesis Kit (Applied Biosystems, Carlsbad, CA) in a in a 20 µl reaction volume 
containing 4 µl 5x RT reaction bufer, 5 µM random hexamer primers, 20U RiboLock RNase 
Inhibitor, 1 mM dNTP, and 200U RT enzyme (all Fermentas/ThermoFisher, Waltham, MA) in 
a Biometra TProfessional thermocycler at 25°C for 5 mins, 42°C for 60 mins, and the reaction 
was stopped at 70°C for 5 mins. Quantitative PCR expression analysis was performed on 
a reaction mixture containing 1-10 ng cDNA equivalent, 0.5 µM sense primers and 0.5 µM 
antisense primers (for microRNA primers see Table S4 and gene transcript primers see 
Table S5, all Biolegio, Leiden, The Netherlands) and FastStart SYBR Green (Roche, Almere, 
The Netherlands). Analyses were run on a Viia7 real-time PCR system (Applied Biosystems, 
Carlsbad, CA) using an initial denaturation step of 94°C for 5 mins and 40 cycles of 94°C 
for 30 sec, 60°C for 1 min. Cycle thresholds (Ct) values were determined at the middle of 
the linear phase. MicroRNA expression was normalized against the expression of RNU6B 
and mRNA expression levels were normalized against the expression of GAPDH prior to 
normalization against control samples.
IMMNUNOFLUORESCENCE  
Heat-induced antigen retrieval was performed with 0.1 M Tris-HCl (pH 9.0, 80°C, 20 
mins) on the formalin ixated, parain-embedded sections prior to immunohistochemistry. 
Sections were allowed to cool to room temperature for 45 mins, and incubated with 
2%BSA/2% normal donkey serum in PBS for 20 mins. Sections were incubated with primary 
antibodies (Table S6) at room temperature for 2 hours, followed by extensive washing in 
TBS-Tween (0.05%). Subsequently, samples were incubated with secondary antibodies in 
DAPI/PBS at room temperature for 1 hour (Table S6) and mounted in CitiFluor AP1 (Electron 
Microscopy Sciences, Hatield, PA). Overview images of porcine aortic trifurcation tissue 
and murine TAC tissue were obtained through ×10 (Plan-Neoluar 0.4 NA, dry, Ph2) and 
×20 (Plan-Neoluar, 1.30 NA, dry, DIC) objectives of an upright epiluorescence microscope 
(Zeiss AxioObserver Z1), controlled by TissueFAXS (TissueGnostics GmbH, Vienna, Austria) 
and analyzed using TissueQuest software (TissueGnostics GmbH, Vienna, Austria). 
Confocal images were obtained using a Leica SP8 spectral confocal microscope through a 
×63 (HCX PL APO 1.40 NA, oil) objective. 555 and 647 channels were scanned sequentially. 
Images were analyzed using Imaris 7.2.1 (Bitplane AG, Zürich, Switzerland), z-stacks were 
created using ImageJ version 1.43u (NIH, USA). 




Whole cell lysates were prepared in RIPA bufer (Thermo Scientiic, IL, USA) 
supplemented with 1% protease inhibitor cocktail (Sigma-Aldrich, Germaby) and 1% 
HALT-phosphatase inhibitor cocktail (ThermoFisher Scientiic). Protein concentrations 
were determined using the detergent compatible protein assay (Bio-Rad, VA), according 
to manufacturer’s protocol. Equal amounts of protein were loaded on a 10% denaturing 
SDS–polyacrylamide gel and separated by gel electrophoresis (110V). Next proteins were 
blotted onto nitrocellulose membranes using the Trans-Blot Turbo System (Bio-Rad, AV) at 
2.5A for 7 mins, according to manufacturer’s instructions. Blots were incubated in Odyssey 
Blocking Bufer (Li-COR Biosciences, NE, USA) in TBS at room temperature for 30 mins and 
incubated at 4°C with primary antibodies (Table S7) in Odyssey Blocking Bufer overnight. 
After extensive washes with TBST, membranes were incubated with secondary antibodies 
(Table S7) in Odyssey Blocking Bufer at room temperature for 1 hour. Protein was detected 
using the Odyssey Infrared Imaging System (Li-COR Biosciences). Densitometric analysis 
was performed using Totallab 120 (Nonlinear Dynamics, Newcastle upon Tyne, England) 
set for automatic lane detection, Rolling ball background subtraction (20 pixel radius) and 
automatic lane detection (minimum slope=100; Noise reduction = 5%, % Max peak=1). 
Lane intensities were corrected for protein-loading using the intensities of GAPDH and 
normalized to the average intensity of control samples.
ANGIOGENIC SPROUTING CAPACITY  
10 µl of MatriGel (BD Biosciences, San Jose, CA) was solidiied in µ-Slide Angiogenesis 
(Ibidi, Martinsried, Germany). 15,000 cells per well were cultured on the solidiied MatriGel 
in endothelial growth medium and the formation of sprouts was analyzed by conventional 
light microscopic analysis after overnight incubation. The number of hexagonal shapes 
per well was quantiied manually.
COLLAGEN CONTRACTION ASSAY 
Cells were suspended in a solution of rat tail Collagen type I (Corning, Corning, NY) 
containing 3 mg·mL-1 NaHCO3 and 0.1M Na2HPO4. Aliquots of 50 µL (containing 100.000 
cells and 0.5 mg Collagen type I) were solidiied at 37°C in a humidiied incubator with 5% 
CO2 for 30 mins. The collagen gels were released from the culture dishes by the addition of 
2 ml endothelial growth medium and were imaged using a common Flatbed-scanner and 
allowed to contract for an additional 24 h. The degree of gel contraction was determined 
by measuring the total gel area and dividing the areas of the contracted gels by the areas 
of the gels before contraction.
STATISTICAL ANALYSIS  
Data are presented as means ± s.e.m. N-values relate to independent experiments/
samples. P-values were calculated using one-way analysis of variance followed by 
Bonferroni’s post-hoc comparisons tests using Prism Graphpad (Graphpad Software, La 




Supplementary igure 1. In silico analysis identiies miR-374 as putative regulator of MAPK7 signaling. 
(A) Overview of the MAPK7 signaling pathway containing the upstream activators Rac1, MAP3K7 (TAK1), MAP3K3 
(MEKK3), MAP2K5 (MEK5), MAPK7 (ERK5), and the downstream transcription factors MEF2A-D and KLF4. (B) In silico 
analysis (miRanda(40, 41)) identiies 12 microRNAs that target MAPK7. SVR-scores indicate the predicted target site 
eicacy.(41) (C) In silico analysis of genes within MAPK7 signaling targeted by microRNA-374, -429, -200b/c, -143, -24, 
-488, -410, -183, -124 and miR-506. The miR-374 family targets 8/9 genes in the MAPK7 signaling pathway. 
Supplemental igure 2. MicroRNA-374b targets MAPK7 signaling. In silico analysis (TarBase(42)) reveals that 
miR-374a and miR-374b collectively have 1305 putative gene targets, of which 527 and 434 are unique to miR-374a 
and miR-374b, respectively. 344 putative gene targets are shared between miR-374a and miR-374b. Analysis of genes 
within the MAPK7 signaling cascade indicates that MAP3K7 (TAK1), MAPK7 (ERK5), MEF2A and MEF2C are putative 
targets of miR-374a and miR-374b, whereas Rac1, MAP3K3 (MEKK3), MEF2D and KLF4 are targets of miR-374b only.
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Supplemental igure 3. TGFβ1-induced microRNA expression. TGFβ1 induced the expression of miR-374a, miR-
374b, miR-143, miR-24 and miR-410 in endothelial cells (p<0.05 vs unstimulated control cells), whereas it decreased 
the expression of miR-488 (p<0.05 vs unstimulated control cells). The expression of miR-429, miR-200b, miR-200c, 




Supplemental igure 4. miR-374b expression levels associate with decreased expression of MAPK7 
signaling members and EndMT. The increased expression of miR-374b in endothelial cells treated with TGFβ1 
(black) compared to TGFβ1 and SB431542-treated endothelial cells (dark grey) or non-stimulated endothelial cells 
(light grey) were associate with decreased expression of MAPK7 signaling members RAC1, MAP3K3, MAPK7, MEF2D 
and KLF4 (A), and associated with decreased expression of endothelial cell markers (VE-Cadherin and eNOS; B) and 
increased expression of mesenchymal cell markers (SM22α and CNN1; C). n=4, Pearson correlation, two-tailed.
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Supplemental igure 5. RNAi-mediated repression of MAPK7 Signaling members. Lentiviral expression 
of shRNA oligonucleotides against MAPK7 signaling members reduced their expression >2-fold compared to 





Table S1. Primers used for 3’-UTR-reporter construct preparations.
3’-UTR R e f e r e n c e 
Sequence
Sense Primer (5’ → 3’) Antisense Primer (5’ → 3’)
KLF4 NM_004235 ATCCCAGACAGTGGATATG CAGATAAAATATTATAGGTT
MAP3K3 NM_203351 GCTCTCACGGCCACACAGCT CTGATATAAATGATCCCTTTTATTG
MAP3K7 NM_003188 TTCTCTGGGACCGTTACATT CAAATACATGAGAAAACAATC
MAPK7 NM_139032 GGCCCCCAGCCTGTGCCTTG CAGGTGCAGAAGGGAACCTT
MEF2A NM_001319206 GGCTTCCAAGCTGATGTTTG AGCATTGTCTTCACCATTTG
MEF2C NM_001193347 TCAGATTATTACTTACTAGT TCACTAAGAAAGCCAGTAAC
MEF2D NM_005920 CGATTCCCACTCCCCTCCTC ATCAGAAACGTGTATTCTTT
RAC1 NM_018890 ATGTCTCAGCCCCTCGTTCT ATGATTCAAGGATTTATTAA
All primers were obtained from Sigma-Aldrich, MO.
Table S2. Oligos used for lentiviral miR-374b and shRNA expression.











All primers were obtained from Sigma-Aldrich, MO.
Table S3. Primers used for the cloning of MAPK7 signaling members.
Gene R e f e r e n c e 
Sequence
Sense Primer (5’ → 3’) Antisense Primer (5’ → 3’)
KLF4-CDS NM_004235 ATGGCTGTCAGCGACGCGCTGCTCC AAAATGCCTCTTCATGT
MAP3K3-CDS NM_203351 ATGGACGAACAGGAGGCATTGAAC GTACATGAGCTGTGCAAAGTGGTG
MAPK7-CDS NM_139032 ATGGCCGAGCCTCTGAAGGAGGAAGA GGGGTCCTGGAGGTCAGGCAGGT
MEF2D-CDS NM_005920 ATGGGGAGGAAAAAGATTCAGATCC CTTTAATGTCCAGGTATC
All primers were obtained from Sigma-Aldrich, MO.
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Table S4. Primers used for microRNA transcript analysis.








































Ampliication reactions for mature microRNAs used the same antisense 
primer (5’-CCAGTGCAGGGTCCGAGGTCCG-3’). All primers were 
obtained from Sigma-Aldrich, MO.
Table S5. Primers used for mRNA transcript analysis.
Gene Name Reference Sequence Sense Primer (5’ → 3’) Antisense Primer (5’ → 3’)
CDH5 NM_001795 GTTCACCTTCTGCGAGGATA GTAGCTGGTGGTGTCCATCT
CNN1 NM_001308341 CCAACCATACACAGGTGCAG TCACCTTGTTTCCTTTCGTCTT
GAPDH NM_002046 AGCCACATCGCTCAGACAC GCCCAATACGACCAAATCC
KLF4 NM_004235 GGGAGAAGACACTGCGTCA GGAAGCACTGGGGGAAGT
MAP3K3 NM_203351 ACGGTGGTTTCTCTGTCAGC AAGGAAAGCAGACGTGTGGA
MAP3K7 NM_003188 AACTCCATCCCAATGGCTTA TTGGGCACGGTGCTAGAG
MAPK7 NM_139032 CCTGATGTCAACCTTGTGACC CCTTTGGTGTGCCTGAGAAC
MEF2D NM_005920 AACGCCGACATCATCGAG GGCTCTGTTCCAGCGAGT
NOS3 NM_000603 CACATGGCCTTGGACTGAA CAGAGCCCTGGCCTTTTC
RAC1 NM_018890 CTGATGCAGGCCATCAAGT CAGGAAATGCATTGGTTGTG
TAGLN NM_003186 CTGAGGACTATGGGGTCATC TAGTGCCCATCATTCTTGGT
All primers were obtained from Sigma-Aldrich, MO.
CHAPTER 3
70
Table S6. Antibodies used for immunoluorescence.
Antigen Supplier Catalogue # Dilution
Primary Antibodies
CD31 Santa Cruz Biotechnology, CA sc-1506 1:200
ESM-1 (Endocan) Lunginnov, France lia-0901 1:200
MAPK7 (Erk5/BMK1) Bioss, MA bs-5486r 1:100
SM22α Abcam, UK ab14106 1:250
VE-Cadherin Cell Signaling, CA 2500 1:100
Secondary Antibodies
anti-Mouse IgG Alexa 594 Life Technologies, The Netherlands A21203 1:500
anti-Goat IgG Alexa 594 Life Technologies, The Netherlands A11058 1:500
anti-Rabbit IgG Alexa 647 Life Technologies, The Netherlands A31573 1:500
Table S7. Antibodies used for immunoblotting.
Antigen Supplier Catalogue # Dilution
Primary Antibodies
Calponin (CNN1) Abcam, UK ab46794 1:1000
eNOS (NOS3) BD Pharmingen 610299 1:500
GAPDH Abcam, UK ab9484 1:5000
MAP3K3 (MEKKK3) Abcam, UK
MAPK7 (Erk5/BMK1) MerckMillipore, MA 07-039 1:1000
SM22α (Transgelin) Abcam, UK ab14106 1:1000
MEF2D Bethyl Laboratories, TX A303-522A 1:100
KLF4 Abcam, UK
VE-Cadherin Cell Signaling, CA 2500 1:1000
Secondary Antibodies
anti-Ms IRDye 800 LI-COR Biosciences, Germany 926-32212 1:10.000
anti-Rb IRDye 680 LI-COR Biosciences, Germany 926-68073 1:10.000
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High uniform luid shear stress (FSS) is atheroprotective and preserves the 
endothelial phenotype and function through activation of downstream mediators 
such as MAPK7 (Erk5). Endothelial cells respond to FSS thanks to mechanotransduction. 
However, how the resulting signaling is integrated and resolved at the epigenetic level, 
remains elusive. We hypothesized that Polycomb methyltransferase EZH2 is involved 
in the efects of FSS in human endothelial cells. 
We showed that FSS decreases the expression of the Polycomb methyltransferase 
EZH2. Despite simultaneous activation of MAPK7, MAPK7 pathway does not directly 
inluence the transcription of EZH2. Interestingly though, the knock down of EZH2 
activates the protective MAPK7 signaling in endothelial cells, even in the absence of FSS. 
To understand the inluence of the FSS-decreased expression of EZH2 on endothelial 
transcriptome, we performed RNA-seq and diferential gene expression analysis. We 
identiied candidate groups of genes dependent on both EZH2 and FSS. Among those, 
Gene Ontology overrepresentation analysis revealed highly signiicant enrichment of 
the cell cycle-related genes, suggesting changes in proliferation. Indeed, the depletion 
of EZH2 strongly inhibited endothelial proliferation, indicating cell cycle arrest. The 
concomitant decrease in CCNA expression suggests the transition of endothelial cells 
into a quiescent phenotype. Further bioinformatical analysis suggested TXNIP as a 
possible mediator between EZH2 and cell cycle-related gene network.
Our data show that EZH2 is a FSS-responsive gene. Decreased EZH2 levels enhance 
the activation of the atheroprotective MAPK7 signaling. Decrease in EZH2 under FSS 
mediates the decrease in the expression of the network of cell cycle-related genes, 
which allows the cells to enter quiescence. EZH2 is therefore important for the 
protective efects of FSS in endothelium. 




Endothelial cells constitute the lining of all blood vessels and are therefore 
exposed to the luid shear stress (FSS) – the frictional force exerted on the vessel 
wall by the low of blood (1, 2). Geometrical features of the arterial tree, such as the 
aortic curve and branches, cause alterations in the patterns of blood low. At these 
so-called atheroprone sites, FSS is low or even absent, which correlates with the 
increased susceptibility of these sites to endothelial dysfunction and atherosclerosis 
(3-5). Endothelial cells sense FSS through mechanotransduction. The FSS-induced 
activation of the MAP2K5-MAPK7 (MEK5-Erk5) signaling pathway, which is sustained 
under prolonged exposure to FSS  (6), exerts protective efects on the endothelium (7-
9).  MEK5 activates MAPK7 through phosphorylation (8, 10),   which results in expression 
of Kruppel-like factor-2 and -4 (KLF2 and KLF4), transcription factors that drive the 
expression of atheroprotective genes (8, 11). 
Gene expression is regulated at the chromatin level through the deposition or 
removal of epigenetic modiications by specialized enzymes. These modiications, to 
histone proteins or to the DNA itself, shape the accessibility of gene promoters to the 
transcriptional machinery. In particular, Polycomb repressive complexes are crucial 
regulators of gene expression, with well-established roles during development and 
carcinogenesis (12).  Enhancer of zeste homolog-2 (EZH2) is the main methyltransferase 
in the Polycomb repressive complex-2 (PRC2). EZH2 methylates histone-3 at lysine-27 
(H3K27me3 mark), which maintains the repression of gene expression (13).   
The epigenetic events that mediate cellular responses to mechanical forces, such 
as the endothelial response to FSS, are still poorly understood. EZH2 regulates the 
diferentiation of mechanosensing Merkel cells in the skin (14). EZH2 was also shown to 
regulate endothelial gene expression and function (15-17). However, the link between 
EZH2 and endothelial mechanotransduction in response to FSS has not been reported. 
We hypothesized that EZH2, through epigenetic regulation of gene expression, 
mediates the response of endothelial cells to the mechanical force of FSS.
MATERIALS AND METHODS 
CELL CULTURE AND FLUID SHEAR STRESS EXPERIMENTS
Human Umbilical Vein Endothelial Cells (HUVEC; Lonza, Basel, Switzerland) were 
used between passages 5 and 8, cultured in endothelial cell medium (ECM) as described 
before (18),  but with 5.5mM glucose and 10% heat-inactivated fetal calf serum (FCS; 
Lonza, Basel, Switzerland) in gelatin-coated dishes. For the FSS experiments, µ-Slides I 
0.4 Luer (Ibidi, Planegg/Martinsried, Germany) were coated with gelatin, HUVEC were 
seeded at full conluency (approximately 60 000 cells/cm2) and incubated overnight 
under standard static cell culture conditions. Slides with conluent cell monolayers 
were attached to a luidic unit (Ibidi, Planegg/Martinsried, Germany), connected to 
the pump (Ibidi, Planegg/Martinsried, Germany), and incubated under standard cell 
culture conditions. Inverted pressure was used to ensure the gas exchange in the
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culture medium. Fluid shear stress (FSS) of 20 dyne/cm2 was applied to the monolayers 
in the slides, for 72h. Static controls were cultured in the same incubator and the same 
medium, refreshed daily. In the stop-low experiments, after FSS was ceased, cells were 
incubated for an additional 1h in static conditions before they were lysed. MAP2K5-
MAPK7 (MEK5-Erk5) pathway inhibitor BIX02189 was used at the concentration of 5µM. 
Simvastatin (Sigma-Aldrich, St. Louis, MO, USA) was used at the concentration of 1µM, 
for 24h. Appropriate volumes of DMSO were used in controls. 
Human Embryonic Kidney (HEK) cells and Phoenix-Ampho cells were cultured in 10% 
FCS DMEM (Lonza, Basel, Switzerland), 2mM L-glutamine (Lonza, Basel, Switzerland), 1% 
penicillin/streptomycin (Gibco/Thermo Fisher Scientiic, Wiltham, MA, USA).
VIRAL TRANSDUCTION
In MEK5D expression experiments, Phoenix-Ampho cell line stably expressing and 
producing retroviral particles with empty vector (pBABE-puro-EV) or constitutively active 
MEK5 (MAP2K5; pBABE-puro-MEK5D) was used. Cells were cultured at subconluent 
densities. The collection of the viral particles was done in 10% FCS ECM medium, 
starting 24h after the last preceding passage. The supernatants were collected 2 times 
at 24h intervals, iltered through 0.45 µm ilters and applied to 30%-conluent HUVEC 
cultures. 24h after the last transduction medium was refreshed and cells were cultured 
until conluent. Upon selection with 2 µg/ml of puromycin (Invitrogen, Carlsbad, CA, 
USA) cells were allowed to proliferate, and then were lysed for further analysis.
For lentiviral transductions to obtain the EZH2 knock down, HEK cells were transfected 
using EndofectinTM-Lenti (Gene Copoeia, Rockville, MD, USA , EFL-1001-01) with the 
following plasmids: pLKO.1-shEZH2 or pLKO.1-SCR, pVSV-G (envelope plasmid) and 
pCMVΔR8.91 (gag-pol 2nd generation packaging plasmid). Virus collection was started 
the day after, in 10% FCS ECM medium. 30%-conluent HUVEC were transduced twice 
at 24h intervals. Every irst transduction was done with 4µg/ml polybrene. After the last 
transduction cells were allowed to proliferate for another 3 days and were then selected 
with 2µg/ml of puromycin. Surviving cells were allowed to proliferate for another 24h. At 
this point, 7 days post-irst transduction, cells were used for downstream experiments 
or analyses. The whole procedure was repeated for each replicate. A complete knock-
out of EZH2 (no protein present in Western blotting analyzes) was conirmed in all EZH2 
knock-down cells used in the experiments in this study.
SIRNA TRANSFECTION
HUVEC were seeded subconluent and transfected at 80-90% conluency, in 12-
well plates. Cells were washed with PBS and pre-incubated with 400µl of OptiMEM 
(Invitrogen, Carlsbad, CA, USA) per well at 37°C. Transfection mixes were prepared with 
Lipofectamine (Invitrogen, Carlsbad, CA, USA) and siRNA against EZH2 (Hs_EZH2_4 
FlexiTube siRNA, cat. no. SI00063973) or AllStars Negative Control siRNA (cat. no. 1027280, 
QIAGEN, Venlo, The Netherlands) and a 100µl of an appropriate mix containing 30 pmol 
of siRNA were added per a well. Cells were incubated at 37°C for 6h, then washed 2 
times with PBS and cultured further in regular culture medium. Medium was refreshed 
once more 48h post-transfection. Cells were lysed 72h post-transfection.
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RNA ISOLATION AND REAL-TIME PCR
Cells were lysed with either RNA-Bee (TEL-TEST, Inc., Friendswood, TX, USA) or 
TriZOL (Invitrogen, Carlsbad, CA, USA). To isolate RNA, standard phenol/chloroform 
extraction was performed in accordance with the manufacturer’s guidelines, followed 
by isopropanol precipitation. RNA pellets were washed twice with ice-cold 75% 
ethanol, dried and resuspended in RNAse-free water. Concentrations were measured 
by spectrophotometry (NanoDrop /Thermo Fisher Scientiic, Waltham, MA, USA). 
cDNA was synthetized with the RevertAidTM First Strand cDNA Synthesis Kit (Thermo 
Fisher Scientiic, Wiltham, MA, USA). Real-time PCR (ViiA7 Real Time PCR system, 
Applied Biosystems, Foster City, CA, USA) was performed with 150nmol of primers 
and 10ng of cDNA input per reaction, using SYBR-Green chemistry (BioRad, Hercules, 
CA, USA, or Roche, Basel, Switzerland). Data were analysed with the ViiA7 software 
(Applied Biosystems, Foster City, CA, USA) and further processed in Excel. Geometrical 
mean of ACTB and GAPDH Ct values, or only GAPDH Ct values (consistent within an 
experimental set) were used for the ΔCt normalization as follows: ΔCt = CtGene of interest - 
CtHousekeeping genes. Fold change over control samples was calculated using ΔΔCt method, 
as 2^- ΔΔCt, where ΔΔCt = ΔCtcontrol - ΔCttreatment.
Primers used in this study are shown in Table 1.



















Cells were lysed with RIPA bufer (Thermo Fisher Scientiic, Wiltham, MA, USA), 
freshly supplemented with proteinase inhibitor cocktail and phosphatase inhibitor 
cocktails-2 and -3 (all from Sigma-Aldrich, St. Louis, MO, USA). Electrophoresis 
was performed in 10% polyacrylamide gels, followed by electrotransfer onto 
nitrocellulose membranes. Membranes were blocked with Odyssey Blocking Bufer 
(Li-COR Biosciences, Lincoln, NE, USA) 1:1 in Tris-Bufered Saline (TBS) for 1h at room 
temperature (RT). Blots were then incubated with primary antibodies at 4˚C, overnight, 
and afterwards with secondary antibodies for 1h at RT. The membranes were washed 
3 times with TBS with 0.1% Tween in between incubations, and additionally with TBS 
before the scanning. Odyssey scanner (Li-COR Biosciences, Lincoln, NE, USA) was used 
to retrieve the digital images of the membranes. These were analysed with Odyssey 
software (Li-COR Biosciences, Lincoln, NE, USA) and densitometry was performed with 
TotalLab 120 software (Nonlinear Dynamics, Newcastle, UK). Images depicted in igures 
were processed in Adobe Photoshop and Illustrator, and if necessary brightness of a 
whole image was adjusted in linear fashion.
The following antibodies were used: NOS3/eNOS (1:1000, BD Biosciences, San 
Jose, CA, USA, 610299), MAPK7/Erk5 (1:500, Upstate/Merck Millipore, Billerica, MA, 
USA, 07-039), EZH2 (1:1000, Cell Signaling, Danvers, MA, USA, 5246), GAPDH (1:1000, 
Abcam, Cambridge, UK, ab9485 or ab9484), KLF2 (1:250, Santa Cruz Biotechnology, 
Dallas, TX, USA, sc-28675), KLF4 (1:250, Santa Cruz Biotechnology, Dallas, TX, USA, sc-
20691), Cyclin A (1:500, Santa Cruz Biotechnology, Dallas, TX, USA, sc-751), Cyclin B1 
(1:500, Santa Cruz Biotechnology, Dallas, TX, USA, sc-s45) and Cyclin E (1:500, Santa 
Cruz Biotechnology, Dallas, TX, USA, sc-247), anti-rabbit IgG IRDye-680LT (1:10 000, Li-
COR Biosciences, Lincoln, NE, USA, 926-68021), anti-mouse IgG IRDye-800CW (1:10 000, 
Li-COR Biosciences, Lincoln, NE, USA, 926-32210). 
RNA-SEQ 
Puromycin-selected HUVEC cells, expressing either scrambled control (SCR) or anti-
EZH2 short-hairpin (shEZH2) constructs (at total 7 days after the irst viral transduction), 
were used in FSS experiments (72h of control static culture or FSS exposure). Each 
replicate experiment consisted of viral transductions (described above) and selection 
of a separate HUVEC batch, followed by the FSS experiment. Two FSS experimental 
sets of the same HUVEC batch were run every time in parallel and lysed at the same 
end time point, one in RNAse-free conditions with RNA-Easy Mini Plus kit RLT Plus lysis 
bufer (QIAGEN, Venlo, The Netherlands), and one with RIPA bufer. The RIPA-lysates 
were analyzed with Western blotting and conirmed the complete (no protein present) 
knock-down of EZH2. 
From the RNA-lysates, RNA was isolated using the RNA-Easy Mini Plus kit (QIAGEN, 
Venlo, The Netherlands). High quality RNA samples (pre-assessed by Nanodrop 
measurements) were (19) further processed in the Genome Analysis Facility of the 
University Medical Center Groningen. The RNA quality and integrity were veriied using 
PerkinElmer Labchip GX with a cut-of value of 9 (scale 1 to 10, where 9 is very high 
quality RNA). RNA library was created in accordance with the TruSeqTM RNA Sample 
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Preparation v2 Guide (Illumina, San Diego, CA, USA), using the PerkinElmer Sciclone 
liquid handler, resulting in 330bp cDNA fragments. The paired-end sequencing (100bp 
reads) was performed using the Illumina HiSeqTM 2500. 
Sequencing data were analysed using the Tuxedo pipeline(19),  with TopHat2 
(v.0.6), Culinks (v.0.0.6), Cufmerge (v.0.0.6), CufDif (v. 0.0.7), as available at the public 
Galaxy platform usegalaxy.org as of August 2014 (20-22). Prior to the alignment, FASTQ 
Groomer (v. 1.0.4) was used to groom the .fq iles, and FastQC (v. 0.52) was used to 
assess the quality of the reads. Trim sequences tool (v. 1.0.0) was used to trim the reads. 
Picard Insertion size metrics tool (v. 1.56.0) was used to estimate the distance between 
mate pairs (paired-end reads). Reads were aligned to the hg_19, and iGenomes hg_19 
(v. 1.1.3) was used for annotation. 
Diferential expression analysis was performed with CufDif, with FPKM (Fragments 
Per Kilobase of exon per Million fragments mapped) normalization method and false 
discovery rate (FDR) correction, where corrected p-values (q-values) <0.05 were 
considered to indicate signiicant changes. 
The CufDif output was explored using CummeRbund (v. 0.1.3) in R-Studio 0.98. 
For the comparisons of interest, the gene sets of signiicantly diferentially expressed 
genes were extracted at alpha=0.05. 
For a scheme of the subsequent analysis low please refer to the Online Figure 
5. Gene Ontology (GO) (23) enrichment analysis was performed using the PANTHER 
database, at the www.PANTHERdb.org website (PANTHER 9.0), as of August 2014 (24). 
Gene lists were analysed with the Overrepresentation tool. The Bonferroni correction 
for multiple testing was applied, and the corrected p-value (q-value) of 0.05 was 
considered the cut-of for signiicantly overrepresented terms. 
The intersection of the lists of genes was performed with the BioVenn tool (25). The 
Venn diagrams were plotted using the R package VennDiagram. Pathway enrichment 
analysis was performed using KEGG database using the Enrichr tools available at the 
Enrichr website (with the combined ranking method)(26). REVIGO online tool was 
used to organize and visualize the enriched GO terms obtained from the PANTHER 
9.0; q-values obtained in PANTHER GO enrichment analysis were used as the rating 
parameter in REVIGO (only the terms with q<0.05 were used)(27).  STRING 9.1 tool was 
used to explore the mutual relationships between the products of the genes(28, 29). 
Additional information on the genes of interest, that can be found in the Online Tables, 
was retrieved from Ensembl (30), using the BioMart tool (31).  The data discussed in 
this publication have been deposited in NCBI’s Gene Expression Omnibus (32) and are 
accessible through GEO Series accession number GSE71164 (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE71164).
KI67 IMMUNOFLUORESCENT STAINING
HUVEC expressing either scrambled control (SCR) or SH-EZH2 constructs were 
seeded at density of 25 000 cells per a well in 24-well plates in 2% FCS ECM and incubated 
for 24h. After that cells were washed with PBS, ixed with 2% paraformaldehyde for 30 
min, washed with PBS, permeabilized with 0.5% Triton-X in PBS for 10 min, washed 
with PBS and blocked with 10% donkey serum in PBS. Cells were then incubated with 
primary antibodies, rabbit-anti-human Ki67 (1:500, Monosan, PSX1028) in 10% donkey 
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serum in PBS, while negative controls were incubated with the 10% donkey serum 
in PBS, at 4˚C overnight. Cells were then washed with PBS with 0.05% Tween-20 and 
incubated with secondary antibodies, donkey-anti-rabbit IgG Alexa Fluor-555 (1:500, 
Life Technologies, Carlsbad, CA, USA, A31572) in 10% human serum in PBS with DAPI 
(1:5000), for 40 min at RT. Cells were next washed with PBS with 0.05% Tween and with 
PBS, and the plates were scanned and images were taken in an automated manner 
with the Tissue FAXS microscope (TissueGnostics, Vienna, Austria). Exposure of the 
images was optimized and regulated by the software, and unprocessed images were 
used in the quantitative analysis, performed with the Tissue Quest 4.0.1.0127 software 
(TissueGnostics, Vienna, Austria), which counts the positive cells and measures the 
luorescence intensity. The data were normalized by dividing the Ki67-positive cell 
numbers by all DAPI-positive cell numbers. The brightness of the representative 
images depicted in Figure 7 was adjusted in a linear manner and to the same extent in 
each image, to better visualize the stained cells.
STATISTICAL ANALYSIS
Statistical analysis was performed in GraphPad Prism 4 or 5 (La Jolla, CA, USA), with 
t-test, or 1-way ANOVA followed by post-hoc tests with corrections speciied in igure 
legends. Graphs depict mean and standard deviation or standard error of the mean 
(speciied in igure legends), the number of independent experiments is indicated 
in the dot-plots and in igure legends. P-values < 0.05 were considered to indicate a 
signiicant diference between means.
RESULTS
FLUID SHEAR STRESS REGULATES EZH2 EXPRESSION IN ENDOTHELIAL CELLS
FSS of 20 dyne/cm2 decreased the expression of EZH2 in HUVEC (Fig. 1 A – C). As 
expected, it also activated MAPK7 signaling (Fig. 1A) and increased expression of KLF2, 
KLF4 and endothelial nitric oxide synthase (NOS3/eNOS) (Online Fig. 1 A – F).
Figure 1. FSS causes a decrease in EZH2 gene and protein expression. HUVEC were cultured for 72h under 
20 dyne/cm2 FSS. A – Representative Western blotting images. B – Gene expression of EZH2 under FSS, n=4, 
**p<0.01, t-test. C – Protein expression of EZH2 under FSS, obtained through the densitometry of the Western 
blotting data, n=3, **p<0.01, t-test.
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Figure 2. The protein expression of EZH2 is decreased along MAPK7 activation. The constitutively 
active MEK5 mutein (MEK5D) was expressed in HUVEC. A – Representative Western blotting images. B – Protein 
expression of EZH2 in cells expressing MEK5D, obtained through the densitometry of the Western blotting data, 
n=6, *p<0.05, t-test. C – Gene expression of EZH2 in cells expressing MEK5D, n=4. 
To evaluate whether the decrease in EZH2 expression under FSS is a result of MAPK7 
activation, we expressed MEK5D, a constitutively active mutant of MEK5/MAP2K5(8), 
in endothelial cells. MEK5D expression resulted in activation of MAPK7 (Fig. 2A) and 
increased the expression of KLF2 and KLF4 (Online Fig. 2A and B), conirming that the 
model worked properly. MAPK7 activation coincided with decreased expression of 
EZH2 at the protein level, but not at the mRNA level (Fig. 2A – C). Pharmacological 
inhibition of MAPK7 activation by the small molecule inhibitor BIX02189 did not 
rescue the expression of EZH2 decreased by FSS (Online Fig. 3A) or by treatment 
with simvastatin (Online Fig. 3B). These data suggested that while FSS decreases the 
expression of EZH2 in HUVEC, MAPK7 is not involved in mediating this efect.
DEPLETION OF EZH2 ENHANCES MAPK7 ACTIVATION 
Although it did not directly regulate the expression of EZH2, MAPK7 is an important 
mediator of FSS in endothelial cells. We therefore investigated how, on the other hand, 
the FSS-induced decrease in EZH2 afects the expression and activity of MAPK7. Knock-
down of EZH2 by either shRNA or siRNA did not alter the gene expression levels of 
MAPK7 in endothelial cells (Fig. 3A and Online Fig.4A and B). However, knock-down of 
EZH2 did increase the basal phosphorylation levels of MAPK7 under static conditions 
(Fig. 3B and C) as well as enhanced the activation of MAPK7 in the cells exposed to FSS 
(Fig. 3D – G). These data imply that the levels of EZH2 determine the activation capacity 
of MAPK7 in endothelial cells. As MAPK7 activation is maintained upon prolonged 
exposure to FSS (6), we checked if the decrease in EZH2 expression under FSS would 
modulate the deactivation (dephosphorylation) of MAPK7 after FSS was stopped. The 
decrease in EZH2 under FSS (Fig. 3H and I) did not afect the dephosphorylation of 
MAPK7 within 1h after the FSS-exposure was stopped, as the MAPK7 phosphorylation 
levels were diminished to a level comparable with static control samples. These data 
suggest that MAPK7 activation, rather than deactivation, is afected by the decrease in 
EZH2 (Fig. 3H and J, “1h stop FSS”/“stop”). 
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Figure 3. EZH2 levels determine the activation capacity of MAPK7. A – Gene expression of MAPK7 in cells 
depleted of EZH2. Anti-EZH2 shRNA was expressed in HUVEC for 7 days by means of lentiviral delivery. Scrambled 
shRNA was used as control, n=3. B – Representative images of Western blotting showing the enhanced activation 
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of MAPK7 in static conditions upon 7-day knock-down of EZH2 in HUVEC. C – Densitometry results showing the 
enhanced activation of MAPK7 in static conditions upon the knock-down of EZH2, derived from the Western 
blotting data, normalized to b-actin (ACTB), n=3, **p<0.01, t-test. D – Representative Western blotting images, 
showing enhanced activation of MAPK7 in EZH2-depleted cells compared to control, both in static and in FSS-
exposed cultures. Dashed line indicates where the images were artiicially connected: they are parts of the same 
membrane (one image), and were only moved to depict the lanes in the order which is easier for interpretation. 
Control and EZH2-depleted HUVEC were cultured under FSS for 3 days. E – Densitometry results of the Western 
blotting data showing the protein expression levels of EZH2, n=3, **p<0.01, ***p<0.001, 1-way ANOVA with Tukey 
post-hoc comparisons between all pairs of means. F and G – Densitometry results of the Western blotting data 
showing the total phosphorylation levels of MAPK7 (normalized to GAPDH) and the ratio of phosphorylated 
MAPK7 to total expressed MAPK7 (both normalized to GAPDH), respectively, n=3, **p<0.01, ***p<0.001, 1-way 
ANOVA with Tukey post-hoc comparisons between all pairs of means. H – Representative Western blotting 
images showing rapid dephosphorylation of MAPK7 upon the cessation of the low. Cells were cultured for 72h 
in static conditions or under FSS; afterwards 1 group was kept for an additional 1h in static conditions before 
cells lysis (“1h stop FSS”). I and J – Densitometry results showing the levels of MAPK7 phosphorylation and EZH2 
protein expression, respectively, normalized to GAPDH. The “stop” caption refers to the 1h stop FSS condition (see 
H), n=3, ***p<0.001, 1-way ANOVA with Tukey post-hoc comparisons between all pairs of means.
Figure 4. Biological Process Gene Ontology terms which were signiicantly overrepresented among 
genes regulated by EZH2 (panel A) or by FSS (panel B). The igure shows the REVIGO representation of GO BP 
terms enriched in the lists of genes regulated 2-fold or more upon EZH2-depletion (A) or FSS-exposure (B). The 
lists of GO signiicantly enriched terms (cut-of q<0.05) were obtained through the overrepresentation analysis 
using PANTHER 9.0. The size of a bubble corresponds to the size of the group of genes in the analysis, belonging 
to the speciic GO term. UP – upregulated genes, DOWN – downregulated genes. For the exact (corrected) 
p-values, please compare Supplementary Tables 2, 3, 5 and 6.
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EZH2 REGULATES GENES INVOLVED IN CELL ADHESION AND CELL CYCLE IN ENDOTHELIAL CELLS
To understand the role of EZH2 in the regulation of transcription in endothelial 
cells in response to FSS we employed a transcriptomic approach (Online Fig. 5). First, 
the genes regulated by the knock-down of EZH2 or by FSS were explored separately, 
to gain insight into the groups of genes afected by either condition. Then, the groups 
of genes regulated by both EZH2-depletion and FSS-exposure were identiied. In 
both cases, Gene Ontology overrepresentation analysis was performed to classify the 
diferentially expressed genes and to identify the most signiicantly enriched groups 
of genes (which are likely to be highly biologically relevant in the conditions tested). 
Overview of the analysis is presented in Online Fig. 5.
Figure 5. The genes regulated by both EZH2 and FSS are the most signiicantly enriched within GO 
terms Cell adhesion and Cell cycle. A – Area-proportional Venn diagram, depicting the intersection of the 
lists of genes upregulated by EZH2-depletion (SCR-static vs. SH-EZH2-static) and genes upregulated by exposure 
to FSS (SCR-static vs. SCR-FSS). B – Area-proportional Venn diagram, depicting the intersection of the lists of 
genes downregulated by EZH2-depletion (SCR-static vs. SH-EZH2-static) and genes downregulated by exposure 
to FSS (SCR-static vs. SCR-FSS). C – REVIGO-derived representation of the most signiicantly overrepresented GO 
BP terms in the list of 103 genes upregulated by both EZH2-depletion and FSS-exposure. D – REVIGO-derived 
representation of the most signiicantly overrepresented GO BP terms in the list of 355 genes downregulated 
by both EZH2-depletion and FSS-exposure. The signiicantly enriched GO terms (q<0.05) were derived from the 
PANTHER 9.0 overrepresentation analysis. The GO-enrichment q-values are available in Supplementary Tables 
9 and 10.
RNA-seq analysis of control (SCR) and EZH2-depleted (SH-EZH2) cells, showed that 
the depletion of EZH2 in endothelial cells increased the expression of 2042 genes 
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(q<0.05), of which 550 were increased ≥2-fold (Online Table 1). Overrepresentation 
analysis of these genes using PANTHER database revealed that the most signiicantly 
overrepresented Biological Process (BP) Gene Ontology (GO) term was Cell adhesion 
(Fig. 4A upper panel and Online Table 2), with 58 genes (Online Fig. 6A). Of 2654 genes 
whose expression was decreased in cells depleted of EZH2 (q<0.05), 760 genes were 
≥2-fold decreased (Online Table 1). The most overrepresented group within these 760 
genes were the genes associated with the BP GO term Cell cycle (Fig. 4A lower panel, 
and Online Table 3), including 136 genes (Online Fig. 6B). 
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Figure 6. Cell cycle-associated genes are a candidate group of genes regulated by the decrease in EZH2 
upon FSS. A – Heatmap representation of relative expression levels of genes associated with the BP GO term Cell 
cycle, which were regulated by both EZH2-depletion and FSS-exposure. B – Real-time PCR validation of the RNA-
seq results for a sub-group of the cell cycle-associated genes, n=3, error bars depict standard error of the mean, 
**p<0.01, ***p<0.001 1-way ANOVA with Tukey post-hoc comparisons between all pairs of means.
FSS-REGULATED GENES IN ENDOTHELIAL CELLS
Next, we analyzed the transcriptomic efects of FSS in endothelial cells. Exposure 
of endothelial cells to FSS increased the expression of 2142 genes (q<0.05) of which 
615 genes were increased ≥2-fold (Online Table 4), with the most signiicantly 
overrepresented groups within the BP GO terms Cellular process, Developmental 
process and Cell adhesion (Fig. 4B upper panel, Online Fig. 7A and Online Table 5). FSS 
decreased the expression of 3035 genes (q<0.05), of which 835 genes were ≥2-fold 
decreased (Online Table 4). The most enriched group was associated with the BP GO 
term Cell cycle (Fig. 4B lower panel, Online Fig. 7B and Online Table 6).
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Figure 7. The downregulation of the network of cell cycle-associated genes leads to the decrease in 
proliferation of endothelial cells. A – Products of the genes associated with the GO term cell cycle, which 
are regulated by both EZH2 and FSS, form a network of interdependencies. The list of genes regulated by both 
EZH2 and FSS belonging to the GO term Cell cycle (most signiicantly enriched group) was analyzed using String 
9.1. Depicted is the evidence view of interactions between the gene products. B – Representative images of the 
immunoluorescent staining detecting the Ki67 protein expression in scrambled control (SCR) and EZH-depleted 
(SH-EZH2) endothelial cells (upper panel). Lower panel depicts DAPI signal, indicating nuclear staining. The 
white bars indicate 100µm. C –The average percentage of proliferating cells, derived as the percentage of Ki67-
positive cells among all the DAPI-positive cells (i.e. Ki67-positive cell numbers are normalized to the number of all 
cells (DAPI) in the quantiied region), showing the decrease in proliferation capacity of the EZH2-depleted cells. 
These results were obtained through the analysis with the TissueFAXS TissueQuest software, n=4, ***p<0.001, 
t-test. D – Representative Western blotting results of protein expression of Cyclins A, B and E. E – Densitometric 
quantiication of the protein expression of Cyclins A, B and E, normalized to GAPDH. n=4, *p<0.05, **p<0.01, 
Student t-test, error bars depict standard error of the mean. F – Heatmap representation of the relative expression 
of MAPK13, TRNP1, TUBA4A, GEM and TXNIP, the cell cycle-related genes whose expression was increased by 
both EZH2-depletion and FSS-exposure in HUVEC.
IDENTIFICATION OF CANDIDATE GENES REGULATED BY EZH2 IN RESPONSE TO FSS IN ENDOTHELIAL CELLS
We next set out to identify the genes that are afected by both EZH2 and FSS, which 
are the candidate genes regulated by the decrease of EZH2 under FSS. The expression 
of 103 genes increased, and the expression of 355 genes decreased upon both the 
depletion of EZH2 and the exposure to FSS (Fig. 5A and B, and Online Table 7 and 8). 
The group of 103 genes with increased expression was the most signiicantly 
enriched in genes belonging to the BP GO term Cell adhesion (Fig. 5C and Online 
Table 9). The group of 355 genes with decreased expression was the most signiicantly 
enriched in genes associated with the BP GO term Cell cycle (Fig. 5D, right panel and 
Online Table 10). Additional pathway enrichment analysis with Enrichr using KEGG 
database showed signiicant enrichment of terms Cell adhesion molecules (genes with 
increased expression, Online  Fig. 8A) and Cell cycle (genes with decreased expression, 
Online  Fig. 8B)
THE FSS-EXERTED DECREASE IN EZH2 INHIBITS ENDOTHELIAL PROLIFERATION THROUGH DOWNREGU-
LATION OF CELL CYCLE-ASSOCIATED NETWORK OF GENES 
The expression of genes associated with the term Cell adhesion, increased by the 
depletion of EZH2 and exposure to FSS, was in most cases also increased in the EZH2-
depleted cells under FSS (Online Fig. 9A). However, most of these genes have not been 
reported to interact with each other (Online Fig. 9B), as they did not seem to form 
a functional network based on String 9.1 analysis.  We therefore continued with the 
analysis of the Cell cycle-associated genes.
The expression of genes associated with the GO term Cell cycle was decreased /
suppressed by EZH2-depletion, FSS-exposure, and in EZH2-depleted cells under FSS 
(Fig. 6A). Real-time PCR validation of a subset of these genes conirmed this expression 
pattern (Fig. 6B). It further conirmed that the expression of master regulators of cell 
cycle progression such as CCNA2, CCNB1 or CCNB2(33) was decreased by both FSS and 
the depletion of EZH2 in endothelial cells (Fig. 6B). 
Most of the products of the cell cycle-related genes we identiied (Fig. 6A) were 
interconnected by mutual relationships (Fig. 7A). These results suggested that 
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the decrease in expression of these cell cycle-related genes could be a part of an 
orchestrated response, regulated by FSS through the decrease in EZH2, and aimed at 
the inhibition of cell cycle progression and proliferation. 
 To conirm that low levels of EZH2 functionally inhibit the cell cycle, we 
demonstrated that the depletion of EZH2 indeed decreased the proliferation rates 
of endothelial cells (Fig. 7B and C). These data suggested that the decrease in EZH2 
(under FSS) could lead to the cell cycle arrest.
To further validate this notion, we analyzed the protein expression of chosen Cyclins 
whose expression was decreased in our transcriptomic data. While Cyclin B (CCNB) and 
Cyclin E (CCNE) did not show consistent changes in protein expression, Cyclin A (CCNA) 
protein levels were decreased both by the depletion of EZH2 and by the exposure to 
FSS (Fig. 7D and E). These patterns of expression, in particular the decrease in Cyclin 
A levels, seemed to be speciically dependent on EZH2, and independent from the 
MEK5/MAPK7 pathway, as they were not observed in MEK5D-expressing cells (Fig. 7D 
and E). 
As EZH2 is an epigenetic repressor, there could be other gene products, likely 
repressors, which are upregulated and mediate between the decrease in EZH2 
availability and the decrease in cell cycle-related gene expression. To explore this 
possibility, we performed an additional GO-overrepresentation analysis of all the 
genes regulated by EZH2-depletion and FSS-exposure (up- and downregulated genes 
together).  As could be expected, the GO term Cell cycle was once more the most 
signiicantly overrepresented. In addition to the downregulated genes identiied 
before (Fig. 6A), this analysis revealed 5 cell cycle-related genes, MAPK13, TRNP1, 
TUBA4A, GEM and TXNIP, whose expression was increased in EZH2-depleted and 
in FSS-exposed cells (Fig. 7F). This small group of genes provides a set of potential 
mediators between EZH2 and the downregulated cell cycle-regulating genes.
DISCUSSION
We demonstrated that EZH2 is a luid shear stress (FSS)-responsive gene. EZH2 levels 
inluence the activation levels of MAPK7. EZH2 regulates the expression of multiple 
groups of genes in endothelial cells. In particular, it regulates the genes associated 
with cell adhesion and cell cycle. The FSS-induced decrease in EZH2 levels elicits an 
orchestrated response of cell cycle-regulating genes, which leads to inhibition of 
endothelial cell proliferation and likely to quiescence. 
Our data altogether suggest that high FSS might keep the EZH2 expression levels 
low, which preserves the protected, quiescent state of endothelium. On the other 
hand, in case of low or absent FSS, e.g. in atheroprone arterial regions, high expression 
of EZH2 could contribute to endothelial dysfunction, e.g. by releasing endothelial cells 
from quiescence and promoting their (excessive) proliferation.
We demonstrated that high FSS is able to decrease the expression of the global 
epigenetic regulator, EZH2, at both mRNA and protein level. This decrease in expression 
of EZH2 seems to mediate some of the beneicial efects of FSS. Our RNA-seq analysis 
identiied groups of genes dependent both on the EZH2 levels and on the presence 
of FSS. It is not surprising that there are several groups of genes (as classiied by Gene 
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Ontology terms) that are afected: on one hand FSS is an important factor regulating 
many aspects of endothelial cell biology, on the other hand EZH2 is a global epigenetic 
regulator, acting on multiple genomic loci. In the current study, we focused on the 
most signiicantly enriched group of cell cycle-related genes. However, exploration of 
the other groups of genes identiied in this study could provide further examples of 
singular pathways regulated by FSS through decrease in EZH2.
The mechanism of the regulation of EZH2 expression by FSS remains to be fully 
elucidated. However, we succeeded in demonstrating that the major known FSS-
induced pathway, MEK5/MAPK7 pathway, is of minor importance for regulation of 
EZH2 expression. Other pathways should be assessed in future studies. Furthermore, 
we established an exciting novel feedback link between EZH2 and MAPK7 pathway, 
by showing that MAPK7 activation capacity is increased when EZH2 levels decrease. 
This means that the protective, long-term activation of MAPK7 by high FSS could be 
mediated by the FSS-induced decrease in EZH2 levels. 
A few other studies that so far reported on the role of EZH2 in endothelial cells 
conirm that EZH2 is involved in the regulation of endothelial gene expression and 
endothelial function (15, 16). In particular, EZH2 regulates angiogenesis in the tumor 
microenvironment, where it is itself regulated by VEGF-miRNA-101 axis(16, 17, 34).  One 
study has so far addressed the role of EZH2 in endothelial cells with a global approach, 
similar to ours, but in static conditions only. Dreger et al. studied the short-term efects 
of a transient (siRNA-mediated) knock-down of EZH2 in HUVEC (15).  They reported 
enrichment of Cell communication and Cell adhesion related genes among the genes 
regulated by EZH2, which corroborates our inding that the Cell adhesion genes are 
the most enriched group among the genes upregulated by the knock-down of EZH2. 
The main diference between the studies is that we used a stable and long-term knock-
down of EZH2 (total knock-down time of 10 days). Our approach allowed us to study 
more downstream (and secondary) efects of EZH2-depletion, which correspond 
well to the efects of the continuously low EZH2 levels under prolonged exposure 
to FSS. These long-standing efects are more similar, and likely more relevant, to the 
conditions of continuous blood low and FSS in the blood vessels. 
Therefore, our results extend the current knowledge on the role of EZH2 in 
endothelial cells, investigated so far only in static conditions, by providing insights 
into the role of EZH2 under mechanical force of FSS. 
FSS also afects some of the other epigenetic regulators, such as histone deacetylases 
(HDACs)(35-37) and miRNAs (37, 38). Moreover, recent studies demonstrated the role of 
DNA-methylation in mediating the efects of FSS in endothelium, further substantiating 
the importance of epigenetic mechanisms in mediating the mechanosignaling (39, 
40). Our study is the irst to add Polycomb and the histone methyltransferase EZH2 to 
the group of epigenetic-level regulators of endothelial response to FSS. 
The genes related to GO term Cell cycle were the most signiicantly enriched 
group regulated by the decrease in EZH2 and by FSS in our study. These genes form 
a dense network of interactions, suggesting that their products function together 
to regulate cell cycle progression. Indeed, for example CDK1 is a major cell cycle 
regulator, which at diferent stages binds CCNA1 (41), CCNA2 (42), CCNB1 (43), and 
CCNB2(44), and all of these genes were downregulated by EZH2-depletion and by FSS 
in our experiments. CDK1 also links directly to EZH2, as it can bind and phosphorylate 
92
CHAPTER 4
EZH2 to change its epigenetic activity (45, 46). The presence of these and many other 
concomitant interactions between the members of this group suggests that it is 
indeed a functional network, whose orchestrated downregulation serves to inhibit 
the cell cycle progression in endothelial cells. Indeed, our results show that depletion 
of EZH2 caused decrease in proliferation of endothelial cell, while others observed 
that high expression of EZH2 promotes the proliferation of many types of cancer 
cells(47-50).  These data imply that the decrease in EZH2 under FSS likely serves as the 
mechanism to downregulate the network of cell cycle regulators, therefore inhibiting 
the proliferation of endothelial cells. 
EZH2 is an epigenetic repressor, which suggests that the decrease in EZH2 
expression is more likely to induce expression of genes, rather than to decrease it. 
However, other groups investigating the transcriptomic efects of EZH2 also found 
that its inhibition or knock-down results in both increase and decrease in expression 
of genes, which is consistent with our indings(51, 52). Nevertheless, we attempted to 
identify a possible link between the Cell cycle-related genes and EZH2 in our study, 
by looking for an upregulated EZH2-dependent and cell cycle-related gene. The 
additional GO overrepresentation analysis revealed 5 cell cycle-related genes, MAPK13, 
TRNP1, TUBA4A, GEM and TXNIP, that were upregulated by both EZH2-depletion and 
FSS-exposure. 
Of those candidate genes, TXNIP is the only one so far reported to be afected by 
EZH2. In the study by Zhou et al., TXNIP expression was increased by EZH2 inhibition, 
which resulted in suppression of cell growth (51).  These data are therefore consistent 
with our indings of TXNIP expression being upregulated and endothelial proliferation 
being inhibited in EZH2-depleted cells. 
TXNIP (thioredoxin interacting protein, also known as VDUP1) is primarily related to 
oxidative stress regulation. However, it has been recognized as a tumour suppressor 
gene whose upregulation inhibits the growth of cancer cells (51, 53, 54). This inhibitory 
efect of TXNIP has been linked to the cell cycle arrest in G1/G0 phase (53, 55). Therefore, 
TXNIP is a likely mediator of the cell cycle arrest occuring after the decrease of EZH2 
under FSS. 
This could happen through the known TXNIP-dependent stabilization of p27 
(CDKN1B) protein, which is a negative regulator of cell cycle (53, 54). CDKN1B 
expression was indeed shown to be reversely correlated with EZH2 levels (56, 57). Our 
results reproduced such increase in CDKN1B levels upon EZH2-depletion (Online Table 
1). However, the CDKN1B expression was not afected by FSS in our dataset, suggesting 
that CDKN1B is not involved in FSS-induced inhibition of cell cycle. 
Another potential target gene downstream of TXNIP is CCNA (Cyclin A). The study 
by Han et al. showed that TXNIP can act as a transcriptional repressor, and is able to 
repress the promoter activity of CCNA2(55). CCNA expression was decreased in our 
experiments both at gene and protein level. Therefore, the EZH2-TXNIP-CCNA2 axis 
provides an interesting example of a link between EZH2 and cell cycle regulation. 
Nevertheless, it might be one of multiple connections feeding into the reported 
network of genes, while the whole network is important for the net efect of cell cycle 
inhibition.
The decrease in expression of EZH2 under FSS, along with the decrease in expression 
of cell cycle regulating machinery, results in the decrease of proliferation, suggesting 
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that the endothelial cells enter quiescence – the arrest of the cell cycle in G1/G0 phase. 
Endothelial cells are known to acquire a quiescent phenotype under high FSS(1, 11, 58). 
Quiescence was also observed upon inhibition of EZH2 in multiple cell lines (59, 60). In 
B lymphocytes, the decrease in EZH2 levels was necessary for entering the quiescent 
state(61). Interestingly, both the increase in TXNIP and the decrease in Cyclin A levels, 
consistently with our indings, have also been associated with G1/G0 arrest, and hence 
the quiescent phenotype (53, 55, 60, 62). 
The quiescent state of endothelium under high FSS is deemed beneicial and 
protective for endothelium. Endothelial cells in the regions of disturbed low 
proliferate intensively, which might result in their early senescence and contribute to 
the susceptibility of such vascular foci to atherosclerotic remodeling (1, 58). We showed 
that the decrease in EZH2 levels also enhances the activation of MAPK7, a major 
FSS-responsive MAP-kinase, which promotes atheroprotection through increased 
expression of KLF2, KLF4 and NOS3(7-9, 63, 64).  Altogether, our results indicate that 
the suppression of EZH2 expression by high FSS is one of the mechanisms mediating 
the beneicial efects of high FSS in endothelial cells. 
Figure 8. Graphical abstract showing the proposed mechanism of action of EZH2 under
Our data establish EZH2 as a regulator of endothelial gene expression, involved 
in the endothelial response to FSS. In particular, we propose that the suppression of 
EZH2 expression by high FSS restricts the expression of a whole network of cell cycle-
regulating genes, which results in the protected quiescent endothelial phenotype 
(Fig. 8). Given the atheroprotective role of high FSS and the availability of several 
EZH2 inhibitors, our results further suggest that EZH2 might become a promising 




Online Figure 1. FSS upregulates gene and protein expression of KLF2, KLF4 and NOS3. Cells were exposed 
to laminar low with FSS of 20 dyne/cm2 for 72h. A – C Gene expression of KLF2, KLF4 and NOS3, respectively, 
n=4, ***p<0.001, t-test. D – F Protein expression of KLF2, KLF4 and NOS3, respectively, n=3, **p<0.01, t-test.
Online Figure 2. Expression of the constitutively active MAP2K5 (MAP2K5D/MEK5D) leads to 
upregulation of MAPK7 target genes, conirming the increase in MAPK7 activity. A and B – Gene 
expression of KLF2 and KLF4, respectively, n=4, **p<0.01, t-test.
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Online Figure 3.  Inhibition of MAP2K5-MAPK7 (MEK5-Erk5) with BIX02189 does not rescue the 
decrease in EZH2 expression. A – Representative Western blotting images (upper panel). Phosphorylated-
MAPK7 (pMAPK7) and EZH2 protein expression derived through densitometry and normalized to GAPDH (lower 
panel). Cells were cultured under FSS for 72h, with or without 5 μM BIX02189 (BIX), n=3, *p<0.05, **p<0.001, 
1-way ANOVA with Tukey post hoc comparisons between all pairs of means. B – Representative Western 
blotting images (upper panel). Phosphorylated-MAPK7 (pMAPK7) and EZH2 protein expression derived through 
densitometry and normalized to GAPDH (lower panel). Cells were treated for 24h with 1 μM simvastatin (statin) 
and/or 5 μM MAP2K5-MAPK7 inhibitor BIX02189 (BIX). *p<0.05, 1-way ANOVA with Tukey post hoc comparisons 
between all pairs of means.
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Online Figure 4. The gene expression of MAPK7 is preserved upon knock-down of EZH2. Cells were 
transfected with siRNA against EZH2 and analysed after 72h post-transfection. A and B – Gene expression of 
EZH2 and MAPK7, respectively, n=3, ***p<0.001, t-test.
Online Figure 9. Exploration of the cell adhesion-related genes upregulated by both EZH2 and FSS, identiied 
based on the GO enrichment analysis. A – A heatmap representation of the relative expression of the cell 
adhesion-related genes upregulated by both EZH2-depletion and FSS-exposure. B – Network representation 
of the mutual relationships of the products of the genes associated with the GO term cell adhesion, String 9.1, 
evidence view. 
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Online Figure 5. Schematic representation of data analysis. DE – diferential expression, GO – Gene Ontology.
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Online Figure 6. Relative expression of genes regulated by EZH2, belonging to the most signiicantly 
enriched GO terms. A – Heatmap representation of the relative expression of the genes upregulated by the 
EZH2-depletion that belong to the BP GO term Cell adhesion. B – Heatmap representation of the relative 
expression of the genes downregulated by the EZH2-depletion that belong to the BP GO term Cell cycle.
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Online Figure 7. Relative expression of genes regulated by FSS, belonging to the most signiicantly 
enriched GO terms. A – Heatmap representation of the relative expression of the genes upregulated by the 
exposure to FSS, that belong to the BP GO term Cell adhesion. B – Heatmap representation of the relative 
expression of the genes downregulated by the exposure to FSS, that belong to the BP GO term Cell cycle.
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Online Figure 8. Pathway enrichment analysis of the genes upregulated or downregulated by both 
EZH2-depletion and FSS-exposure. A – Pathway enrichment analysis of the 103 genes upregulated by both 
EZH2-depletion and FSS-exposure. B – Pathway enrichment analysis of the list of the 355 genes downregulated 
by both EZH2-depletion and FSS-exposure. The lists of genes were analysed using Enrichr and KEGG database, 
using the combined score ranking. The brighter the colour, the more signiicantly enriched the term is. The inserts 
represent the network of dependencies between the enriched terms (the force ield has been neglected).
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Online Figure 9. Exploration of the cell adhesion-related genes upregulated by both EZH2 and FSS, 
identiied based on the GO enrichment analysis. A – A heatmap representation of the relative expression 
of the cell adhesion-related genes upregulated by both EZH2-depletion and FSS-exposure. B – Network 
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representation of the mutual relationships of the products of the genes associated with the GO term cell 
adhesion, String 9.1, evidence view.
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Endothelial-Mesenchymal Transition (EndMT) is a speciic form of endothelial 
dysfunction wherein endothelial cells acquire a mesenchymal phenotype and lose their 
endothelial functions. We, and others, recently described that EndMT contributes to 
intimal hyperplasia and atherosclerosis. 
The mitogen activated protein kinase 7 (MAPK7, also known as Erk5) inhibits EndMT. 
MAPK7 activation decreases the expression of the histone methyltransferase Enhancer-
of-Zeste homologue 2 (Ezh2) thereby maintaining endothelial quiescence. This decrease 
in Ezh2 expression may therefore be responsible for the protective efects of MAPK7 
activation. Ezh2 is the catalytic subunit of the Polycomb Repressive Complex 2 that 
methylates lysine 27 on histone 3 (H3K27me3). it is elusive how the crosstalk between 
MAPK7 and Ezh2 is regulated in the endothelium and if the balance between MAPK7 and 
EZH2 is disturbed during intimal hyperplasia.
In this study, we showed that in endothelial cells there is reciprocity between MAPK7 
signaling and EZH2 expression and that disturbances in this reciprocal signaling circuit 
associate with the induction of EndMT and severity of human coronary artery stenosis. 
The reciprocity between MAPK7 and EZH2 is governed by a complex mechanism involving 
microRNAs and the phosphatases DUSP-1 and DUSP-6. 




Neointimal hyperplasia is characterized by an increasing amount of ibroproliferative 
cells and extracellular matrix in the neointimal lesion, resulting in vascular lumen 
narrowing and eventually obstruction of the vessel. Endothelial cells play a pivotal role in 
the formation of neointimal lesions by the acquisition of a ibro-proliferative phenotype 
through endothelial-to-mesenchymal transition (EndMT)(1-5). EndMT is characterized by 
a change from an endothelial phenotype into a phenotype comprising of mesenchymal-
like properties, in which the expression of endothelial cells markers, such as eNOS, 
PECAM-1 and VE-cadherin is lost, and the expression of mesenchymal genes, including 
SM22α, αSMA and vimentin is gained. Moreover, EndMT-derived ibroproliferative cells 
secrete extracellular matrix components, which might contribute to the buildup of the 
neointima(6).
EndMT was originally identiied during embryogenesis, where it plays a pivotal role in 
cardiac valve, septum and endocardial cushion formation(7). In adults, EndMT contributes 
to ibroproliferative diseases, including atherosclerosis(1-5), cerebral cavernous 
malformation(8), pulmonary ibrosis(9), kidney ibrosis(10) and cardiac ibrosis(11).
Uniform laminar shear stress (LSS) conveys atheroprotective efects to the endothelium, 
while endothelial cells exposed to disturbed or low oscillatory shear stress are prone to 
EndMT(12, 13). Uniform LSS activates the mitogen-activated protein kinase 7 (MAPK7) - 
also known as extracellular signal-related kinase 5 (Erk5) and big-mitogen kinase-1 (BMK-
1) - which suppresses EndMT(5, 14, 15). Concurrently, the loss of MAPK7 signaling facilitates 
EndMT(5, 16). Currently, it is elusive how MAPK7 activity is regulated in ibroproliferative 
disease. 
The histone methyltransferase Enhancer of Zeste Homolog 2 (EZH2), which is the 
catalytic subunit of the Polycomb Repressive Complex 2, plays a pivotal role in endothelial 
dysfunction(17-19). EZH2 is responsible for the trimethylation of lysine 27 on histone 3, 
which silences gene expression and is elevated in endothelial cells in atherosclerotic 
lesions(20). Serendipically, we uncovered that uniform LSS reduces the expression of 
EZH2, whereas the RNAi-mediated repression of EZH2 reciprocally activates MAPK7 
signaling in endothelial cells even in the absence of LSS(18). Currently, it is elusive how 
the crosstalk between MAPK7 and EZH2 is regulated in the endothelium and whether the 
balance between MAPK7 and EZH2 is disturbed during intimal hyperplasia and coronary 
artery stenosis. 
Here, we describe the reciprocity that exists between MAPK7 and EZH2 in the 
regulation of EndMT and in human coronary artery stenosis. In uniform LSS-stimulated 
endothelial cells, activation of MAPK7 increases the expression of microRNA (miR)-101, 
which represses the expression of EZH2. Reciprocally, the loss of EZH2 coincides with a 
decreased expression of the Dual Speciicity Phosphatase (DUSP)-1 and DUSP-6 – the 
phosphatases responsible for the dephosphorylation of MAPK7(21) - which facilitates 
the activation of MAPK7. Disbalances in this reciprocal signaling circuit culminate in the 




HUMAN CORONARY ARTERY SAMPLES 
Human coronary arteries were obtained from autopsy specimens from 10 patients 
(age 59.1±2.6 years, range 39-69) that died from an acute coronary episode at the Heart 
Institute (InCor), Sao Paulo, Brazil. Hypertension was resent in 9 subjects, and diabetes 
in 6. Five individuals were active smokers. Next-of-kin gave informed consent and the 
investigation was performed according to institutional guidelines (InCor, Sao Paulo #SDC 
3723/11/141 and #CAPPesq 482/11) and the Declaration of Helsinki. During necropsy each 
dissected coronary artery was ixed in neutral-bufered formalin with constant perfusion 
at a quasi-normal perfusion pressure before parain embedding.
DETERMINATION OF INTIMA-MEDIA THICKNESS 
Four micron-tick sections were prepared from human coronary artery samples and 
deparainized using Xylol and rehydrated using a series of EtOH solutions of decreasing 
concentration. Samples were stained in Verhoef’s solution (92 mM hematoxylin, 137 
mM FeCl3, 27 mM KI, 4 mM I2 in 55% EtOH) at room temperature for 1 hour. Samples 
were diferentiated in FeCl3 (123 mM in dH2O) for 1 minute and treated with Sodium 
Thiosulphate (316 mM in dH2O) at room temperature for 1 min. Samples were dehydrated 
using increasing concentrations of EtOH and cleared in 100% xylene. Samples were 
mounted in Permount resinous mounting medium. The intimal thickness was determined 
as the distance between the inner elastic lamina and the lumen and the medial thickness 
was determined by measuring the distance between the inner elastic lamina and the 
outer elastic lamina at 10 spots within 1 samples. Intimal/Medial thickness was calculated 
by dividing the average intimal thickness by the average medial thickness.  
HUMAN UMBILICAL VEIN ENDOTHELIAL CELL CULTURE AND SHEAR STRESS EXPERIMENTS 
 Human umbilical vein endothelial cells (HUVEC, Lonza #C2519) were cultured in 
endothelial cell culture medium (ECM) as described previously(5, 22). EndMT was the 
addition of 10 ng/ml TGFβ1 to the culture medium as described before(5, 23). For shear 
stress experiments, HUVEC (60 000  cells/cm2) were seeded on 0.1% gelatin-coated 
µ-Slides I 0.4 Luer (Ibidi GmbH, Martinsried, Germany) and allowed to adhere under 
standard culture conditions overnight. Slides with a conluent endothelial cell monolayer 
were exposed to uniform laminar shear stress (20 dyne/cm2) for 24hours. Where indicated 
5µM of the small molecule inhibitor to DUSP-1/6 (BCI, Axon Medchem, Groningen, The 
Netherlands) was applied.
VIRAL TRANSDUCTION OF ENDOTHELIAL CELLS 
 pLKO.1-shEZH2 and pLKO.1-SCR were kindly provided by Prof.dr. J.J. Schuringa (dept. 
Hematology, UMCG). HEK293 cells were co-transfected with pLKO.1-shEZH2 or pLKO.1-
SCR, pVSVG (envelope plasmid) and pCMV-R8.91 (gag-pol 2nd generation packaging 
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plasmid) using Endofectin-Lenti (Gene Copoeia, Rockville, MD, USA). At 48 and 72 hours 
post-transfection, viral supernatants were collected. 
A retroviral construct encoding the constitutively active rat MEK5-α1 (pBabePuro-
MEK5D) and empty vector controls were kindly provided by Prof.dr. M. Schmidt (Dept. 
Dermatology, University Würzburg, Germany). Retroviral transduction of HUVEC was 
performed as detailed before(24). In brief, virus-producing Phoenix cells were cultured 
until 70% conluency, after which basal medium was replaced by ECM after which viral 
supernatants were collected twice at 24 hours intervals.
Viral supernatants were supplemented with polybrene (6µg/ml; Sigma, St.Louis, 
MO) and applied to 30% conluent HUVEC for two consecutive rounds of 24h exposure. 
Transduced HUVECs were passaged twice and transduced cells were selected by 
puromycin (4µg/ml; Invitrogen, Carlsbad, CA, USA).
MICRORNA TRANSFECTIONS IN ENDOTHELIAL CELLS  
HUVEC or COS7 cells were seeded in antibiotic free medium at a density of 20 000/
cm2. Cells were transfected with 50 pmol of microRNA mimics (miR-101 (#PM11414), miR-
200a (#PM10991), miR-200b (#PM10492), miR-200c (#PM11714), miR-141 (#PM10860), miR-
429 (#PM10221) or scrambled control (#AM17110, all Ambion/Life Technologies, Carlsbad, 
CA) using the siRNA reagent system (Santa Cruz, #sc-45064, Santa Cruz, CA) according to 
manufacturer’s instructions. 
IMMUNOFLUORESCENCE 
Cells were ixed using 2% paraformaldehyde in PBS at room temperature for 30 
minutes. For the analysis of intracellular proteins, cells were permeabilized by 0.05% 
Triton X-100 solution for 10 minutes. Blocking of non-speciic antibody binding was 
performed using 5% donkey serum in PBS for 10 minutes. Samples were incubated with 
antibodies to VE-Cadherin (1:200, R&D #9381, Minnepolis, MN) or SM22α (1:200, Abcam 
#14106, Cambridge, UK) in PBS containing 2% donkey serum at 4°C overnight. Samples 
were washed extensively with 0,05% Tween-20 in PBS and incubated with Alexa Fluor® 
594-conjugated antibodies to Rabbit IgG (Life Technologies, Carlsbad, CA, #A21207) 
in DAPI/PBS with 2% human serum at RT for 1 hour. Image analysis was performed on 
TissueFAXS (TissueGnostics, Vienna, Austria) in luorescence mode, in combination with 
Zeiss AxioObserver Z1 microscope. Data analysis was performed using TissueQuest 
luorescence (TissueGnostics, Vienna, Austria) software.
IMMUNOBLOTTING
Cells were harvested in RIPA bufer (Thermo Fisher Scientiic, Wiltham, MA) 
supplemented with 1% v/v protease inhibitor cocktail (Sigma Aldrich, St Louis, MO) and 1% 
v/v phosphatase inhibitor cocktail (Sigma Aldrich, St Louis, MO). Samples were sonicated 
and protein concentration was determined with a DC protein assay (BioRad, Hercules, 
CA). Equal amount of protein were separated by electrophoresis on 10% polyacrylamide 
gels after which proteins were blotted onto nitrocellulose membranes using the semi dry 
Transblot Turbo system (Bio-rad, Hercules, CA). Membranes were blocked with Odyssey 
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Blocking bufer (Li-COR Biosciences, Lincolin, NE) at RT for 1 hour, and incubated with 
antibodies against β-actin (1:2000, Cell Signaling, Danvers, MA, USA), EZH2 (1:1000, Cell 
Signaling, Danvers, MA, USA ), MAPK7 (1:1000, Merck Millipore, Billerica, MA, USA), MKP-
1(DUSP-1, 1:1000, Abcam #195261) or MKP-3 (DUSP-6, 1:500, Santa cruz, #sc377070) at 40C 
overnight. Membranes were washed in TBS Tween (0.1%) and developed using IrDye-
conjugated antibodies to rabbit IgG (1:10,000, #926-68021), mouse IgG (1:10,000, # 926-
32210, both Li-COR Biosciences) or AP-conjugated antibodies to rabbit IgG (1:2000, #7054S, 
Cell Signaling) at RT for 1hour. Protein detection was done using the Odyssey Infrared 
Imaging System (Li-COR Biosciences). The development of  AP-conjugated antibodies, 
membranes were incubated with AP-detection bufer (100nM NaCl, 100mM Tris, 50mM 
MgCl2, pH 9.5) supplemented with nitro-blue tetrazolium chloride (NBT) (330µg/mL) and 
5-bromo-4-chloro-3’-indolyphosphate p-toluidine salt (BCIP) (165µg/mL). Densitometry 
analysis was performed using Totallab 120 (Nonlinear Dynamics, Newcastle upon Tyne, 
England).
RNA ISOLATION AND GENE EXPRESSION ANALYSIS 
RNA was isolated using the TRIzol reagent (Invitrogen Corp, CA, USA) according to 
the manufacturer’s protocol. RNA concentration and purity were assessed using UV 
spectrometry (Nanodrop 1000, Thermo Scientiic MA, USA) and RNA integrity validated 
on 1% agarose gels. For gene expression analysis, cDNA synthesis was performed using 
RevertAid™ First Strand cDNA Synthesis Kit (Thermo Scientiic, MA, USA), according to 
the manufacturer’s protocol. For microRNA transcript analysis, 10ng of total RNA was 
reversely transcribed using the ABI Taqman microRNA reverse transcription kit (#4366597, 
ThermoFisher Scientiic ) according to manufactures instructions using 1.0 µM microRNA-
speciic stemloop primers (table 1). For all transcript analyses, the cDNA was ampliied on 
a VIIA7 thermal cycling system (Applied Biosystems, Carlsbad, CA) in a reaction containing 
0.6 µM primers (table 2) using SYBR Green chemistry (Bio-Rad, VA, USA). Cycle threshold 
(CT) values for individual reactions were determined and normalized against GAPDH/ACTB 
(gene transcript analysis) or RNU6 (microRNA transcript analysis). All cDNA samples were 
ampliied in triplicate. Relative expression was calculated using the ΔCT method. Data are 
presented as fold change compared with control.
Gene Sequence
miR-101 Stem loop: GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTTCAGTTA
Sense: TGCGGTACAGTACTGTGAT  
miR-141 Stem loop: GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCCATCTTTAC
Sense: TGCGGTAACACTGTCTG 
miR-200a Stem loop: GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACACATCGTT
Sense: TGCGGTAACACTGTCTGGT 
miR-200b Stem loop: GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTCATCATTAC
Sense: TGCGGTAATACTGCCTG 
miR-200c Stem loop: GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCCAAACACTG
Sense: TGCGGCGTCTTACCCAG 
miR-429 Stem loop: GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACACGGTTTTAC
Sense: TGCGGTAATACTGTCTG 
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U6 Stem loop: GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAAAAATATGG
Sense: TGCGGCTGCGCAAGGATGA
U24 Stem loop: GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTGCATCAGCG
Sense: TGCGGTGCAGATGATGTAA
Antisense: GTGCAGGGTCCGAGGT
Table 1. Primer sequences for microRNA expression analysis
Gene Name Forward Primer Reverse Primer
DUSP1 TGGGTACATCAAGTCCATCTGA GCAAAAAGAAACCGGATCAC




Table 2. Primer sequences for gene expression analysis
3’UTR BINDING ASSAYS   
3’UTR fragments were isolated from a cDNA pool of various human tissues using 
speciic primers for EZH2-3’UTR (sense 5’-CATCTGCTACCTCCTCCCCC-3’, antisense 
5’-GACAAGTTCAAGTATTCTTT-3’), DUSP-1-3’UTR (sense 5’-AAGGCCACGGGAGGTGAGGC-3’, 
antisense 5’-CAATAGAAATGCCATAATTT-3’), and DUSP-6-3’UTR (sense 
5’-AAGACCCCACACCCCTCCTT-3’, antisense 5’-CAATAGCCAAAATAGTTATT-3’, all 0.6 µM, 
Biologio, Leiden, The Netherlands). Sense and antisense primers were extended with 
SgfI (GCGATCGC) and NotI (GCGGCCGC) restriction sequences, respectively. Ampliication 
was performed using the DyNAzyme EXT PCR kit (Finnzymes, Vantaa, Finland) according 
to manufacturers’ instructions. Amplicon size was validated by gel electrophoresis on 
1% agarose gels prior to puriication using the QIAquick PCR Puriication kit (Qiagen, 
Venlo, The Netherlands) and cloning into the dual luciferase reporter vector psiCHECK-2 
(Promega, Madison, WI) using T4 DNA Ligase (Fermentas/Thermo Fisher Sci., Waltham, 
MA) according to standard protocols.
COS7 cells were transfected with 100 ng UTR reporter plasmid and 50 pmol microRNA 
mimics as detailed above. 48 hours post-transfection, luciferase activity was assayed using 
the DualGlo Luciferase assay system (Promega, Madison, WI) and recorded for 500 ms 
on a Luminoskan ASCENT (Thermo Scientiic, Waltham, MA) according to manufacturer’s 
instructions. Relative luciferase activity was calculated by dividing the luminescence 
from Renilla luciferase activity by the luminescence from irely luciferase activity and 
normalized to control samples.
HISTONE CHROMATIN-IMMUNOPRECIPITATION (CHIP)  
Cells were harvested using accutase, pelleted and the chromatin crosslinked using 
1% formaldehyde (37% F1268 Sigma-Aldrich) for 8 minutes. Crosslinking activity was 
quenched using 125mM glycine (104201 Merck). Cell pellets were lysed on ice with SDS 
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Genomic Region Chr. Sense Sequence Antisense Sequence
miR-200b/a/429
-2.5kb 1 GGAGGAGCTGGTGTGTTCTC CAAAGCCGCCATTTCACC
-2.0kb 1 GCGGTGATGATTAACCCAAC GTGGCCACAGGTCAAGAAAT
-1.5kb 1 GGTGAGAACGCAATGACTGA CTCCCACTGCCAGGTTCA
-1.0kb 1 TTGGAGGAGGAGACTGGAAC AGTTTTCTGGCACCTTCCAC
-0.5kb 1 GACCAGCAGACACACAAACC GACCCCTCTCCCATGCTG
TSS 1 TACTGAGCTTCCCAGCGAGT AATGCTGCCCAGTAAGATGG
+0.5kb 1 GAGCAGGACCCAACAGAGG CAGGAGGGAAGATGGCTGT
miR-200c/141
-2.5kb 12 CACCTCCAGGTTCCAGCTAC AAATGCTTCCACAGGGTCAG
-2.0kb 12 ACAGGGTGGTTGTGAAAAGC CGCCACGGTAAAATGAGAAT
-1.5kb 12 CATGTCAGGAGTGGGGTTTC CTTTGGGACCTGTGCTGTCT
-1.0kb 12 GACTCCACTGAGGGCTGTG TGAAGTTACCCACCGCTACC
-0.5kb 12 GCCTAGAGGAGTGGCCAAG GGTGTGTCCTCCTGCCATAG
TSS 12 AGGGCTCACCAGGAAGTGT AGGATCCCTGCGGAAAAG
+0.5kb 12 CCCTGTAGCAACTGGTGAGC GGGAGCCATCTTTACCAGAC
miR-101-1
-2.5kb 1 CCACAGGCCTGGTTGTAGAT AATCATTGGCCTTGGTGAAG
-2.0kb 1 TGGGTAGAGCAGAGGGAAGA ATCCTTCATTGTGCCAGTCC
-1.5kb 1 TGACCGCAGACTGAGACTCTT GCCAGGGAGAGAAAAACCAT
-1.0kb 1 TGGAGGTTGAAGATGTGTGC CTGGTCTTGACCTCCTGAGC
-0.5kb 1 TGACAGCAGCAGCAATAACA 
TSS 1 TTCTTCCTGGGTACGGTGAG CCGACACAGTGACTGACAGG
+0.5kb 1 ACTGACTGTGCCTCCCTGAC TGAGCACTTTGAAGACAGGA
DUSP-1 (MKP-1)
-2.5kb 5 CCTCACCCCTGCTCTTTATG ATGGCTTGCAGTGACCTTCT
-2.0kb 5 CAGCAAGGGAGGAGAGAGAA GCCTGGTGACAGAGCAAGAC
-1.5kb 5 GCCTCGCTTAGCTTGTGTGT CACTCCATGCCCTGAACTTT
-1.0kb 5 GCAGTGGATTCCAGGGTTT GAAAGGGATGGAGAAGCTCA
-0.5kb 5 GCTTCCTGTGCTTTTGCATAC CCCCAGTAGTGTGGTTCTGG
TSS 5 CGCTTTTGGACTGAGAGAGG CTCGCTGCGAAGGACATT
+0.5kb 5 AGGGCGTACCTTTGAGGAAG GTGGTGTTGCTGGACGAG
DUSP-6 (MKP-3)
-2.5kb 12 AGGCCTAGGTTGCCAATTTT AAAATGGTGCGGAGAGGAG
-2.0kb 12 ATTGGAAGCCGGATGGAG GCAGGCTTCGGCACTTTTAT
-1.5kb 12 AATGATTTCTGGGCAAGGAG GGTCTTGCGGGAGGACTT
-1.0kb 12 GACCCAAGTTCGCCTTAACC ACACAGCCTCGGCTAAAAGA
-0.5kb 12 AGGCAGCTCCTCAATGGATA TCATCAACACAACCTGTTCCA
TSS 12 GTCTTGCTGATCGCCATTTC AGCTCGACCCCCATGATAG
+0.5kb 12 GGAAGCGAGTGGATTCTGAG CGCGTGGATTGAAAATACCT
Table 3. Primers used for histone CHIP RT- PCR assays
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lysis bufer (1% SDS, 50mM Tris HCl pH 8.0, 10mM EDTA) supplemented with freshly added 
100mM protease inhibitor cocktail (Sigma Aldrich P8340) for 15 minutes. The chromatin 
was fragmented by Biorupter (Diagenode, Seraing, Belgium) with 5 cycles of (30’ ON/
OFF). The sonicated sample was centrifuged and chromatin containing supernatant 
was kept for further analysis. The chromatin was diluted 10 times with RIPA bufer 
(0.1% SDS, 0.1% Sodiumdeoxycholate, 1% Triton-X100, 1mM EDTA, 10mM Tris-HCl pH 
7.5, 140mM NaCl, 0,5mM EGTA) supplemented with 100 mM protease inhibitor cocktail. 
Immunoprecipitation was performed by 4µg H3K27Me3 antibody (Merk Millipore 07-
449) or IgG control (Abcam ab46540) added to the 40uL Dynabeads Protein-A (Life 
technologies, 10002D) coated tubes. Subsequently, the chromatin of 0.8*106 cells was 
added to antibody bound beads and incubated overnight at 40C while rotating. The 
beads were washed 3 times with ice cold PBS and the remaining complexes were eluted 
with 100nM NaHCO3 and 1% SDS in PBS. 5M NaCl and RNAse (Roche #11119915001) were 
added to the eluted samples and incubated at 620C to reversing the crosslink for 4 hours. 
2µL Proteinase K (Roche #03115828001) was added and incubated at 620C for 1 hour 
to liberate the DNA from the histones. DNA fragments were puriied using a QIAquick 
PCR puriication kit (Qiagen) according to manufacturers’ instructions. Precipitated DNA 
was analyzed by qPCR using 7 sets of primers for each promoter area. (Table 3; all 0.6µM 
Biolegio) Enrichment of promoter sequences in the precipitate was calculated relative to 
the percentage of input.
ANGIOGENIC SPROUTING ASSAY  
10µL Matrigel (BD Corning, 356230) was added into the bottom compartment of µ 
slide Angiogenesis (81501, Ibidi GmbH, Martinsried, Germany) and incubated at 370C, 5% 
CO2 for 1 hour. Cells were diluted to 2*10
6 cells/ml. 50µl cell suspension was added on top 
compartment. After 6 hours incubation at 370C, 5% CO2, light microscopy images were 
obtained and complete octamer niches were counted by eye. 
COLLAGEN CONTRACTION ASSAY 
Cells were dissociated using trypsin-EDTA, pelleted and suspended at a concentration 
of 22.5*106 cells/ml ECM. 45µL cell suspension was added to a collagen solution (3.3mg/ml 
rat tail collagen type I (#354236, BD, San Jose, CA), 100mM Na2HPO4 and 5mg/ml NaHCO3) 
of neutral pH. The cell/collagen mixture was immediately aliquoted into 50ul droplets and 
allowed to polymerize at 370C, 5% CO2
 for 30 min. Polymerized gels were released and 1mL 
of ECM was added. At time points t=0 hours and t=24 hours, gels were visualized using a 
regular latbed scanner and the gel surface area quantiied using with ImageJ (NIH). Gel 
contraction was calculated as the relative reduction in gel surface area at 24 hours. 
PERMEABILITY ASSAY 
Cells (5*104/cm2) were cultured on polycarbonate cell culture inserts strips (pore size 
0.4µm, porosity, 0.9*108/cm2 Fisher Scientiic, #15639536) coated with 0.1% gelatin for 72 
hours to establish a monolayer. Monolayer permeability was assessed by the addition 
of 5 µg/mL FITC dextran (Sigma) in upper compartment. Fluorescence was measured 
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in the bottom compartment on luorescence reader at Ex485/Em519 30 minutes 
after the addition of dextran. Relative permeability levels were calculated using the 
luorescence signal of a naked strip (100% permeability) or the luorescence signal from 
the culture medium (0% permeable). Permeability was calculated by following formula: 
Permeability=(Em519(sample)- Em519(ECM))/ Em519(Empty well)*100.
DATA REPRESENTATION OF STATISTICAL ANALYSES 
Data are expressed as mean ± s.e.m. from at least ive independent experiments. Where 
the mean of two groups were compared, p-values were calculated using student t-tests. 
Otherwise, p-values were calculated using the one-way analysis of variance (ANOVA) 
followed by Bonferroni’s post-hoc comparisons tests using Prism Graphpad (Graphpad 
Software, La Jolla, CA, USA). P < 0.05 was considered statistically signiicant. 
RESULTS
RECIPROCITY BETWEEN MAPK7 AND EZH2 IN CORONARY ARTERY STENOSIS
Human coronary artery samples were stratiied into three groups based on their intima/
media thickness, ranging from mild stenosis (IMT <1 µm·µm-1), medium (IMT 1-3 µm·µm-1) 
and severe stenosis (IMT >3 µm·µm-1; ig,1a-d). Coronary artery stenosis is characterized 
by progressively increasing intima-media thickness (ig.1a-d), wherein coronary artery 
MAPK7 expression decreases with an increasing stenosis (r2=0.2517, p=0.04; ig.1f). In 
contrast, EZH2 expression is elevated in coronary artery stenosis (ig.1g,h) and increasing 
stenosis associates with increased EZH2 expression (r2=0.4417, p=0.004, ig.1h),




Figure 1. Reciprocity between MAPK7 and EZH2 in human coronary artery stenosis. (a-c) Representative 
pictures of Verhoef-stained human coronary artery samples with mild (IMT<1, a), medium (IMT 1-3, b) or severe 
(IMT >3, c) stenosis. Intima-media thickness was measured (µm/µm) and divided in groups based on their intima-
media thickness (d). MAPK7 expression levels were determined by qPCR and normalized to mild stenosis (e). MAPK7 
decreases with increasing stenosis (f). EZH2 expression levels were determined by qPCR and normalized to mild 
stenosis (g). EZH2 expression increased with stenosis severity (h). *p<0.05, ***p<0.001.
RECIPROCAL SIGNALING BETWEEN MAPK7 AND EZH2 IN ENDOTHELIAL CELLS
We recently uncovered that disturbed luid shear stress contributes to intima 
hyperplasia by the induction of endothelial-mesenchymal transition (EndMT)(5), partially 
mediated by EZH2(18). Atheroprotective uniform laminar shear stress (LSS) decreases 
EZH2 expression at both the gene (2.2-fold, p<0.001; ig.2a) and protein (1.9-fold, p=0.028; 
ig.2b) level. Uniform laminar shear stress does not change the expression of MAPK7, 
neither on transcript (ig.2c) nor on protein level, however, FSS increases the activity 
of MAPK7 as indicated by the increased phosphorylation (3.5-fold, p=0.036, ig.2d). 
Knockdown of EZH2 does not alter its expression, whereas MAPK7 activity is increased 
upon EZH2 reduction (1.9-fold, p=0.049; ig. 2d). Moreover, protein expression levels of 
EZH2 associate with MAPK7 activation (r2=0.7723, p=0.021; ig.2e) proving evidence of the 




Figure 2. Reciprocal signaling between MAPK7 and EZH2 in endothelial cells. EZH2 expression levels were 
determined by qPCR in HUVEC exposed to FSS (20dyne/cm2) compared to static controls (a). EZH2 protein levels 
were determined by western blot in HUVEC exposed to FSS and compared to static control (b). MAPK7 expression 
levels were determined by qPCR in HUVEC exposed to FSS, and HUVEC that are deicient in EZH2 (shEZH2)(c). MAPK7 
activation (pMAPK7) levels were determined by immunoblotting and normalized to total MAPK7 protein levels (d 
Protein expression of EZH2 and MAPK7 activation were associated in endothelial cells (e). ***p<0.001.
 
MAPK7 DECREASES EZH2 THROUGH MICRORNA-101
As MAPK7 decreases EZH2 post-transcriptionally(18), we investigated whether 
miRNA-101 - a known translational repressor of EZH2 in endothelial cells(25) - is regulated 
by MAPK7 signaling. FSS increased the expression of miR-101 in a MAPK7-dependent 
manner (2.3-fold, p<0.01; ig. 3a). In luciferase reporter assays, miR-101 binds to the 3’UTR 
of EZH2, reducing the luminescence signal (1.9-fold, p<0.001; ig.3b). In endothelial cells, 
ectopic expression of miR-101 decreases EZH2 expression at both the gene (2.6-fold, 
p=0.002; ig. 3c) and protein (2.9-fold, p=0.008; ig. 3c) level, whereas miRNA-101 has 
no efect on MAPK7 gene expression (ig. 3e) or MAPK7 protein expression level (ig.3f). 
In human coronary artery stenosis, miR-101 expression is decreased (p<0.01, ig.3g) and 
increased stenosis associates with a progressive decrease in miR-101 (r2=0.5109, p=0.001, 
ig.3h). Moreover, the expression level of miR-101 associates with MAPK7 (r2=0.4262, 
p=0.005; ig.3i) and EZH2 (r2=0.2304, p=0.051; ig.3j) in coronary artery stenosis, where a 
negative association between MAPK7 and EZH2 expression (r2=0.2568, p=0.038; ig.3kj) is 
present. Collectively, these data suggest that in coronary artery stenosis, the reciprocity 
between MAPK7 activity and EZH2 expression is regulated by miR-101. 
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Figure 3. MAPK7 decreases EZH2 through miRNA-101. MiR-101 expression levels were determined 
by qPCR in HUVEC exposed to FSS (20dyne/cm2) with or without the MAPK7 inhibitor BIX02189 and 
normalized to the level of static controls (a). Luciferase reporter binding assays were performed for 
the 3’UTR of EZH2 in HUVEC with ectopic expression of miR-101 or scrambled control sequences 
(scr). Luciferase activity was normalized to non-transfected cells (b). EZH2 and MAPK7 expression 
levels were determined by qPCR in HUVEC with ectopic expression of miR-101 or SCR and normalized 
to control (c, e). EZH2 and MAPK7 protein levels were determined by western blot in HUVEC with 
ectopic expression of miR-101 and control (d, f). MiR-101 expression levels were determined by qPCR 
and normalized to mild stenosis (g). MiR-101 decreases with stenosis severity (h), and associates with 
MAPK7 (i) and EZH2 (j) expression levels. In coronary artery stenosis, MAPK7 expression negatively 
correlates to EZH2 expression (k). *p<0.05, **p<0.01, ***p<0.001.
EZH2 REGULATES DUSP-1 AND DUSP-6 EXPRESSION THROUGH MIR200A-C
However, EZH2 is a transcriptional repressor that cannot directly regulate the activity 
of a kinase. MAPK7 activity is regulated by the Dual Speciicity Phosphatases (DUSP)-1 and 
DUSP-6(21), yet a reduction in EZH2 expression is associated with a decreased expression 
of DUSP-1 and DUSP-6(26, 27). Therefore, we investigated alternative mechanisms that 
might decrease DUSP expression upon the reduction of EZH2. In silico analysis, using 
Targetscan.org(28), putatively identiies the microRNA-200 family (miR-200a, miR-
200b, miR-200c, miR-141 and miR-429) as regulators of DUSP-1 and DUSP-6. Therefore, 
we investigated if the expression of the miR-200b/a/429 cluster on chromosome 1 and 
the miR-200c/141 cluster on chromosome 12 are under control of EZH2.  Uniform LSS 
increased the expression of miR-200b (2.5-fold, p=0.008) and miR-200c expression (2.5-
fold, p=0.001; ig.4a,e). Moreover, knockdown of EZH2 increased the expression of miR-
200b and miR-200c to a similar extend (ig.4a,e). 
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Figure 4. EZH2 regulates DUSP-1 and DUSP-6 expression through miR200a-c. MiR-200b (a) and miR-200c (e) 
expression levels were determined by qPCR in HUVEC exposed to FSS (20 dyne/cm2), transduced HUVEC with scr or 
shEZH2 and normalized to static or scr control cells. H3K27me3 enrichment around the transcription start site (TSS) 
of the miR-200b/a/429 cluster was determined using ChIP in shEZH2-HUVEC and scr-HUVEC (b) and MEK5D-HUVEC 
and EV-HUVEC (c). H3K27me3 enrichment is shown as area under the curve (AUC) compared to input samples (d). 
H3K27me3 enrichment at the around the TSS of miR-200c/141 cluster was determined using ChIP in scr-HUVEC and 
shEZH2 (f) and in MEK5D-HUVEC and EV-HUVEC (g). H3K27me3 enrichment is shown as AUC compared to input 
samples (h). Luciferase reporter assays for microRNA binding were performed for the 3’UTR of DUSP-1 in HUVEC with 
ectopic expression of miR-200a, -200b, -200c, -141, -429 or SCR (i). DUSP-1 expression levels were determined by qPCR 
in HUVEC with ectopic expression of miR-200b, miR-200a, miR-429, miR-200c, miR-141 or scr, normalized to control 
(j). Luciferase reporter assay identiied miR-200a and miR-141 to target DUSP-6 (k) and ectopic expression of miR-
200a or miR-141 decreases DUSP-6 expression in endothelial cells (l). *P<0.05, **P<0.01, ***P<0.001.
INHIBITION OF DUSP ACTIVITY INCREASES MAPK7 ACTIVITY AND DECREASES EZH2 EXPRESSION
H3K27Me3, the repressive histone mark placed by EZH2, is abundantly present in 
the promoter regions of the miR-200b/a/429 and miR-200c/141 gene clusters (ig.4b,f). 
Endothelial cells deicient in EZH2 have reduced levels of H3K27Me3 at these gene 
promoters (ig.4b,f), which associates with the increased expression of miR-200b and 
miR-200c. In endothelial cells with constitutively active MAPK7 signaling (MEK5D), the 
enrichment of H3K27Me3 at the promoter regions of miR-200b/a/429 (1.6-fold, p=0.034; 
ig.4c,d) and miR-200c/141 (1.9-fold, p=0.035; ig.4g,h) is decreased, suggesting that 
RECIPROCITY OF MAPK7 AND EZH2 ACTIVITY IN CORONARY ARTERY STENOSIS
121
5
MAPK7 activation results in the increased expression of miR-200 family members through 
the decrease in EZH2 activity. 
In luciferase reporter assays, all miR-200 family members were able to bind to the 
3’UTR of DUSP-1 (ig.4i), but only miR-200a and miR-141 were able to bind the 3’UTR of 
DUSP-6 (ig.4k). Corroboratively, exogenous expression of all miR-200 family members 
in endothelial cells decreased DUSP-1 expression (ig.4j), whereas only miR-200a and 
miR-141 decreased the expression of DUSP-6 (ig.4l). Collectively, these data imply that 
the activation of MAPK7 by uniform LSS decreases the expression of DUSP-1 and DUSP-
6 expression via the EZH2-dependent regulation of miR-200b/a/429 and miR-200c/141 
expression. 
Figure 5. Inhibition of DUSP activity increases MAPK7 activity and decreases EZH2 expression. 
MAPK7 (a) and EZH2 (b) protein expressions were determined using western blotting, in HUVEC 
treated with 5µM of the DUSP-1/6 small molecule inhibitor BCI and normalized to untreated control 
cells. DUSP-1 expression levels were determined in uman coronary artery stenosis samples by qPCR 
and normalized to mild stenosis (c). DUSP-1 expression increases with increasing stenosis severity 
(d) and is associated to EZH2 expression levels (e). DUSP-1 levels show a negative correlation with 
MAPK7 levels in stenosis (f). DUSP-6 expression levels were determined by qPCR and normalized to 
mild stenosis (g). DUSP-6 expression is elevated in coronary artery stenosis, but does not associate 




We investigated if the pharmacological inhibition of DUSP-1 and DUSP-6 activity in 
endothelial cells would activate MAPK7 signaling and decrease the expression of EZH2. 
BCI-treated endothelial cells increased MAPK7 phosphorylation (1.9-fold, p=0.007; ig.5a) 
and decreased EZH2 expression (1.8-fold, p=0.002; ig.5b). In human coronary artery 
stenosis, DUSP-1 is increased (p<0.001, ig. 5c) and increased stenosis associates with 
increased DUSP-1 expression (r2=0.2767, p=0.0301; ig.5d). Moreover, the increase in DUSP-
1 expression associates with increased EZH2 expression in stenosis (r2=0.4541, p=0.0030; 
ig.5e) and increase in DUSP-1 expression seems to correlate with decreased MAPK7 
expression (r2=0.1686, p=0.1016; ig.5f), although not signiicantly. Also DUSP-6 seems to 
be increased in coronary artery stenosis (p<0.1, ig.5g), the increase in DUSP-6 expression 
does not associate with the severity of stenosis (r2=0.0681, p=0.3116; ig.5h), nor do the 
expression levels of DUSP-6 associate with EZH2 (r2=0.0734, p=0.2929; ig.5i) and MAPK7 
expression (r2=0.0163, p=0.6251; ig.5j).
Figure 6. Ectopic expression of miRNA-101, miRNA-141 and miRNA-200a inhibits endothelial 
dysfunction and EndMT. MAPK7 (a) and EZH2 (b) protein expressions were determined using 
western blotting, in HUVEC treated with 10ng/ml TGFb1 with ectopic expression of miRs-101, -200a 
and -141 and normalized to untreated control cells. The expression of VE-Cadherin (c,d) and SM22a 
RECIPROCITY OF MAPK7 AND EZH2 ACTIVITY IN CORONARY ARTERY STENOSIS
123
5
(c,e) were assessed by immunoluorescence and quantiied using TissueFaxs analyses. Endothelial cell 
permeability was assessed using transwell FITC-dextran leakage (f) and collagen gel contraction (g) 
was assessed as a mesenchymal cell function. The angiogenic sprouting behavior of endothelial cells 
was assessed using the Matrigel assay (h). *p<0.05, **p<0.01, ***p<0.001.
As coronary artery stenosis is associated with EndMT(1, 29), we investigated if the 
ectopic expression of miR-101 or miR-200 family members could preclude EndMT. 
Endothelial cells transfected with only a single microRNA were susceptible to TGFβ1-
induced EndMT (data not shown), however, when miR-101, miR-200a and miR-141 were 
transfected in combination, endothelial cells increased their MAPK7 activity (ig.6a) and 
showed reduced expression levels of EZH2 (ig.6b). Corroborating the protective efects 
of MAPK7 signaling in the preclusion of EndMT(5), TGFβ1 stimulation did not decrease 
VE-Cadherin expression (ig.6c,d) nor induce the expression of the mesenchymal marker 
protein SM22α (ig.6c,e) in endothelial cells transfected with miRs-101/200a and -141. 
Moreover, the ectopic microRNA expression reduced the TGFβ1-induced increase in 
endothelial permeability by ~40% (ig.6f) and precluded the TGFβ1-induced collagen 
contraction (ig.6g) – two functional adaptations associated with EndMT – and maintained 
the endothelial angiogenic sprouting capacity (ig.6h).
 DISCUSSION
In this study, we show that reciprocity exists between the atheroprotective MAPK7 
activation and the expression of histone methyltransferase EZH2 in endothelial cells. The 
reciprocity is regulated by the MAPK7-induced silencing of EZH2 expression by miR-101 
and the EZH2-mediated silencing of the miR-200 family, which increases DUSP-1 and 
DUSP-6 expression and inhibits MAPK7 activation. The reciprocity between MAPK7-
EZH2 might relect an autoregulatory feedback loop in endothelial cells that ensures 
endothelial homeostasis. As such, disturbances in this reciprocity leading to increased 
EZH2 expression can induce endothelial dysfunction and EndMT. In contrary artery 
stenosis - a condition associated with EndMT(1, 29) – the reciprocity between MAPK7 and 
EZH2 is disturbed, resulting in elevated expression of DUSP-1 and EZH2 and the decreased 
expression of MAPK7. Restoring the reciprocity by ectopic expression of miR-101/200a/141 
precludes EndMT and might ofer therapeutic beneit in coronary artery stenosis. 
EndMT contributes to intimal hyperplasia during coronary artery stenosis(1-5), wherein 
MAPK7 signaling plays a protective role(5, 16). Yet, during intimal hyperplasia the signaling 
activity of MAPK7 is rapidly lost (Vanchin et al., J. Pathol, under revision). DUSP-1 and 
DUSP-6 expression levels are elevated in a number of cardiovascular diseases and DUSP-
1 deicient mice are protected from atherosclerosis development (30, 31). The elevated 
expression of DUSPs might explain the loss in protective MAPK7 signaling activity during 
coronary artery stenosis, which is corroborated by our inding that pharmacological 
inhibition of DUSP-1/6 is suicient to activate MAPK7 signaling.
The expression of DUSP-1 and -6 is associated with high expression of EZH2 in various 
oncology’s(26, 27), albeit by a currently unknown mechanism. We found that EZH2 silences 
the expression of the microRNA-200 family, which posttranscriptionally regulate the 
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expression of DUSP-1 and DUSP-6 (ig.7). The loss of EZH2 expression by luid shear stress 
therefore might increase the expression of miR-200 family members and decrease the 
expression of the DUSPs culminating in atheroprotective MAPK7 activation. Interestingly, 
the endothelial cell-speciic overexpression of miR-200b precludes EndMT and alleviates 
diabetic cardiomyopathy in mice(32). In coronary artery stenosis, EZH2 expression levels 
are elevated and high EZH2 expression is associated with endothelial dysfunction(18, 19).
 
Figure 7. Schematic representation of the reciprocity between MAPK7 activity and EZH2 
expression. Hemodynamic force (laminar shear stress) induces the activation of MAPK7 signaling, 
resulting in the expression of microRNA-101 that posttranscriptionally silences EZH2 expression. This 
culminates in the hypomethylation of H3K27 at the promoters of the miR-200 family and the miR-200-
mediated silencing of DUSP-1/6. In the absence of laminar shear stress – e.g. during coronary artery 
stenosis – EZH2 expression is increased resulting in the reduction of miR-200 expression and increase 
in DUSP-1/6 expression. DUSP-1/6 dephosphorylate MAPK7 culminating in a decrease in its activation.
In combination, our current data might explain these observations and uniies them 
into a single mechanism, linking endothelial mechanotransduction to the epigenetic 
regulation of MAPK7 activity through DUSP-1/6 (ig.7). This double negative feedback 
loop might resemble a sensitive autoregulatory mechanism that ensures endothelial 
homeostasis, which when disturbed culminates in EndMT and possibly coronary artery 
stenosis. 
In summary, we show that in endothelial cells there is reciprocity between MAPK7 
signaling and EZH2 expression and that disturbances in this reciprocal signaling circuit 
associate with the induction of EndMT and severity of human coronary artery stenosis. 
The reciprocity between MAPK7 and EZH2 is governed by a complex mechanism involving 
microRNAs and the phosphatases DUSP-1 and DUSP-6 (ig.7). Our study contributes to 
a better understanding of the molecular and epigenetic cascades that underlie EndMT 
during coronary artery stenosis and might identify novel targets for therapy. 
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Endothelial cells give rise to a population of myoibroblasts in cardiac ibrosis through 
a mechanism called endothelial-mesenchymal transition (EndMT). The process by which 
EndMT takes place in cardiac ibrosis is incompletely understood. Galectin-3 (Gal-3) has 
been identiied as a novel biomarker for heart failure and its pharmacological inhibition 
reduced cardiac ibrosis. Here, we investigated if inhibition of Gal-3 is able to attenuate 
EndMT in vitro. The expression and function of Gal-3 in TGFβ1-induced EndMT was 
studied in Human Umbilical Vein Endothelial cells (HUVECs). TGFβ1-induced EndMT 
leads to increased Gal-3 transcription and expression. siRNA-mediated knockdown of 
Gal-3 attenuates TGFβ1-induced EndMT whereas recombinant GAL-3 did not induce, not 
aggravate TGFβ-induced mesenchymal transition. Our indings indicate that intracellular 
Gal-3 facilitates EndMT, suggesting a role for Gal-3 as transcriptional coactivator in EndMT. 




Heart failure (HF) is a clinical syndrome in which the heart is unable to pump a suicient 
amount of blood to meet the body’s needs. Based on the ejection fraction, the heart 
failure is classiied into the heart failure with preserved, mid-range and reduced ejection 
fraction (1). Heart failure with preserved ejection fraction (HFpEF) or diastolic dysfunction 
is more common in older individuals, with risk factors such as hypertension, obesity or 
coronary artery diseases (2). The pathologic basis of HFpEF is left ventricular remodeling, 
especially abnormal left ventricular relaxation and an increased left ventricular myocardial 
stifness (3). The pathologic basis of the myocardial stifness in the heart is explained by 
cardiac ibrosis, which encompasses hyperproliferation of myoibroblasts and excessive 
deposition of extracellular matrix in the cardiac muscle. 
Cardiac ibroblasts are responsible for the production of extracellular matrix (ECM). 
The ECM serves as a structural scafold for cardiomyocytes, distributing mechanical forces 
throughout the cardiac tissue and mediating electronic conduction. The production of 
ECM is a continuous process where older collagen is broken down and new collagen is 
deposited (4, 5). However, in response to injuries (e.g. ischemia, hypertension, degeneration 
etc), ibroblasts undergo a phenotypic transition into myoibroblast (6). Myoibroblasts 
secrete excessive amounts of collagen and produce alpha smooth muscle actin (αSMA), 
a protein encoded by the ACTA2 gene.  Together with myosin, αSMA forms a contractile 
complex involved in wound closure (7, 8).  The excessive deposition of ECM culminates in 
several pathologies, such as reduced cardiac contractility, diastolic dysfunction, impaired 
coronary blood low and malignant arrhythmias. Altogether, these processes lead to a 
decrease in tissue compliance and impairs cardiac function, ultimately accelerating the 
progression of heart failure (9). 
The myoibroblasts in cardiac tissue displays a large heterogeneity that can partially 
be explained by the diferent origins of the myoibroblasts. Next to resident ibroblasts 
(10), also bone marrow-derived myoibroblasts (11), circulating monocyte-derived 
myoibroblasts (12) and endothelium-derived myoibroblasts (13) have been identiied. 
The process by which endothelial cells progressively lose their endothelial functionality 
and gain myoibroblast-like properties is called endothelial-to-mesenchymal transition 
(EndMT). A protein associated with heart failure, as well as ibrosis is Galectin-3 (Gal-3), 
which is encoded by the LGALS3 gene. Increased levels of circulating Gal-3 were measured 
in heart failure patients (14, 15), and the infusion of Gal-3 into the pericardial sac of rats 
resulted in increased myocardial ibrosis and cardiac dysfunction(16). Furthermore, the 
genetic and pharmacological inhibition of Gal-3 in murine models for HFpEF attenuated 
ibrosis and αSMA expression in ibroblasts compared to the controls(17). Hence, we 
hypothesized that GAL-3 might be involved in EndMT as an underlying pathological 
process in cardiac ibrosis. In this study, we investigated efects of Gal-3 on EndMT and 




CELL CULTURE AND STIMULATION
Human umbilical vein endothelial cells (HUVEC, Lonza, Walkersville, MD) were cultured 
on 1% gelatin-coated (Sigma, #G9391, St. Louis, MO) lasks or wells. Cells were detached 
using Trypsin EDTA in PBS (TEP, GIBCO #15400054) solution. Experiments were performed 
between passage 5 to 7. Cells were cultured in endothelial cell medium (ECM) consisting 
of RPMI 1640 basal medium (Lonza, #BE12-702F, Verviers, Belgium) with heat inactivated 
Fetal Bovine Serum (Lonza, 20% v/v), Heparin (LEO, #BE013587 5U/ml),  Endothelial Cell 
Growth Factor (ECGF; own preparation 50 µg/ml), penicillin / streptomycin (Gibco, #15140-
122, (1%v/v)) and L-Glutamine (Lonza, #BE17-605E 2nM) at 37°C, 5% CO2. 
Unless stated otherwise, TGFβ1 stimulation was performed by culturing cells for 96h 
in ECM without ECGF, with 10ng mL-1 TGFβ1 (R&D systems, #240b, batch 15072). Control 
conditions were cultured in regular ECM.  For recombinant human Gal-3 (rh-Gal-3) 
stimulation, cells were stimulated with TGFβ1 as described, of which the inal 18h of 
stimulation 20µg/mL rh-Gal-3 (Acro Biosystems, GA3-H5129) was added. During TGFβ1 
stimulation, medium was refreshed daily.  
SIRNA TRANSFECTION
HUVEC were transfected at 60-80% conluency. Prior to transfection, cells were pre-
incubated with Opti-MeM (ThermoFischer, #31985062) at 37°C. siRNA transfection mixes 
(315.6nM siRNA and 315.7 nM Lipofactamine 2000 (Invitrogen, #19155578)) prepared with 
either siRNA against Gal-3 (LGAL3 silencer select siRNA, Ambion, #4392421) or the control 
siRNA (All-star negative control siRNA, Qiagen, #1027281). Transfections were performed 
by adding 26.3 uL Lipofectamine / siRNA transfection mix per cm2 culture area. Cells 
were incubated with transfection mix for 8h at 37°C and 5% CO2, after which transfection 
medium was replaced by ECM. After a recovery period of 18h cells were stimulated with 
TGFβ1 as described earlier. 
GENE EXPRESSION ANALYSIS
Cells were lysed in TriZOL (Ambion, #15596-018). RNA was isolated by phenol/
chloroform (Emparta) extraction in accordance with the TriZOL manufacturers’ guidelines. 
RNA was precipitated using 75% Ethanol, air-dried and resuspended in RNAse-free water. 
RNA concentration and purity were determined via Nanodrop 1000 spectrophotometer 
(Thermo Scientiic) and checked the integrity by gel electrophoresis. cDNA was synthesized 
using the Revert Aid First strand cDNA synthesis kit (Thermo scientiic, #K1622) according 
to the manufacturers guidelines using 500ng RNA as input material. Real-time PCR (ViiA7 
Real Time PCR System, Thermo Fischer) was performed by combining cDNA (1ng/µl) with 
primer master mix (1.2 µm forward and reverse primers, 2x SYBR Green, (Roche, FastStart 
Universal SYBR Green Master, #04913914001)) in a 1:1 ratio in a total volume of 10µl per 
well. Data was analyzed using the ViiA7 software (Thermo Scientiic) and fold change was 
calculated using the 2-∆∆Ct method. Primer sequences are shown in table 1.
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Cells were lysed in RIPA bufer (Thermo Scientiic, #89901) supplemented with 
protease inhibitor cocktail (Sigma-Aldrich #P8340, 1:100v/v) and phosphatase inhibitor 
cocktail (Thermo Fisher Scientiic, #78420 (1:250 v/v)). Samples were loaded on 4-20% 
precast gradient gel (Bio-Rad, #4561083). SDS-PAGE gels were blotted onto nitrocellulose 
membranes (Bio-Rad, #1704270) using the transblot turbo system (Bio-Rad) according to 
the guidelines of the manufacturer. Membranes were blocked for 1h in odyssey blocking 
bufer (Li-Cor #92740000). Membranes were incubated overnight at 4°C with primary 
antibodies for either Gal-3 (Cell Signaling #87985, 1:500v/v) or β-Actin (Cell signaling 4967L, 
1:2000). Membranes were washed three times in TBS with 0.1% tween (Sigma, #p2287)
(TBST) and incubated with secondary antibody (goat anti-rabbit IgG [Li-Cor #926-68021] 
1:10000 v/v in blocking bufer) for 1h at room temperature. Membranes were washed 2 
times with TBST, 1 time with TBS and scanned with the Odyssey® CLx (Li-Cor), using the 
700 nm channel. Scans were analyzed using Image Studio lite edition (Odyssey, V5.2). 
IMMUNOFLUORESCENCE
12 Hours prior to immunoluorescence analysis, transfected and stimulated HUVEC 
were re-seeded at 80% conluency in NUNC LAB-TEK 8 well chamber slides (Sigma-Aldrich, 
C7182-1CS). After overnight incubation, cells were ixed with 2% paraformaldehyde for 
20 min and permeabilized with 0.5% Triton X in PBS for 5 min. Samples were blocked 
in 3% Bovine Serum Albumin (Sanquin, #800228065) in PBS for 20 min, and incubated 
with primary antibodies against Collagen 3 (Cell Signaling, #ab7778 1:50 v/v), or eNOS 
(BD Pharmingen, #610299 1:100v/v) diluted in PBS containing 2% BSA for 1 hour at room 
temperature. Cells were washed with PBS and incubated with Goat anti-Rabbit IgG (H+L) 
Alexa Fluor 594 secondary antibody (Invitrogen, #A11037 1:500 v/v) and DAPI (Sigma-
Aldrich #D9542 1:5000v/v) in PBS containing 2% BSA for 20 minutes at RT. Image was 




Cells were harvested by trypsinization and incubated with CD31-PE (IQ Products, 
#IQP-552R50 1:10 v/v) and matching isotype controls (IQ Products, #IQP-191 1:20 v/v) in 
FACS Bufer (2mM EDTA (Sigma, #ED-100G) and 0.5% FBS in PBS) at 4°C for 30 min. Cells 
were washed in FACS bufer, ixed in 2% PFA (w/v) in PBS for 20 min, washed in FACS 
bufer, permeabilized in ( 0.1% Saponin (Sigma, 47036-50G-F), 0.5% FBS in PBS) for 10 min, 
incubated for 30 min at 4°C with αSMA (Abcam, #Ab7817 (1:50v/v)) and FSP1 (Biorbyt, 
#ORB88159(1:250 v/v)) conjugated to FITC using the FITC conjugation kit (Abcam,  #188285) 
prior to the staining. Samples were analyzed on a BD FACSCALIBUR low cytometer. 
Analysis was performed using Kaluza analysis software (Beckman)
ANGIOGENIC SPROUTING CAPACITY
µ-Slides (Ibidi, #81506) were coated with 10 µl Matrigel (Corning, #354248)) and allowed 
to solidify for 1 hour.  Cells were harvested by trypsinization and seeded at a density of 
15.000 cells per well. Images were recorded 24h post-seeding. Sprouting capability was 
quantiied by counting complete hexagonal shapes. 
STATISTICAL ANALYSIS
Data are presented as means± s.e.m. Multiple comparison one-way ANOVA was 
performed to evaluate the diference between groups and p-values < 0.05 were 
considered to statistically signiicant.
RESULTS
TGFβ1 INDUCES GAL-3 EXPRESSION IN ENDOTHELIAL CELLS
In order to study the efect of a Gal-3 on EndMT, we induced siRNA mediated knockdown 
of LGALS3. Silencing of Gal-3 in endothelial cells reduced LGALS3 gene expression to an 
almost undetectable level (ig. 1a) and a 5-fold (p=0.549) decrease at the protein level 
was observed. These indings indicate that siRNA mediated intracellular Gal-3 silencing 
was efective. The TGFβ is main inducer of EndMT, hence we questioned whether TGFβ 
modulates Gal-3 expression.  TGFβ1 stimulation increased the expression of LGALS3 
(~3-fold,p<0.05) and protein expression of Gal-3 (p<0.01) compared to unstimulated 
controls (ig. 1a and ig.1b). These results indicate that TGFβ1 induce Gal-3 gene and 
protein expression in endothelial cells.





Figure 1. GAL-3 expression is induced by TGFβ1 and successfully inhibited by siGAL3.  a) LGALS3 expression 
levels were determined by quantitative RT-PCR. Under TGFβ1 stimulation, GAL3 is upregulated, whereas siGAL 
transfection successfully decreased GAL3 expression. B) Representative western blots of Gal-3 expression. Quantiied 
GAL-3 protein expression normalized against β-actin.  Statistical analysis in this picture: one-way ANOVA test 
*p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001
SIGAL-3 INDUCED KNOCKDOWN OF GAL-3 ATTENUATES ENDMT PROGRESSION 
Since Gal-3 expression increased upon TGFβ1 stimulation, we studied its efect on 
EndMT. TGFβ1-induces EndMT in HUVEC via the canonical and non-canonical pathway. 
HUVECs deicient in GAL-3 had lower expression levels ACTA2 (p< 0.05), S100A4 (p< 0.01), 
and COL3A1 (p< 0.01),  as compared to TGFβ1-treated cells (ig. 2a). At the protein level, 
αSMA (p< 0.0001)  and FSP1 (p< 0.001) expression was increased in endothelial cells 
treated with TGFβ1 compared to control HUVECs. Knockdown of GAL-3 reduced the TGFb-
induced expression of αSMA (p< 0.01), FSP1 (p< 0.05) (ig. 2b) and Collagen III (ig. 2c).
EndMT is not only characterized by the increased mesenchymal gene expression but 
also by the loss of endothelial speciic gene expression and functions. eNOS expression 
was higher in Gal-3 deciient cells compared to their control HUVECs. TGFβ1-treatment 
abrogated eNOS expression and siRNA against Gal-3 mildly rescued the TGFβ1-induced 
eNOS decline. (ig. 2d)
Moreover, TGFβ1-stimulation lead to less angiogenic sprouting capacity of endothelial 
cells compared to unstimulated controls. A knockdown of Gal-3 slightly improved the 
angiogenic sprouting capability after 24h (ig. 2e, ig. 2f). Combined, these data indicate 
that Gal-3 inhibition attenuates EndMT.
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Figure 2. siGAL3 mediated knockdown of Gal-3 attenuates EndMT progression. a) ACTA2, S100A4 and 
COL3A1 transcription levels were determined by quantitative RT-PCR and normalized against its control condi-
tions. siGAL3 attenuates TGFβ1 induced ACTA2, S100A4 and COL3A1 transcriptional increment. b) Gal-3 deicient 
endothelial cells have signiicantly lower expression of αSMA  and FSP1 upon TGFβ1 stimulation compared to TGFβ1 
stimulated negative controls  c) Collagen III  level was evaluated by the immunoluorescence staining and DAPI 
(blue) and COL3A1 (red) are shown. Upon TGFβ1 stimulation Collagen III protein expression increases, whereas this 
increment is attenuated by the siRNA against GAL-3. d). Representative immunoluorescence images of DAPI (blue) 
and eNOS (red). TGFβ1 stimulation reduces eNOS expression, whereas a knockdown of Gal-3 directly increases 
eNOS expression compared to ECM control conditions. e) Representative bright ield images of sprouting capabili-
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ties of HUVECs. Although it is not statistically signiicant, the TGFβ1 treated cells lose their endothelial functionality 
compared to their controls. There has tendency that siGAL3 attenuates the loss of endothelial functionality. f) 
Quantiication of angiogenic sprouting capability by scoring intact meshes after 24h. Statistical analysis in this 
igure: one-way ANOVA test *p<0.05, **p<0.01, ***p<0.001 and ****p<0.000
EXTRACELLULAR GAL-3 DOES NOT MODULATE TGFΒ1-INDUCED ENDMT 
Galectin-3 facilitates EndMT, albeit through an unknown mechanism. We investigated 
if Gal-3 signaling through its receptors might induce or aggravate of EndMT by treating 
HUVEC with recombinant Gal3. rhGAL3 did not induce the expression of αSMA and FSP1 
in control endothelial cells, nor did the addition of rhGal3 aggravate the TGFβ1-induced 
expression of αSMA and FSP1. These indings suggest that extracellular GAL3 does not 
inluence EndMT, but rather intracellular levels of GAL3 modulate EndMT  in vitro (ig. 3).
Figure 3. Extracellular Gal-3 doesn’t modulate EndMT. Population of cells undergoing EndMT were analyzed 
via low cytometry by double staining for endothelial marker CD31 and mesenchymal marker aSMA or FSP1. TGFβ1-
induced aSMA and FSP1 expressions is unaltered by rh-Gal-3. *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001
ENDMT TRANSCRIPTION FACTOR SNAI1, SNAI2 AND TWIST1 ARE MODULATED VIA INTRACELLULAR GAL-3
GAL3 knockdown had no direct efect on the expression of the EndMT transcription 
factors Snai1, Snai2 and Twist1, whereas TGFβ1 stimulation increased their expression. 
TGFβ1 -stimulated endothelial cells that were deicient in GAL3 had reduced expression 
levels of SNAI1 (p< 0.01), SNAI2 (p< 0.05) and TWIST1 (p=0.512), indicating that GAL3 is 
involved in the transmission of TGFβ1 -induced signaling. (ig. 4) These indings suggest 
that intracellular Gal-3 might be a transcriptional coactivator to TGFβ during EndMT. 
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Figure 4. Gal-3 modulate EndMT transcription factors expression in endothelial cells. SNAI1, SNAI2 and 
TWIST1 gene expression levels were determined by quantitative RT-PCR and data is normalized to GAPDH. TGFβ1 
increased expression of SNAI1, SNAI2 and TWIST1 gene expression and siGAL-3 normalized the expression. *p<0.05, 
**p<0.01, ***p<0.001 
DISCUSSION
In this study we found that Gal-3 facilitates TGFβ-induced EndMT. In the absence of 
TGFβ, Gal-3 does not induce or aggravate EndMT, however in the presence of TGFβ the loss 
of GAL3 expression inhibits EndMT.  In contrast, rhGAL3 didn’t show any efect on both 
control and TGFβ - stimulated condition, suggesting that this modulation is happening 
through intracellular Gal-3. Moreover, our data suggests the GAL3 is not an independent 
modiier of EndMT, but rather acts as an intracellular modulator of TGFβ signaling. 
In this study, gene expression and immunoblotting analysis clearly showed that Gal-3 
expression was induced by TGFβ1. We also showed that a knockdown of Gal-3 is able to 
attenuate the expression of EndMT-related transcription factors SNAI1, SNAI2 and TWIST1. 
However, it remains elusive how GAL-3 modulates this gene expressions. Transcriptional 
control of ibrosis encompasses a highly interactive multi-protein signaling system 
including TGFβ, WNT, YAP/TAZ and other signaling mechanism (18). (19). Herein, Gal-3 can 
bind to the β-catenin/Tcf complex and facilitate its nuclear translocation (20). β-catenin 
is an important part of the WNT signaling cascade and this inding may explain the 
merge between TGFβ and WNT signaling in cardiac ibrosis. During idiopathic pulmonary 
ibrosis, Gal-3 inhibition prevented TGFβ and bleomycin-induced ibrosis via β-catenin 
phosphorylation and nuclear translocation(21). Combined, these data suggest that 
during EndMT, GAL3 might act as a transcriptional coactivator for TGFβ signaling. Further 
research will be needed to identify its signaling partners. 
In conclusion, we show here that intracellular Gal-3 facilitates TGFβ-induced 
endothelial-mesenchymal transition in endothelial cells, possibly via the potentiation of 
TGFβ signaling. 
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The ultimate goal of cardiovascular medicine is to reduce the global burden of 
cardiovascular disease and to improve the patients’ quality-of-life. Fundamental to 
the development of successful medical treatments for cardiovascular diseases is an 
in-depth knowledge of the disease process, i.e. knowledge on the molecular signaling 
cascades in healthy cells and an in-depth understanding of how these molecular 
pathways get disturbed during disease. Endothelial homeostasis plays crucial role in 
vascular health by preventing unwarranted thrombosis, inlammation and regulating 
vascular tone. Endothelial dysfunction is a culprit in the development of many 
cardiovascular pathologies (1-3). Hence, insight into the molecular mechanisms that 
underlie endothelial dysfunction might allow for the discovery of innovative drugable 
targets to reduce the cardiovascular disease burden.
Adverse endothelial plasticity and its specialized form Endothelial-mesenchymal 
transition (EndMT) contributes to the development of multiple cardiovascular diseases 
including atherosclerosis (4, 5) and cardiac ibrosis (6). The pleiotropic cytokine TGFβ(7), 
inlammation (8) and oxidative stress (9) are established inducers of EndMT through 
the activation of canonical and non-canonical TGFβ signaling and the concurrent 
induction of mesenchymal gene expression by the transcription factors SNAIL, SLUG, 
TWIST1 and GATA4 (10, 11). The induction of gene expression is not only regulated 
by changes in transcription factor binding to the DNA, but also by the accessibility 
of the DNA to these transcription factors, which is tightly regulated by epigenetics. 
(Chapter 1 and Chapter 2) Epigenetic modiications, through changes in histone tail 
modiications and DNA methylation, facilitate the compaction and decompaction of 
the DNA, thereby orchestrating its accessibility to transcription factors. Furthermore, 
transcribed genes are not always translated into proteins, as non-coding RNAs might 
induce posttranscriptional inhibition. In Chapter 2, we proposed to therapeutically 
target epigenetic enzymes in the pro-atherogenic endothelium to ameliorate 
atherosclerosis development. We used the histone methyltransferase EZH2 and the 
histone deacetylase SIRT1 to exemplify how their pleiotropic functions can preclude 
atherosclerosis pathways and safeguard endothelial homeostasis. 
In following chapters, we investigated the molecular mechanisms that drive EndMT 
with a focus on the multi-layered regulatory system consisting of epigenetic and post-
transcriptional modiications. Furthermore, we investigated how these mechanisms 
contribute to the development of intimal hyperplasia and cardiac ibrosis. 
ADVERSE ENDOTHELIAL PLASTICITY CONTRIBUTES TO THE DEVELOPMENT OF INTIMAL HYPERPLASIA
Intimal hyperplasia is an initiating event of atherosclerosis development and yet the 
molecular epigenetic mechanism is still elusive. Intimal hyperplasia is the consequence 
of migration and proliferation of ibro-proliferative cells in the tunica intima and which 
thickens the vascular wall (12). The origin of these ibro-proliferative cells is extensively 
investigated, and at least four types of cells are shown to give rise myoibroblast-like 
cells in the hyperplastic intima, i.e. resident ibroblasts, smooth muscle cells, endothelial 




coronary artery bypass surgery (CABG) can trigger intimal hyperplasia and occlude the 
grafted vein (13), suggesting the importance of the EndMT in development of intimal 
hyperplasia. Also, endothelium-derived ibroproliferative cells accumulate in vascular 
areas exposed to low oscillatory shear stress where intimal hyperplasia is eminent (5)
(14). Vice versa, vascular areas exposed to high laminar shear stress contain quiescent 
endothelial cells that are refractory to EndMT (14). Collectively, these data imply that 
luid shear stress is a pivotal determinant of EndMT.
Figure 1.  High laminar shear stress-induced MAPK7 activation precludes TGFβ-induced Endothelial-
Mesenchymal transition. Upon high laminar shear stress, endothelial MAPK7 signaling is activated. The 
downstream transcription factors of MAPK7, such as KLF4, are known to induce production of nitric oxide. The 
activation of MAPK7 signaling further results in the inhibition of TGFβ signaling by SMAD2/SMAD3, thereby 
inhibiting EndMT (14)
In Chapter 3, we uncovered that at sites of intimal hyperplasia, MAPK7 expression 
and activity is silenced by microRNA-374b. MicroRNA-374b expression is induced by 
TGFβ and silences 4 target genes in the MAPK7 signaling cascade, i.e. MAP3K3, MAPK7, 
MEF2D and KLF4. Ectopic expression of microRNA-374b in endothelial cells, induces 
EndMT in the absence of exogenous TGFβ, suggesting that the microRNA-374b-
dependent silencing of MAPK7 signaling is pivotal to intimal hyperplasia. Indeed, 
the expression of microRNA-374b is increased in experimental models of intimal 
hyperplasia where MAPK7 signaling is lost. (Figure 2). Moreover, in patients sufering 
from coronary artery disease, the expression of microRNA-374b associates with disease 
severity and with a decreased expression of MAPK7.
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Figure 2. MicroRNA - 374b inhibits MAPK7 signaling and induces EndMT. MicroRNA-374b is induced upon TGFβ1 
stimulation and silences 4 members of the MAPK7 signaling cascade. This silencing mechanism explains how the MAPK7 
signaling cascade is silenced by TGFβ in endothelial cells. 
Intimal hyperplasia is progressive process, which narrows the vascular lumen by the 
accumulation of ibroproliferative cells. How endothelium-derived ibroproliferative cells lose 
their quiescence and acquire this hyper-proliferative behavior is still elusive. 
In Chapter 4, we uncovered that under atheroprotective - high laminar shear stress, the 
expression of the histone methyltransferase EZH2 is decreased. EZH2 is an epigenetic enzyme 
that tri-methylates lysine 27 on histone 3  (H3K27me3), which results in transcriptional 
repression (15). The increase in EZH2 is associated with elevated expression of cell cycle genes 
and increased proliferation of endothelial cells.  It is still elusive how the reduction in EZH2 can 
result in a reduced cell cycling ability of endothelial cells, we conclude that the high laminar 





Figure 3. Uniform laminar shear stress mediated endothelial quiescence is mediated by the EZH2 
decline. Under the shear stress MAPK7 get phosphorylated and activated. This activation led to the decline in 
histone methyltransferase EZH2 protein level. RNA sequencing result revealed that both EZH2 decline and high 
laminar shear stress can inhibit cell cycle genes, which may explain to a certain extend how endothelial cells 
acquire endothelial quiescence. 
In Chapter 4, we noted that there was reciprocity between MAPK7 signaling and 
EZH2 expression, which cannot be explained by a direct interaction.  Therefore, in 
Chapter 5, we investigated the reciprocity between MAPK7 and EZH2. Uniform laminar 
shear stress induces the MAPK7-dependent expression of microRNA-101 that silences 
EZH2 expression. Reciprocally, the loss of EZH2 expression results in the expression 
of microRNAs that target DUSP1 and 6, which inactivate MAPK7. In human coronary 
artery stenosis, EZH2, DUSP1 and DUSP6 level are increased whereas MAPK7 expression 
is reduced. Moreover microRNA-101 expression is decreased which is associated with 
an increase in EZH2 and the severity of the stenosis. These data might explain the 
diference in the development of intimal hyperplasia at sites exposed of high laminar 
shear stress and low oscillatory shear stress (Figure 4).  
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Figure 4.  Reciprocal crosstalk between pMAPK7 and EZH2. Upon high laminar shear stress MAPK7 gets 
activated which induces the expression of miR-101. Consequentially, the expression of EZH2 is silenced. On 
the other hand, EZH2 modulates the expression of miRNAs through H3k27me3 – a repressive chromatin mark. 
The decline of EZH2 leads to open chromatin, which elevates the expression level of these microRNAs. The 
microRNAs further silence the DUSP1 and DUSP6. This leads less protein expression of MKP-1 and MKP-3 which 
removes MAPK7 phosphorylation mark, thereby MAPK7 phosphorylation kept high. 
ADVERSE ENDOTHELIAL PLASTICITY IN CARDIAC FIBROSIS 
Cardiac ibrosis is the fundamental pathology underlying heart failure for which 
no efective treatment is currently available. Plasma Galectin-3 levels are associated 
with all-cause mortality rate and recognized as a prognostic biomarker of cardiac 
ibrosis(17). GAL-3 knockdown attenuates cardiac ibrosis, indicating that Gal3 is not 
only a biomarker, but also a key molecule in the initiation of cardiac ibrosis (18). It 
has been reported that during cardiac ibrosis myoibroblast are derived from the 
endothelial lineage through EndMT(6).  Hence, in Chapter 6, we investigated if Gal-
3 could induce of EndMT.  Although Gal-3 is generally believed to signal through a 
number of receptors, the addition of recombinant human Gal-3 did not induce or 
aggravate EndMT. In contrast, the loss of endogenous Gal-3 precluded TGFβ-induced 
EndMT via unknown mechanism. These data suggest that Gal-3 might act as a 
transcriptional co-activation during TGFβ-induced EndMT (19, 20), which is currently 
under investigation 
CONCLUSIONS
Endothelial-mesenchymal transition is a crucial component of atherosclerosis and 
cardiac ibrosis development and shown to be modulated by luid shear stress. In this 




levels by MAPK7, EZH2 and microRNAs and found dysregulation of these factors in 
experimental models of intimal hyperplasia and in human coronary artery disease. 
We uncovered a number of pivotal regulators of EndMT that might have therapeutic 
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OUTCOME OF THIS THESIS
In this thesis, we studied the mechanisms that safeguard endothelial homeostasis 
with a focus on the signaling induced by laminar shear stress. We uncovered an 
intrinsic multi-layered mechanism that encompasses classical signal transduction 
and converges with regulatory mechanisms depending on epigenetics and 
posttranscriptional repression. Dysregulation of these mechanisms culminate 
in endothelial to mesenchymal transition (EndMT) and might contribute to the 
development of intimal hyperplasia and cardiac ibrosis. The in-depth knowledge 
on the factors that induce, facilitate or aggravate EndMT may contributes to the 
development of novel therapeutic approaches to treat intimal hyperplasia and cardiac 
ibrosis in the future. 
MOLECULAR INSIGHTS ON ADVERSE ENDOTHELIAL PLASTICITY – POSSIBLE TARGET?
Despite the fact that endothelial cells throughout the body have the same origin 
– the hemangioblast (1) -  there are distinct functional and structural diferences 
between endothelial cells originating from their function in speciic organs or 
the microenvironment the endothelial cells are in (2). This cellular heterogeneity 
is a relection of the physiological endothelial plasticity and enables the optimal 
functioning of the residing organ(3). For instance, the endothelium in the blood-
brain barrier forms a non-fenestrated endothelial layer which is impermeable to toxic 
substances thereby safeguarding the proper functioning of the brain(4), whereas a 
highly fenestrated endothelial layer is present in the liver sinusoid that enables the fast 
uptake of metabolites, plasma proteins and even drug molecules by the hepatocytes 
and hepatic satellite cells(5). 
In the medium and large sized arteries, non-fenestrated endothelial cells reside on 
the basement membrane and align to the direction of blood low. The biomechanical 
signal originating from the laminar shear stress sensed by the endothelium, is a key 
driving force of signaling pathways by which the endothelium safeguards the vascular 
integrity (e.g. endothelial cell-cell junctions and anti-inlammatory signaling) and 
maintains the blood low (e.g. vasodilatory and anti-thrombogenic pathways). It is well 
established that at sites of vascular curvatures and bifurcation, endothelial cells are 
exposed to low and oscillatory shear stress(LOSS)(6, 7) and might undergo endothelial-
mesenchymal transition(8), an adverse form of plasticity. Endothelial cells exposed to 
LOSS induce the expression of proinlammatory genes while reducing antioxidant 
gene expression (9-11). This distinct change in gene expression proile can partly be 
explained by the activities of the LOSS-induced transcription factors SMAD2/3 (12), 
SNAI1 (8), TWIST (13) and others. We uncovered that EZH2-dependent (Chapter 4 and 
5) H3K27me3 bears important role in modulating the expression of protein coding 
genes as well as the microRNAs in response to the loss of laminar shear stress, thereby 
modulate endothelial quiescence (14). 
EndMT contributes to the development of several pathologies including intimal 
hyperplasia, atherosclerosis, cardiac ibrosis and other ibroproliferative diseases. The 




further characterized in atherosclerosis and cardiac ibrosis models. The future looks 
bright because we and other researchers recognized intrinsic protectives signaling 
molecules such as pMAPK7(15), BMP7(16) and FGFRI (17) are capable of inhibiting 
EndMT. In this thesis, we uncovered that a combination of microRNA miR-101, miR-200a 
and miR-141 can preclude EndMT in endothelial cell models. Moreover, we uncovered 
that the antimir-374b inhibits the induction of EndMT in endothelial cell. These data 
suggest that microRNA mimetics or antimiRs might have anti-atherosclerosis potential 
through the maintenance of endothelial homeostasis. MicroRNAs “ine-tune” key 
signaling cascades and their therapeutic potential is exempliied in preclinical 
atherosclerosis models (18). For instance, miR-92a is a low responsive microRNA 
that targets the mRNA of transcription factors KLF2 and KLF4, which are essential to 
endothelial homeostasis. The speciic inhibition of miR-92a ameliorates endothelial 
activation and reduces plaque size in LDLR-/- mice (19). In humans, synthetic 
antisense oligonucleotides similar in chemistry to miR mimics or antimiRs have been 
therapeutically used. Mipomersen, a second-generation anti-sense oligonucleotide 
molecule targeting the messenger RNA encoding for ApoB, efectively reduces the 
LDL-C level among patients sufering from familiarly hypercholesterolemia and 
coronary heart disease patients non-responding to the maximum tolerated dose of 
other LDL-C lowering medications (20, 21), providing support for , future RNA-based 
treatment possibilities. 
Likewise, small molecule drugs that alter the activity of speciic epigenetic enzymes 
might have an anti-atherosclerosis potential and are starting to enter the clinics. 
Although data on cardiovascular endpoints are scarce in the initial clinical studies, 
these drugs have proven safe in oncology trials, which warrant their transition for 
treatment of cardiovascular disease. This transition allows to test the hypothesis that 
treating epigenetic dysregulations in endothelial cells (e.g. SIRT1 deactivation or EZH2 
innervation in atherosclerosis), precludes the development of atherosclerosis and 
potentially reduces the disease burden. The review only addressed to the early stage 
of atherosclerosis and the efect may difer late stages of atherosclerosis, especially in 
vulnerable plaques.
Also, we found that inhibition of intracellular Gal-3 attenuated EndMT. This inding 
can be linked with study which showed Gal-3 knockdown in mice lead to less cardiac 
ibrosis and improved cardiac function (22). Since reduction of GAL-3 reduces nuclear 
accumulation of β-catenin/TCF4 in colorectal cells (23) and induces gene expression 
of SNAI1, SNAI2 and TWIST1 in endothelial cells, the beneicial efect may explained via 
occurring through modulation of EndMT transcription factors. 
TARGETING ADVERSE ENDOTHELIAL PLASTICITY IN ATHEROSCLEROSIS AND CARDIAC FIBROSIS
There is ample experimental and clinical evidence that high laminar shear stress 
beneits endothelial function and homeostasis and suppresses adverse endothelial 
plasticity and dysfunction. The easiest, reliable and risk-free way to physically induce 
shear stress magnitude is doing optimal regular physical exercise, which results in 
favorable efects in heart and vessel (24, 25). Thereby supporting physical activity 
among general population is important for endothelial health. 
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CHAPTER 8
Although, vascular bifurcations and curvatures remain at risk due to their 
geometry – and these areas are atheroprone areas. In order to tackling this issue, we 
stated our prospect of ameliorating atherosclerosis via targeting pro-atherogenic 
endothelium using pre-exemplifying epigenetic enzymes namely SIRT1 activation 
and EZH2 inhibition in Chapter 2. Treatment against adverse endothelial plasticity is 
also inquired after successful coronary artery bypass graft (CABG) or percutaneous 
coronary intervention (PCI) to prevent from vein graft failure or restenosis, since the 
underlying pathology of these complications are due to the EndMT-derived intimal 
hyperplasia (30). Targeted delivery to endothelium such as with immunoliposomes 
(26) is obligatory to deliver intrinsic EndMT inhibiting molecules in vivo. Because we 
need to take into account that targets of miRNAs and functions of epigenetic enzymes 
vary in diferent cell types, systemic administration of these molecules may result 
in adverse of-target efects. The promising targeting delivery method is immune-
liposome based technology which can selectively deliver siRNAs to the activated 
endothelial cells using surface markers such as E-selectin (27, 28). 
Regarding cardiac ibrosis, targeting endMT during cardiac ibrosis may be a novel 
therapeutic strategy, because 30% of the myoibroblasts are derived via EndMT (16). 
Successful inhibition of EndMT in heart may ameliorate ibrosis in certain extend. 
The net result may be not only happening through the inhibition of EndMT-derived 
myoibroblast diferentiation but also reducing hypoxia via maintaining endothelial 
phenotype. As hypoxia is well established to promote myoibroblast diferentiation.    
CONCLUDING REMARKS
Adverse endothelial plasticity is fundamental basis of multiple adult pathologies 
including atherosclerosis, intimal hyperplasia and cardiac ibrosis. We uncovered a 
number of signaling mechanisms, including signaling intermediates, epigenetics and 
post-transcriptional silencing that might preclude the development or progression 
of atherosclerosis and cardiac ibrosis. These mechanisms need to be investigated in 
future research by interventional studies in diseased animal models. Advances in the 
ield of targeted drug delivery are essential to deliver therapeutic molecules in the 
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Het ultieme doel van cardiovasculaire geneeskunde is het voorkomen en genezen 
van ziektes aan het hart en vaatstelsel en zo de kwaliteit-van-leven te verbeteren voor 
patiënten met een cardiovasculaire ziekte. Fundamenteel in de ontwikkeling van 
nieuwe therapieën gericht tegen cardiovasculaire ziekten, is een gedegen begrip van 
het onderliggende ziekteproces, i.e. de moleculaire processen die ten grondslag liggen 
aan gezondheid en welke gedereguleerd worden tijdens ziekte. Homeostase van het 
endotheel – de binnenste cellaag in alle bloedvaten – speelt een belangrijke rol in 
het voorkomen van trombose, ontsteking en bij de regulatie van de vasculaire tonus. 
Dysfunctie van het endotheel is veelvoorkomend tijdens cardiovasculaire ziekten (1-
3). Het is daarom belangrijk om meer inzicht te krijgen in de moleculaire mechanismen 
die leiden tot endotheelceldysfunctie, zodat mogelijk nieuwe aangrijpingspunten 
gevonden kunnen worden voor de ontwikkeling van innovatieve therapieën tegen 
cardiovasculaire ziekten.
Averse plasticiteit van het endotheel, en de transitie van endotheel naar 
mesenchym (EndMT) speelt een belangrijke rol in het ontstaan van atherosclerose (4, 
5) en de verlidtekening van het hart (cardiale ibrose) (6). Hierbij wordt de inductie 
van genexpressie van mesenchymale genen niet alleen gereguleerd door de binding 
van transcriptiefactoren aan het DNA, maar ook door de bereikbaarheid van het DNA 
voor deze transcriptiefactoren, welke bepaald wordt door epigenetica. Epigenetische 
modiicaties, door alteraties aan histon eiwitten of DNA methylatie, bepalen de 
toegankelijkheid van het DNA voor transcriptiefactoren. Een tweede regulatoir 
mechanisme wordt gevonden in microRNAs, die de translatie van messenger RNA 
naar eiwit posttranscriptioneel kan inhiberen.
 
ADVERSE ENDOTHEELCELPLASTICITEIT IN HET ONTSTAAN VAN INTIMALE HYPERPLASIE
Het ontstaan van intimale hyperplasie is een van de initiële processen van 
atherogenese. Het moleculaire mechanisme hiervan is niet geheel bekend. Intimale 
hyperplasie is het gevolg van de migratie en deling van ibroproliferatieve cellen in de 
vaatwand die hierdoor verdikt (12). De oorsprong van deze ibroproliferatieve cellen 
wordt veelvuldig onderzocht, en tenminste 4 celtypen kunnen diferentiëren in deze 
zogenaamde myoibroblast-achtige cellen in de hyperplastische intima; ibroblasten, 
gladde spiercellen, endotheelcellen en circulerende voorlopercellen. De transplantatie 
van een vene naar een arteriële omgeving tijden bypass chirurgie leidt tot EndMT en 
kan de vorming van intimale hyperplasie veroorzaken, waarbij de getransplanteerde 
vene verstopt raakt (13), suggestief voor een rol van EndMT in het ontstaan van 
intimale hyperplasie. Daarnaast worden endotheelcel-afkomstige ibroproliferatieve 
cellen vaak gevonden in vaatgebieden waarbinnen atherosclerose ontwikkeld, i.e. 
vaatgebieden die blootgesteld worden aan zogenaamde ‘low oscilatory shear stress’ 
(5)(14). Andersom, in vaatgebieden die beschermd lijken tegen de ontwikkeling van 
atherosclerose, i.e. vaatgebieden die blootgesteld worden aan zogenaamde ‘high 




induceren (14), hetgeen impliceert dat het patroon waarmee het bloed door de vaten 
stroomt een bepalende factor is in de inductie van EndMT.
In hoofdstuk 3, hebben wij gevonden dat in vaatgebieden waar intimale 
hyperplasie plaatsvindt, de expressie van MAPK7 wordt voorkomen door microRNA-
374b. De expressie van microRNA-374b wordt geïnduceerd door TGFβ en microRNA-
374b voorkomt de eiwitexpressie van 4 genen in de MAPK7 signaaltransductiecascade, 
i.e. MAP3K3, MAPK7, MEF2D en KLF4. De ectopische expressie van microRNA-374b 
in het endotheel leidt tot EndMT in de afwezigheid van TGFβ stimulatie, hetgeen 
suggereert dat de inhibitie van MAPK7 signalering door microRNA-374b een essentiële 
voorwaarde is voor de ontwikkeling van intimale hyperplasie. In experimentele 
modellen voor intimale hyperplasie komt microRNA-374b verhoogt tot expressie en 
is de expressie van MAPK7 verlaagt. Daarnaast is het expressieniveau van microRNA-
374b geassocieerd met het expressieniveau van MAPK7 en de ernst van intimale 
hyperplasie in de coronair arteriën van patiënten die zijn overleden aan coronaire 
hartziekte.
Intimale hyperplasie is een progressieve aandoening die leidt tot de vernauwing 
van der arteriën. Hierin speelt hyperproliferatie van ibroproliferative cellen een rol. 
Echter, het mechanisme waardoor endotheelcel-afkomstige ibroproliferatieve cellen 
hun quiescence verliezen en een hyperproliferatief fenotype aannemen is onbekend. 
In hoofdstuk 4 laten wij zien dat het epigenetisch enzym EZH2 een belangrijke rol 
speelt in deze transitie. EZH2 is een epignetisch enzym dat verantwoordelijk is voor 
de tri-methylatie van lysine 27 op histon 3 (H3K27Me3), hetgeen leidt tot repressie 
van genexpressie (15). Onder atheroprotectieve condities is de expressie van EZH2 
laag. De toename in EZH2 expressie in vaatgebieden die gevoelig zijn voor de 
ontwikkeling van intimale hyperplasie, gaat gepaard met een toename in de expressie 
van celcyclus genen. Hoewel wij het precieze mechanisme achter de regulatie van 
celcyclus door EZH2 niet hebben kunnen bepalen, hebben we aangetoond dat EZH2, 
en dus epigenetische mechanismen,  een belangrijke rol spelen in de regulatie van 
endotheliale quiescence en hyperproliferatie (16)(Figuur 3).
In ons onderzoek naar de regulatie van de celcyclus door EZH2, viel ons op dat 
er reciprociteit bestaan tussen de expressie van EZH2 en de activatie status van 
MAPK7. Deze interactie kan niet verklaart worden door een directe interactie tussen 
EZH2 en MAPK7. In hoofdstuk 5 hebben we onderzocht hoe de activiteit van MAPK7 
wordt beïnvloedt door EZH2 en waarom de expressie van EZH2 afhankelijk is van 
de mate van activatie van MAPK7. Atheroprotectieve laminaire shear stress zorgt 
voor de activatie van MAPK7, hetgeen leidt tot de expressie van microRNA-101. De 
expressie van microRNA-101 leidt tot een verlaagde expressie van EZH2. Visa versa 
leidt een verhoogde expressie van EZH2 tot een verlaagde expressie van microRNA-
200a, -b, -c en microRNA-141. Deze microRNAs reguleren de activiteit van MAPK7 door 
de inhibitoren van MAPK7 activiteit, i.e. de Dual-speciicity phosphatase (DUSP)-1 
en DUSP-6, te verlagen. Een toename in EZH2 leidt dus tot een hogere inhibitie van 
MAPK7 activiteit in het endotheel. Deze interactie hebben we niet alleen kunnen 
vinden in “gezonde” endotheelcellen in vitro, maar is ook aanwezig in vaatweefsel van 
patiënten die leiden aan coronaire hartziekte (iguur 4).
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CHAPTER 9
ADVERSE ENDOTHEELCELPLASTICITEIT IN HET ONTSTAAN VAN CARDIALE FIBROSE
Cardiale ibrose, oftewel verlittekening van het hart, is het pathologische proces 
dat ten grondslag ligt aan het ontstaan van hartfalen, waarvoor geen efectieve 
therapie beschikbaar is. Het niveau van galectin-3 in het bloedplasma van patiënten 
die leiden aan hartfalen is geassocieerd met hun overleving, en een prognostische 
biomarker in de kliniek (17). Een verminderde expressie van galectin-3 reduceert 
de ontwikkeling van hartfalen, hetgeen duidt op een op mechanistische functie 
voor galectin-3 in cardiale ibrose (18). Cardiale ibrose wordt gekenmerkt door de 
accumulatie van ibroproliferatieve cellen in het hart, waarvan een deel afkomstig zijn 
vanuit het endotheel (6). Om deze reden hebben wij in hoofdstuk 6 onderzocht of de 
expressie van galectin-3 geassocieerd is met de inductie van EndMT. Het is algemeen 
geaccepteerd dat galectine-3 zijn functie uitoefent via binding aan zijn receptor in 
het celmembraan, echter leidt de additie van galectin-3 aan endotheelcellen niet tot 
EndMT of tot een verhoogde efectiviteit van TGFβ-geïnduceerde EndMT. Wel leidt de 
inhibitie van endogene galectin-3 productie tot een verlaging van TGFβ-geïnduceerde 
EndMT. Tezamen duiden deze data op een intracellulaire rol voor galectin-3 in de 
regulatie van EndMT, mogelijk als transcriptionele coactivator (19, 20). Deze hypothese 
wordt momenteel onderzocht.
CONCLUSIE
De transitie van endotheel naar mesenchym is een belangrijke component in 
de ontwikkeling van atherosclerose (intimale hyperplasie) en hartfalen (cardiale 
ibrose) en wordt gereguleerd door biomechanische krachten, zoals het patroon van 
de bloedstroom. In dit proefschrift hebben wij laten zien dat EndMT gereguleerd 
wordt door MAPK7, EZH2 en microRNAs en gevonden dat de expressie van deze 
moleculen gedereguleerd is in experimentele modellen voor intimale hyperplasie en 
in humane coronaire hartziekte. We hebben een aantal belangrijke regulatoren van 
EndMT geïdentiiceerd die mogelijk een therapeutische efect kunnen hebben om de 
ontwikkeling van intimale hyperplasie of het ontstaan van hartfalen tegen te gaan. 
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A p p e n d i c e s
A b b r e v i a t i o n s
C u r r i c u l u m  v i t a e




αSMA  alpha smooth muscle actin 
ACTB  actin beta
APOE-/-  apolipoprotein-E knockout mice 
BMK-1  big mitogen activated protein kinase 1
BMP7  bone morphogenic protein 7  
BSA   bovine serum albumin
CABG  coronary Artery Bypass Graft
CD31  cluster of Diferentiation 31
CD144  cluster of Diferentiation 144, CDH5
CNN1  calponin 1
CpG   cytosine followed immediately by guanine base
CVD   cardiovascular Diseases
DMSO  dimethyl sulfoxide
DNMT1  DNA methyltransferase 1
DNMT3a  DNA methyltransferase 3 alpha
DNMT3b  DNA methyltransferase 3 beta
DNA   deoxyribonucleic acid
DUSP1  dual speciicity Phosphatase 1
DUSP6  dual speciicity Phosphatase 6
EC   endothelial cells
ECM   endothelial cell medium
ECGF  endothelial cell growth factor
EDCF  endothelial-derived contracting factor
EDRF  Endothelial-derived relaxing factor
EDTA  ethylenediaminetetraacetic acid
EED   embryonic ectorderm development
EMT   epithelial-mesenchymal transition
EndMT  endothelial-eesenchymal transition
eNOS  endothelial nitric oxide synthase, NOS3
ERK5   extracellular signal-regulated kinase 5
EZH1  enhancer of zeste homologue 1
EZH2  enhancer of zeste homologue 2
FBS   fetal bovine serum
FGF2  ibroblast Growth Factor 2
FSP1   ibroblast speciic protein
FSS   luid shear stress
Gal-3  galectin 3
GAPDH  glyceraldehyde 3-phosphate dehydrogenase
H202  hydrogen peroxide
H2A   histone 2A
H2B   histone 2B
H3   histone 3
H3K9  histone 3 lysine 9
H3k27me3  histone 3 lysine 27 trimethylation
ABBREVIATIONS
171 APP
H4   histone 4
HF   heart failure
HFpEF  heart failure with preserved ejection fraction
HUVEC  human umbilical vein endothelial cells
IL-6   interleukin 6
IL1β   interleukin 1β
IMT   intima-Media thickness
KLF2   kruppel like factor 2
KLF4   kruppel like factor 4
LDL-C  low density lipoprotein cholesterol
LSS     laminar shear stress
MAP3k3  mitogen activated protein kinase kinase kinase 3
MAPK7  mitogen activated protein kinase 7
MCP1  monocyte chemoattractant protein 1
MEF2D  myocyte enhancer factor 2D
MEF2C  myocyte enhancer factor 2C
MEK   extracellular signal-regulated kinase kinase
MEK5D  constitutive active MEK5   
miRNA  micro RNA
NADH  nicotinamide adenine dinucleotide
NADPH  nicotinamide adenine dinucleotide phosphate
NFkB  nucleic factor kappa B
NO   nitric oxide
Ox-LDL  oxidized low density lipoprotein
PAR-1  protease activated receptor
PCI   percutaneous coronary intervention
PCSK9  proprotein convertase subtilisin/kexin type 9
PFA   paraformaldehyde
pMAPK7  phosphorylated MAPK7
PRC 1  polycomb repressive complex 1
PRC 2  polycomb repressive complex 2
RbAP48  retinoblastoma binding protein 48
RISC complex  RNA-induced silencing complex
RNA   ribonucleic acid
ROS   reactive oxygen species
SEM   standard error of the mean
sm22α  smooth muscle 22 alpha
SUZ12  suppressor of zeste 12
TAGLN  transgelin (sm22α)
TGFβ1  transforming growth factor beta 1
TGFβR  transforming growth factor beta receptor
TNFα  tumor necrosis factor alpha
VCAM1  vascular cell adhesion protein 1
VE-cad  vascular endothelial cadherin
VEGF  vascular endothelial growth factor
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